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DOACs have relatively recently been licensed for stroke and systemic 
embolism prevention in patients with non-valvular atrial fibrillation (AF) and 
have replaced warfarin as the first line agent of choice over warfarin. The aim 
of this research was to determine prescribers’ views and experiences of the 
use of DOACs for the management of non-valvular AF. 
The first phase was a PROSPERO registered systematic review of clinicians’ 
views and experiences of DOACs for the management of non-valvular atrial 
fibrillation. Ten studies were identified; in those studies reporting clinician 
preference, DOACs were first choice over warfarin in naïve patients, based on 
perceptions of evidence of effectiveness equivalent or superior to warfarin 
and superior safety. Other advantageous factors were in those with an 
unstable International Normalized Ratio and likely to miss appointments. 
There were, however, concerns relating to management of over-
anticoagulation and experiences of observed bleeding rates. In addition to 
the lack of studies, none of the studies had used theory in the development 
of the data collection tools or analysis indicating a gap in the literature  
The second phase was a cross-sectional survey of prescriber’s views, 
behaviours and experiences related to prescribing DOACs for the 
management of non-valvular AF. The survey was conducted in NHS Highland, 
inviting all medical and non-medical prescribers to participate. Items on 
potential influences on DOAC prescribing were based on the Theoretical 
Domains Framework (TDF). Principal component analysis (PCA) of the TDF 
items gave four components. Component scores for (i) role of professionals, 
their knowledge and skills and (ii) influences on prescribing were positive. 
There did, however, appear to be issues in switching from warfarin to DOACs 
or from one DOAC to another. Scores for (iii) consequences of prescribing 
and (iv) monitoring for safety and effectiveness were more neutral. There 
were low levels of agreement for statements relating to DOACs being more 
effective, safer and cost‐eff ective than warfarin. There were similar 
responses around the complexity of bleeding management and detection of 
over and under‐an ticoag u la tion .  Less experienced prescribers were 






terms of the consequences of prescribing (p<0.05). Content analysis of the 
responses to the open questions identified that the overwhelming perceived 
benefit was the absence of need for INR monitoring, with the main limitations 
being the lack of a suitable reversal agent and ability to monitor 
anticoagulation status. 
Given the updated recommendations of Healthcare Improvement Scotland 
(HIS) to use edoxaban first line, the final phase was a cross-sectional survey 
of prescriber’s views, behaviours and experiences related to prescribing 
edoxaban for the management of non-valvular AF. Responses were received 
from 103 prescribers in NHS Highland. While almost all respondents had been 
encouraged to implement this recommendation of prescribing edoxaban, less 
than one third had either switched patients from warfarin or other DOACs to 
edoxaban. The following three PCA components identified in the previous 
survey were applied to the TDF determinants: the role of professionals, their 
knowledge and skills; influences on prescribing; and consequences of 
prescribing. While component scores for the first two components were 
positive, the scores for consequences of prescribing were more neutral. 
Although a number of respondents described edoxaban (and other DOAC) 
related adverse drug reactions (ADRs), very few had submitted a Yellow Card 
report to the Medicines and Healthcare products Regulatory Agency (MHRA). 
Content analysis of the responses to the open questions identified benefits 
and limitations similar to the previous survey.    
This doctoral research has generated original findings in terms of DOACs views, 
experiences and behaviours related to management of non-valvular AF. There 
is merit in reviewing the local and national guidelines, particularly in relation 
to switching and awareness of the evidence base. Attention should be paid to 
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CHAPTER 1: GENERAL INTRODUCTION 
This introductory chapter provides an overview of atrial fibrillation (AF), with 
particular emphasis on non-valvular AF, the diagnosis in the vast majority of 
patients and the subject of this doctoral research. The role of oral 
anticoagulants and the issues relating to the use of warfarin in the 
management of non-valvular AF is described. This is followed by the clinical 
pharmacology of a new class of oral anticoagulants, the direct-acting oral 
anticoagulants (DOACs), and the evidence base of efficacy, effectiveness and 
safety. The rationale for the doctoral research on prescribers’ views and 
experiences of DOACs is given, along with the overall research aim and the 
aims of the different phases of research.  
1.1 Research strategy terms  
A systematic approach to the identification, retrieval and review of relevant 
literature was adopted throughout the doctoral research. The aims were to 
gain a thorough understanding of policies, guidelines, reviews and primary 
research related to DOAC prescribing in the management of non-valvular AF, 
and to maintain this throughout the research journey.  
The search strategy focused on the following databases: Medline, Cumulative 
Index to Nursing and Allied Health Literature (CINHAL), International 
Pharmaceutical Abstracts and Google Scholar. 
The search was conducted from Jan 2006 (two years prior to the launch of 
DOACs) until the completion of the research. Where possible, alerts were set 
up in the databases to enable continuous updating.  
While the specific search terms, and application of Boolean operators, varied 
from database to database, the following provides an indication of the 
approach.  
• Related to non-valvular AF; ‘atrial fibrillation’ OR ‘non-valvular atrial 
fibrillation’ OR ‘non-valvular AF’ 
• Related to DOACs; ‘direct acting oral anticoagulant*’ OR ‘novel oral 
anticoagulant*’ OR ‘DOAC*’ OR ‘NOAC*’ OR ‘dabigatran’ OR ‘ 
rivaroxaban’ OR ‘edoxaban’ OR ‘warfarin*’   






• Related to health professionals; ‘health professional*’ OR ‘healthcare 
professional*’ OR ‘doctor*’ OR ‘prescriber*’ OR ‘physician*’ OR 
‘pharmacist*’ OR ‘nurse*’  
These terms were applied as MESH headings (where possible), title, abstract or 
keywords. The search in Google Scholar was adapted due to the limitations of the 
search function.  
1.2 Atrial fibrillation 
1.2.1 Atrial fibrillation classification 
AF is the most common sustained cardiac arrhythmia, defined as a 
‘supraventricular tachyarrhythmia with uncoordinated atrial activation and 
consequently ineffective atrial’ (Camm et al., 2010, Kirchhof et al., 2016, 
January et al., 2014).  In 2016, the European Society of Cardiology, in 
collaboration with the Task Force for the management of atrial fibrillation of 
the European Society of Cardiology, published updated guidelines. The 
guidelines were also developed with contributions from the European Heart 
Rhythm Association of the European Society of Cardiology and endorsed by 
the European Stroke Organisation. The classification of AF as described in the 







Table 1.1. European Society of Cardiology classification of AF (Kirchhof et al., 2016) 
Classification of AF Definition  
 
First diagnosed AF AF that has not been diagnosed before, irrespective 
of the duration of the arrhythmia or the presence 
and severity of AF-related symptoms. 
 
Paroxysmal AF Self-terminating, in most cases within 48 hours. 
Some AF paroxysms may continue for up to 7 days. 
AF episodes that are cardioverted within 
7 days should be considered paroxysmal. 
 
Persistent AF AF that lasts longer than 7 days, including episodes 
that are terminated by cardioversion, either with 
drugs or by direct current cardioversion, after 
7 days or more. 
 
Long-standing persistent AF Continuous AF lasting for ≥1 year when it is decided 
to adopt a rhythm control strategy. 
 
Permanent AF AF that is accepted by the patient (and physician). 
Hence, rhythm control interventions are, by 
AF. Should a rhythm control strategy be adopted, 
the 
arrhythmia would be re-classified as ‘long-standing 




In 2014, the American College of Cardiology/ American Heart Association 
Task Force on Practice Guidelines and the Heart Rhythm Society published 
their updated guidance for the management of AF, with classification largely 








Table 1.2.American College of Cardiology/ American Heart Association Task Force on 




The key difference between these two classifications is the inclusion of non-
valvular AF within the American guidelines. While the term ‘non-valvular AF’ 
is not listed within the classification of the ESC guidelines, it is explained that 
‘Traditionally, patients with AF have been dichotomized into ‘valvular’ and 
‘non-valvular’ AF… we have decided to replace the historic term ‘non-valvular’ 
AF with reference to the specific underlying conditions.’ However, given that 
‘non-valvular AF’ is still widely used in the United Kingdom (UK) and is the 
term used in key UK guidelines (NICE, 2014), this term has been adopted for 
this doctoral research. The term ‘non-valvular AF’ represents the majority of 
patients with a diagnosis of AF.  
1.2.2 Atrial fibrillation prevalence and clinical outcomes 
The prevalence of AF varies depending on the population and cohort being 
studied, with prevalence varying with age, sex and ethnicity. AF has recently 
been referred to as a global epidemic, with worldwide prevalence estimated 
at up to 33.5 million, and is known to be increasing (Morin et al., 2016; 
Rahman et al., 2014). Prevalence is more clearly established in the western 
world, at around 1-2% of the adult population. Data consistently demonstrate 
prevalence increasing with age, being higher in males than females and 
higher in white individuals compared to black or Asian (Camm et al., 2010. 
Classification of AF Definition  
Paroxysmal AF Terminates spontaneously or with intervention within 
seven days of onset. 
 
Persistent AF Continuous and sustained for more than seven days. 
 
Long-standing persistent AF Continuous and sustained for more than 12 months.  
 
Permanent AF Patient and clinician make a joint decision to stop 
further attempts to restore and/or maintain sinus 
rhythm. 
 
Non-valvular AF In the absence of rheumatic mitral stenosis, a 








Martinez et al., 2015). Findings of a relatively recent systematic review 
illustrate that AF is present in 0.12–0.16% of those under 49 years of age, 
3.7–4.2% in those aged 60–70 years and 10–17%in those aged 80 years and 
over (Zoni-Berisso et al., 2014). 
Permanent AF occurs in approximately 50% of patients, and paroxysmal and 
persistent AF in 25% each (Zoni-Berisso et al., 2014), with non-valvular AF 
much more prevalent than valvular AF. Due to the significant reduction of 
rheumatic disease in western countries, the prevalence of valvular heart 
disease is very low with figures from the United States (US) of approximately 
2.5% of those with AF. The prevalence of rheumatic heart disease is similar 
at an estimated 2-3% (Lung et al., 2011). 
The aetiology and pathophysiology of AF are complex and beyond the scope 
of this doctoral research. Essentially, AF occurs when atrial structural 
abnormalities and/or atrial electrical abnormalities alter atrial tissue to 
promote abnormal impulse formation and/or propagation (Camm et al., 
2010, Staerk et al., 2017). Many factors, modifiable and non-modifiable, can 
increase the risk of AF. Modifiable factors include: smoking, lack of exercise, 
excess alcohol intake, diabetes mellitus, heart failure, hypertension and 
hyperthyroidism. Non-modifiable risk factors include: increasing age, family 
history and valvular heart disease (Camm et al., 2010,Staerk et al., 2017). 







Table 1.3. Clinical outcomes of AF (Camm et al., 2010, Staerk et al., 2017) 
 
Clinical outcomes Description 
Death Death rates may be doubled. 
 
Stroke Associated with increased risk of stroke 
and transient ischemic attack, up to 20-
30% of strokes due to AF . Increased 
risk of long-term disability or death. 
Risk of stroke is variable and affected by 
other risk factors and AF management, 
can be in patients with a ‘silent’ and 
paroxysmal AF.  
 
Cognitive decline and vascular dementia AF is associated with an adjusted 
increased risk of cognitive impairment, 
dementia, Alzheimer’s dementia, and 
vascular dementia in patients with and 
without a history of stroke. 
 
Heart failure Clinical outcome as well as a risk factor 
for AF. 
 
Hospitalisation  10-40% patients with AF are 
hospitalized every year. 
 
Quality of life  Patients quality of life is decreased 




Symptoms of AF include heart palpitations, shortness of breath, weakness, 
dizziness, chest pain, confusion, lowered ability to exercise (Camm et al., 
2010). 
1.3 Management of AF 
The goals in managing AF are to reduce symptoms and prevent complications 
listed in Table 1.3. The management of AF is described in national and 
international evidence-based guidelines (January et al., 2014, Camm et al., 
2010, NICE, 2014, SIGN 129, 2013). Pharmacological approaches include the 
use of anticoagulants to reduce the risk of stroke, and antiarrhythmics to 
restore or maintain heart rhythm or to slow the heart rate in people who 
remain in AF. Non-pharmacological management includes electrical 
cardioversion, and catheter or surgical ablation. A pathway for AF treatment 








Figure 1.1. AF management pathway, as described in the European Society of 
Cardiology guidelines, 2016 (Krchhof et al., 2016) 
 
 
Given that this doctoral research focuses on the use of oral anticoagulants in 
the management of non-valvular AF, detailed coverage of the mechanism of 
action and properties of anti-arrhythmic agents, electrical cardioversion, and 
catheter or surgical ablation is beyond the scope of this introduction.  
From this point forward, the thesis focuses on non-valvular AF.  
1.4 Use of oral anticoagulation in the management of non-valvular AF 
As highlighted in Figure 1.2 oral anticoagulants feature heavily in the 
management of AF (valvular and non-valvular), with the main goal being to 
achieve anticoagulation thus preventing stroke while minimizing the risk of 
bleeding (January et al. 2014, Camm et al., 2010 ). The decision whether to 
commence an oral anticoagulant or not should be made in conjunction with 
the patient and with consideration of the risks of stroke and bleeding (Camm 
et al., 2010).  
1.4.1 Stroke risk assessment 
CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes 
mellitus, prior stroke or TIA or thromboembolism [doubled]) was initially 
introduced as a stroke risk predictor in patients and replaced by the updated 






[doubled], diabetes mellitus, prior stroke or TIA or thromboembolism 
[doubled], vascular disease, age 65 to 74 years, sex category) (Kirchohof, et 
al., 2016). CHA2DS2-VASc has a wider total score range (0-9) and includes a 
larger number of risk factors than CHADS2. Table 1.4 describes the allocation 
of scores and the maximum possible scores for CHADS2 and CHA2DS2-VASc 
Table 1.4. Stroke risk assessment tools 
 Score 
CHADS2 
   Congestive heart failure  
   Hypertension  
   Age≥ 75 years  
   Diabetes  
   Stroke/TIA 








Maximum possible score 6 
CHA2DS2-VASc 
Congestive heart failure  
Hypertension  
Age ≥ 75 years  
Diabetes  
Stoke/TIA 
Vascular disease (MI, aortic plaque, peripheral artery disease) 

















The CHA2DS2-VASc score informs the decision whether or not to commence 
an oral anticoagulant, taking account of the risk benefit ratio. If the score is 1 
and above for males and 2 and above for females then an oral anticoagulant 
is indicated (Kirchohof, et al., 2016).  
1.4.2 Bleeding risk assessment 
In addition to considering the risk of stroke prior to initiating an oral 
anticoagulant, clinicians should also consider the risk of bleeding. While 
bleeding risk is not necessarily a contraindication to anticoagulant use, the 
risk should be borne in mind. Of the different risk assessment tools, the most 
commonly used is HAS-BLED (hypertension, abnormal renal/liver function, 
stoke, history of bleeding, liable INR, elderly, drug/alcohol abuse [1 point 






informed treatment of atrial fibrillation), ABC (age, biomarkers, clinical 
history), RIETE (computerized registry of patients with venous 
thromboembolism), HEMORR2HAGES (hepatic or renal disease, ethanol 
abuse, malignancy, older age, reduced platelet count or function, rebleeding, 
hypertension, anaemia, genetic factors, excessive fall risk and stroke) and 
ATRIA (anticoagulation and risk factors in atrial fibrillation) (January et al., 
2014).  
1.5 Warfarin in the management of non-valvular AF 
1.5.1 Warfarin mechanism of action 
For over 60 years warfarin has been the oral anticoagulant of choice for the 
management of non-valvular AF. Phenindione, the other coumarin 
anticoagulant is rarely used and reserved for those sensitive (allergic) to the 
effects of warfarin. Warfarin inhibits the activity of vitamin K dependent 
coagulation factors (II, VII, IX and X) of the coagulation cascade (Figure 1.2) 
through the inhibition of vitamin K epoxide reductase. This leads to the 
hepatic production of partially carboxylated and decarboxylated  proteins with 







Figure 1.2. Simplified coagulation cascade. (Blann et al., 2002) 
 
1.5.2 Warfarin pharmacokinetics 
Warfarin is a mixture of two optically active isomers (the R and S forms) in 
almost equal proportions. It is completely absorbed from the gastrointestinal 









Table 1.5. Pharmacokinetic properties of warfarin (Xiong  et al., 2015, Lip et al., 2010) 
 
1.5.3 Warfarin disadvantages 
There are major issues associated with the use of warfarin which compromise 
both effectiveness and safety. 
1. Narrow therapeutic window 
As warfarin has a non-linear pharmacokinetic profile and a very narrow 
therapeutic window, a small change in plasma concentration can have a 
marked effect on the likelihood of adverse effects, the most important of 
which is bleeding. It is therefore difficult to predict the dose for an individual 
patient which will maximise effectiveness while minimising these adverse 
effects.  
2. Need for regular monitoring 
Given these issues, regular monitoring of prothrombin time is required during 
initiation of therapy and on an ongoing basis. Prothrombin is an important 
procoagulant component of a coagulation pathway (factors VII, X, V, 
prothrombin, fibrinogen), as highlighted in Figure 1.3. The prothrombin time 
is expressed as the International Normalized Ratio (INR) which is the ratio of 
the patient’s prothrombin time to control (patient prothrombin time/control 
prothrombin time)ISI. The control prothrombin time is taken from the 
geometric mean of 20 or more healthy subjects, and the ISI is the 









Time to peak concentration  72-96 hours  
 
Plasma protein bounding 
 
Tightly bound to albumin 99% 
Metabolism Mixed function P450 oxidases (CYP2C9, CYP3A4, CYP1A2) 
 







specific apparatus used into account (Porte et al., 2010). The 
pharmacokinetic profile also dictates that warfarin is given as a loading dose 
followed by a maintenance dose.  
The relationship between the INR and effectiveness and likely bleeding is 
given in Figure 1.3, also demonstrating the narrow therapeutic window.  
 
Figure 1.3. The relationship between INR, likely effectiveness and risk of bleeding 
(Masotti et al., 2013) 
 
3. Potential for drug-drug interactions 
One further complication in the use of warfarin is the potential for drug-drug 
interactions. As warfarin is metabolised by cytochrome P450 enzymes 
(CYP2C9, CYP3A4 and CYP1A2) there is potential for warfarin plasma 
concentrations to be significantly increased or decreased by enzyme 
inhibitors and inducers respectively. This could have consequences of altering 
effectiveness and the likelihood of adverse effects.  
Key commonly prescribed enzyme inducers include carbamazepine and 
phenytoin. 
Key commonly prescribed enzyme inhibitors include amiodarone, citalopram, 
erythromycin, fluconazole and omeprazole. 
Other mechanisms of interactions include altering gastrointestinal absorption, 
protein binding displacement and excretion. Several interacting drugs may be 
obtained in the UK without a prescription (e.g. St John’s Wort, omeprazole, 






there is evidence for some co-prescription), they may require increased 
monitoring and vigilance (NHS Highland, 2018).  
 
4. Potential for food-drug interactions  
In addition to drug-drug interactions, there is potential for food-warfarin 
interactions. The most clinically important is in relation to foods high in 
vitamin K (e.g. broccoli, spinach, cabbage, brussel sprouts and lettuce) and 
changes in the consumption of these may lead to alterations in INR (Lip et 
al., 2010).  Drinking alcohol to excess may also interfere with warfarin 
metabolism (Nutescu et al., 2006).  
5. Genetic factors 
Complex genetic factors can lead to affected individuals having a low 
tolerance to warfarin. This effect is due to polymorphism of in two main 
genes (CYP2C9 and VKORC1). Studies have confirmed variation in the 
prevalence of these different polymorphisms in different populations. It is 
estimated that these genetic factors, in addition to the non-genetic factors 
described above, account for up to 50% of warfarin dose variability. Several 
algorithms of patient characteristics to consider in relation to genetic factors 
have been developed by the Warfarin Pharmacogenetics Consortium (Johnson 
et al., 2011) 
In summary, while there are very many systematic reviews highlighting the 
safe and effective use of warfarin in the management of non-valvular AF, it is 
far from ideal. Recent years have seen marked changes in the availability and 
prescription of oral anticoagulants worldwide with the introduction of a new 
class of agents, the Direct Acting Oral Anticoagulants, the subject of this 
doctoral research. 
1.6 Direct Acting Oral Anticoagulants (DOACs) 
1.6.1 Name of drug class 
The introduction of dabigatran to the UK market in 2008 was followed by 






‘new’ or ‘novel’ oral anticoagulants (NOACs), the International Society of 
Thrombosis and Haemostasis has suggested that ‘direct-acting oral 
anticoagulant (DOAC)’ be adopted universally (Barnes et al., 2015). This is 
more consistent with the pharmacotherapeutic classifications of direct 
thrombin inhibitors (dabigatran) or directed Factor Xa inhibitors (rivaroxaban, 
apixaban, edoxaban) (Gomez-Outes et al., 2015). The term DOAC will 
therefore be used throughout this thesis.  
1.6.2 Mechanism of action of DOACs 
Figure 1.4 illustrates the sites of action of DOACs on the coagulation cascade (Mejaj 
et al., 2015).  
 
 
As DOACs directly inhibit either thrombin or activated factor X, they have a 
faster onset and offset of action compared to warfarin. In the UK, all four 
DOACs are licensed for stroke prevention in the management of non-valvular 
AF.  
1.6.3 DOAC pharmacokinetics 
In comparison to warfarin, DOACs have predictable pharmacokinetics. In 
general, they are rapidly absorbed following oral administration and have 
relatively short half-lives. A comparison of key pharmacokinetic properties of 










1.6.4 Disadvantages of DOACs 
In addition to predictable pharmacokinetics, the pharmacodynamic properties 
of DOACs are also predictable. Drug dosages are fixed (other than in those 
with hepatic or renal impairment) hence there is no need for monitoring 
anticoagulation status (Mosotti et al., 2013). Disadvantages of DOACs are 
described using the same headings as warfarin.   
Pharmacokinetic 
parameter 
Dabigtatran Rivaroxaban Apixaban Edoxaban 
Bioavailability (%) 6 80-100 50 62 
Time to maximum 
concentration (hrs)  
0.5-2  2-4 3-4 1.5 
Protein binding (%) 35 92-95 87 55 
Half-life (h) 14-17 5-13 12 6-11 
Metabolism Glucuronidation CYP3A4 CYP3A4/5 CYP3A4/5 
Renal excretion (% 
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Protein binding (%) 35 92-95 87 55 
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1. Therapeutic window 
Unlike warfarin, DOACs have wide therapeutic windows hence the potential 
for adverse events is reduced. Reported adverse events include bleeding, 
abdominal pain, nausea, vomiting, dyspepsia and diarrhoea. Reversal of 
over-anticoagulation with DOACs is less straightforward than warfarin. 
Idarucizumab has only very recently been licensed for use in the UK and is 
indicated to reverse dabigatran in patients with life threatening haemorrhage 
or need for urgent surgery (Pollack et al., 2015). No antidotes are currently 
available for the other three DOACs. Given that DOACs are relatively new to 
the market, post-surveillance monitoring and spontaneous reporting of all 
suspected adverse events is required (Mekaj et al., 2015 ).  
 
2. Need for regular monitoring 
As noted above, there is no requirement for monitoring anticoagulation 
status. Furthermore, the results of INR testing in patients prescribed DOACs 
are unreliable given the different modes of action on the coagulation cascade 
(Jackson et al., 2014).  
 
3. Potential drug-drug interactions 
The potential for clinically important interactions between DOACs and other 
drugs is greatly reduced in comparison to warfarin. Drug interactions can, 
however, occur during absorption, distribution and clearance. 
Pharmacokinetic interactions are medicated by the P-gp transporter protein 
and the cytochrome P450 enzymes, with inhibitors including clarithromycin 
and inducers including carbamazepine. Pharmacodynamic interactions include 
the risk of bleeding when given concomitantly with non-steroidal anti-
inflammatory drugs (NSAIDs) (Hellwig  et al., 2013). 
 
4. Potential drug-food interactions  
DOACs can be administrated before, during or after food, including vitamin-K 






5. Genetic factors  
The evidence base relating to polymorphism and DOACs is emerging, 
highlighted by the considerable inter-individual variations which have been 
detected. The first study on dabigatran polymorphism was published in 2011 
and since then further polymorphisms for all DOACs hence been identified. 
The significance of these effects and implications for clinical practice are now 
being studied.  
 (Asic  et al., 2018).  
 
1.6.5. Evidence of effectiveness and safety 
There is an extensive evidence base to support the adoption of DOACs into 
clinical practice. A search of Medline for was conducted for each of the years 
from 2008 to 2018, using the terms  
[‘systematic review*’ OR ‘meta-analysis’] in the title  
AND 
[‘direct oral anticoagulant*’ OR ‘new oral anticoagulant*’ OR ‘novel oral 
anticoagulant* OR ‘dabigatran’ OR ‘rivaroxaban’ OR ‘edoxaban’ OR 
‘apixaban’] in the title. 
This search identified 240 systematic reviews, largely relating to efficacy, 
effectiveness and safety. The increase in systematic reviews since the entry 
of DOACs to the market in 2008 is given in Figure 1.5. At the time of 
commencing this doctoral research, there was a major gap in relation to 
clinicians’ views and experiences of prescribing DOACs for non-valvular AF. 
The one systematic review on this topic published in 2018 is from this thesis 
and described in Chapter 4 (Generalova et al., 2019). Further research on 
aspects of prescribers’ views and experiences in prescribing DOACs is 








Figure 1.5. Graph of the number of published DOAC-related systematic reviews per 
year  
 
1.7 Guidelines on the use of DOACs in the management of non-
valvular AF 
As a result of the evidence supporting the use of DOACs in the management 
of non-valvular AF, these have now been incorporated into local, national and 
international prescribing guidance and policy statements. The following 
sections describe international and national guidelines (UK and Scotland). 
Guidelines available in NHS Highland (the setting for the primary research, 
see later) are also described.  
 
1.7.1 International guidelines 
There are many examples of international guidelines on the use of DOACs 
generally and specifically relating to non-valvular AF. Key examples are those 
developed by the European Society of Cardiology (Camm et al., 2010), the 
American College of Cardiology/ American Heart Association Task Force on 
Practice Guidelines and the Heart Rhythm Society (January et al., 2014), and 
the recently updated 2018 Practical Guide from the European Heart Rhythm 
Association (Steffel et al., 2018). Table 1.7 describes the key content of 



































recommended by the American College of Cardiology guidelines, these 
preceded the introduction of edoxaban. As the guidelines of the European 
Heart Rhythm Association specifically focus on DOACs, there are much more 
detailed in relation to all aspects of DOACs including switching, advice for 






Table 1.7. Content of international guidelines in relation to the use of DOACs in non-valvular AF (January et al. 2014, Kirchhof et 
al., 2016, Steffel et al., 2018).  
Key content of 
guideline  
American College of 
Cardiology/ American Heart 
Association Task Force on 
Practice Guidelines and the 
Heart Rhythm Society 
European Society of Cardiology European Heart Rhythm 
Association 
Year of publication 
 
2014 2016 2018 
Title 
 
Guideline for the management of 
patients with AF 
Guidelines for the management of 
AF 
 
Practical guide on the use of non-
vitamin K antagonist oral 
anticoagulants in patients 
with AF 
Includes guidance on the 
selection of an oral 
anticoagulant  
(DOAC or warfarin)  
 
Yes  Yes  Yes  
 
DOAC recommended first 
choice in preference to 
warfarin 
 




Dabigatran, rivoroxaban, apixaban Dabigatran, rivaroxaban, apixaban, 
edoxaban  






Yes  Yes  Yes  
Guidance on switching 
to/from warfarin 
 
No guidance No specific guidance but 
recommended switch from warfarin 
if time in therapeutic is not well 
controlled despite good adherence, 
or if patient preference without 
contra-indications  
Yes, specific and detailed guidance 
on how to switch  
Recommended patient 
involvement in decision 










1.7.2 UK guidelines 
The National institute for Health and Care Excellence (NICE), provides advice 
to improve health and social care in England and Wales (NICE, 2014). In 
2014, NICE disseminated guidance on the management of AF which 
recommended dabigatran, rivaroxaban, apixaban or warfarin in those with 
non-valvular AF (NICE, 2014). As with the American College of Cardiology 
guidelines, NICE guidance preceded the introduction of edoxaban. This 
guidance has translated into practice, evidenced by a 
pharmacoepidemiological study of DOAC prescribing in primary care in the UK 
from 2009 to 2015. Data were extracted from the UK Clinical Practice 
Research Datalink. Results highlighted substantial increases in prescribing 
over the study period. The rate of new DOAC users increased, particularly 
from 2012 onwards with a 17-fold from 2012 to 2015. By 2015, DOACs had 
surpassed warfarin as the oral anticoagulants of choice, particularly for the 
management of AF (Loo et al., 2017).  
1.7.3 Scottish guidelines 
Healthcare Improvement Scotland (HIS) is the national healthcare 
improvement organisation for Scotland (HIS, 2012 ). The five key priorities 
are: 
• Enabling people to make informed decisions about their care and 
treatment. 
• Helping health and social care organisations to redesign and 
continuously improve services. 
• Provide evidence and share knowledge that enables people to get the 
best out of the services they use and helps services improve. 
• Provide quality assurance that gives people confidence in the services 
and supports providers to improve. 
• Making the best use of resources, we aim to ensure every pound 
invested in our work adds value to the care people receive. 
In 2017, HIS updated their guidance on the use of DOACs with the 
publication of ‘A review of the clinical effectiveness of direct oral 
anticoagulants for the prevention of stroke and systemic embolism in adult 






recommended dabigatran, rivaroxaban and apixaban for patients not 
responding well to warfarin (HIS, 2012). The update noted a lack of direct 
comparisons between DOACs hence the recommendations were based 
entirely on indirect evidence from published network meta-analyses. 
Edoxaban is recommended as first line treatment with the other three DOACs 
being second line.   
1.7.4 NHS Highland guidelines 
The primary research described in Chapters 4 and 5 was conducted within the 
NHS Highland region of Scotland hence further emphasis is placed on the 
specific guidelines within that health board. The seventh edition of the NHS 
Highland formulary was published in January 2018. The formulary is 
described as ‘…limited list of medicines approved for local use in hospitals and 
primary care’. Choice is made on the basis of clinical effectiveness, cost-
effectiveness, comparative safety and patient acceptability. 
Recommendations for oral anticoagulants in the management of non-valvular 
AF follow the national guidance of HIS (NHS Highland, 2018).  
1.8 NHS Highlands 
As described above, the primary research was conducted within the 
geographical area of NHS Highland.  NHS Highland is largest geographical 
health board in the UK, covering approximately 32500 km2 and 41% of the 
entire land mass of Scotland. This is significant given that the population is 
320,000 people which is less than 10% of Scotland population. One quarter 
of the population live in ‘urban areas’ (defined as settlements ≥10000 people 
compared to 69.5% of the entire population of Scotland. Moreover 40.4% of 
population live in remote and rural areas (areas with a population of less than 
3,000 people). Studies have demonstrated that for many people, access to 
hospitals, general medical practices and community pharmacies is limited 
(Stewart et al., 2017). Responsibility for the management of stroke 
prevention in patients with non-valvular AF is usually undertaken in primary 
care although patients can also be initiated on therapy in secondary care if 
they attend outpatient clinics or during admission. Figure 1.6 provides 
analysis of primary care prescribing of warfarin and DOACs indicating a 






While these data relate to prescribing for all indications, it is highly likely that 




Figure 1.6. Number of items of warfarin and DOACs dispensed, NHS Highland  
 
It is clear that DOACs are now first line for the management of non-valvular 
AF. There is a vast array of evidence from systematic reviews and meta-
analyses of effectiveness, efficacy and safety and this evidence has translated 
into clinical guidelines and daily practice. However, there is a dearth of 
evidence on the views and experiences of prescribers. This information is 
critical as positive or negative views and experiences may impact prescribing 
behaviours. This doctoral research set out to provide robust and rigorous 































1.9 Aims and objectives of the doctoral research 
 
The overall aim of this research was to determine clinicians’ views and 
experiences of the use of DOACs for the management of non-valvular AF.  
There are three phases of the doctoral research each with aims as described 
below. 
Phase 1: To critically appraise, synthesise and present the available 
evidence of clinicians’ views and experiences of the use of DOACs for the 
management of non-valvular AF.  
In relation to DOACs for the management of non-valvular AF: 
1. what are clinicians’ views of the use of DOACs? 
2. what are the influences on clinician’s use of DOACs? 
3. what are clinician’s experiences, both positive and negative? 
 
Phase 2: To determine prescribers’ views, experiences and behaviours 
relating to prescribing DOACs for the management of non-valvular AF. 
 
In relation to prescribers and DOACs, the research questions were: 
1. how are DOACs initiated, prescribed and monitored? 
2. which behavioural determinants impact behaviours around prescribing 
DOACs?  
3. what are the perceived benefits and limitations of prescribing DOACs?  
4. what are the positive and negative experiences of prescribing DOACs? 









Phase 3: To determine prescribers’ views, experiences and behaviours 
relating to prescribing edoxaban for the management of non-valvular AF. 
 
The detailed research objectives in relation to prescribing edoxaban for the 
management of non-valvular AF:  
1. how is edoxaban initiated, prescribed and monitored? 
2. which behavioural determinants potentially impact behaviours around 
prescribing edoxaban?  
3. what are the perceived benefits and limitations of prescribing DOACs?  
4. what are the positive and negative experiences of prescribing DOACs? 
 
 1.10. Chapter summary 
This chapter has described the background literature on AF, non-valvular AF, 
stroke protection and the role and place of oral anticoagulants. It is clear that 
there is a need to research the perspectives of DOAC prescribers and this 







CHAPTER 2: RESEARCH METHODOLOGIES 
This chapter provides justification of the research approaches employed, with 
consideration of the value in conducting systematic reviews and the use of 
quantitative and qualitative approaches. Research methodologies are 
outlined, with emphasis on the application of theories and theoretical 
frameworks. Issues of robustness, rigour and bias are described, along with 
approaches to enhance robustness and rigour whilst minimizing bias.  
  
2.1 Research Philosophy 
This section provides an overview of different philosophical approaches in 
conducting research, with justification for the approach selected and applied 
in this doctoral research.  
The following figure of the ‘research onion’ highlights the interplay between 
philosophy, approaches and methodologies.  
 
Figure 2.1. The research onion (Understanding the Research Onion)   
While there are many different philosophical approaches, depending on the 






and pragmatism. Other sources extend this to include constructivism, 
hermeneutics, feminism, radicalised discourses, critical theory, Marxist 
models, cultural studies, queer theory etc. (Creswell, 2014). Positivism 
assumes that reality exists and can be measured; a deductive 
approach is taken starting with generation of a hypothesis which is tested 
using quantitative approaches. The methods and results are capable of being 
replicated by other researchers. The positivist approach has often been 
considered as the ‘scientific’ or ‘traditional’ approach, using experiments to 
study objective outcomes. The researcher collects data to allow conclusions 
of accepting or rejecting a null hypothesis (and hence accepting the 
alternative hypothesis (Creswell, 2014). The positivist philosophical approach 
therefore aligns with quantitative research methodologies.  
At a certain level, realism and positivism share many similarities. Realism, 
however, attempts to distinguish between the 'real' world and the 
'observable' world. While the ‘observable’ world is observed or as perceived 
by individuals (or groups, populations and societies), the 'real' world is real 
and not as observed. It there exists independently from human perceptions, 
theories, and constructions (Dean, 2006).  
Interpretivism involves researchers using observations to interpret elements 
of study thus integrating human interest. Access to reality (given or socially 
constructed) is through social constructions such as language, consciousness, 
shared meanings, and instruments (Myers, 2008). Interpretivism therefore 
aligns with qualitative research methodologies and may involve generation of 
the theories which can then be tested using positivist approaches.  
The pragmatic approach is considered to be a worldview of actions, situations 
and consequences in which researchers use all approaches available to 
understand the problem and answer specific research questions. This 
approach is frequently used in applied research, with many aligning it with 
mixed methods research. Researchers choose the methods, techniques and 
procedures of research which meet their needs and purposes (Creswell, 
2014).    
This doctoral research most closely aligns with the positivist stance. The 






studies which were therefore objective in nature. The cross-sectional surveys 
presented in Chapters 4 and 5 were, by definition, quantitative 
methodologies designed to answer specific research aims and objectives and 
involved many quantitative statistical approaches including testing of 
hypotheses and drawing conclusions based on probability values. While the 
analysis included a qualitative content analysis approach, this was not a pure 
qualitative methodology hence the data generated and the subsequent 
synthesis were limited.  
The next layer of the research onion classifies research as deductive or 
inductive. Essentially, the deductive approach relates to testing theory or 
theoretical assumptions. The four stages of the deductive approach are: 
stating the existing theory; developing the hypothesis; collecting data; and 
analysing the data to draw conclusions relating to the hypothesis (Streefkerk, 
2019). The deductive approach therefore aligns with a quantitative, positivist 
approach, although this term is also used in relation to approaches to 
qualitative data analysis in situations where data generation and analysis is 
driven by a theory or framework.  
With an inductive approach, the focus is more on developing, rather than 
testing, a theory. The three stages are: observation; observing patterns; and 
developing theory (Streefkerk, 2019). Inductive approaches are generally 
used for analysing qualitative data involving condensing raw textual data into 
a brief, summary format. This is followed by establishing clear links to 
develop a framework of the underlying structure of experiences or processes 
(Thomas, 2006). An inductive approach was employed in this doctoral 
research in relation to the analysis of textual comments provided by 











2.2 RESEARCH DESIGN  
The doctoral research was conducted in three specific phases, each aligned to 
the research aims and objectives outlined in Chapter 1, as follows 
Phase 1  
Aim To critically appraise, synthesise and present the available 
evidence of views and experiences of healthcare 
professionals surrounding DOACs for the management of 
non-valvular AF 
Design   Systematic review of the peer-reviewed literature 
 
Phase 2 
Aim To determine prescribers’ views and experiences relating 
to prescribing DOACs for the management of non-valvular 
AF 
Design   Cross-sectional survey  
Phase 3  
Aim  To determine prescribers’ views and experiences relating 
to prescribing edoxaban for the management of non-
valvular AF 
Design   Cross-sectional survey  
 
2.3 SYSTEMATIC REVIEW OF THE PEER-REVIEWED LITERATURE    
2.3.1 TYPOLOGY OF LITERATURE REVIEWS  
There are very many different terms used to describe the various types of 









Table 2.1. Typology of literature reviews (Grant M., et al., 2009) 
Types of review  Description 
Critical review  Review with emphasis on critical evaluation 
 
Mapping review  Categorises literature, often used to commission primary 
research by identifying gaps in the literature 
 
Narrative review  Traditional overview of the literature in a specific field  
 
Rapid review  Review conducted rapidly, often only including very recently 
published literature; used in developing policy 
 





Review of recent literature in a specific field, with findings 




Conducted to answer a very clear review question, with 
approach outlined in a detailed review protocol. May include 





A truncated version of a systematic review 
Umbrella review  Pools evidence from several systematic reviews  
  
Narrative literature reviews and systematic reviews are the two most 
frequently published within the healthcare literature. While narrative reviews 
are broad overviews within a research field, systematic reviews aim to 
answer specific review questions. For this doctoral research, a systematic 
review was the most appropriate to generate pooled data on health 
professionals’ views and experiences of DOACs in the management of non-
valvular AF.  
Systematic reviews are considered to provide the very highest level of 







Table 2.2. Descriptions of levels of evidence applied to therapeutic studies (SIGN, 
2013) 
Level  Type of evidence 
1++ High-quality meta-analyses, high-quality systematic reviews of clinical trials 
with very little risk of bias 
 
1+ Well-conducted meta-analyses, systematic review of clinical trials or well-
conducted clinical trials with low risk of bias. 1- Meta-analyses, systematic 
reviews of clinical trials or clinical trials with high risk of bias 
 
2++ High-quality systematic reviews of cohort or case and control studies; cohort 
or case and control studies with very low risk of bias and high probability of 
establishing a causal relationship 
 
2+ Well-conducted cohort or case and control studies with low risk of bias and 




Cohort or case and control studies with high risk of bias and significant risk 










It should be noted that while the systematic review presented in Chapter 3 
provided pooled and synthesised data, the studies were largely cross-
sectional surveys hence the review itself provided a lower quality of evidence 
that a review of RCTs.  
 
2.3.2 Conducting systematic reviews 
Systematic reviews are conducted according to a protocol meeting defined 
criteria and standards. The PRISMA-P (Preferred Reporting Items for 
Systematic reviews and Meta-Analyses for Protocols) is a 17 items checklist 
categorised in three main sections of administrative information, introduction, 
and methods (Moher et al., 2015). The systematic review protocol was 
registered with the International Prospective Register of Ongoing Systematic 
Reviews (PROSPERO), an international database of all registered systematic 
reviews established by the Centre for Reviews and Dissemination, University 







2.4 Primary research approaches 
2.4.1 Quantitative and qualitative research methodologies 
Primary research methodologies in healthcare are classified as quantitative or 
qualitative (referred to as ‘mono’ method in the research onion in Figure 2.1). 
Mixed methods approaches describe the application of both quantitative and 
qualitative approaches (sequentially, in parallel or nested) to answer the 
same or related research questions. Multi-methods studies involve utilizing a 
number of approaches to answer distinct research questions. 
 
While research phases 2 and 3 were essentially quantitative in nature (cross-
sectional surveys), a more qualitative approach was also employed in the 
analysis of textual responses and summative content analysis). A comparison 
of quantitative and qualitative research approaches is given below describing 
how these differ with respect to the research aim, research questions, 
objectives, data collection and generation instruments, and data they 
produce (Rwegoshora, 2016). 
 
As described earlier, quantitative approaches align with a positivist 
philosophy, assuming that reality exists and can be measured. Quantitative 
approaches rely on numerical data (i.e. outcome measures linked to specific 
research questions or objectives) which can be measured, with steps taken to 
assure the validity (accuracy) and reliability (consistency) of the data 
collection tools, methods and the data collected (Creswell, 2014). The 
common quantitative methodologies are experimental (randomised controlled 
trials) and non-experimental (cohort studies, case control studies and 
surveys). The research questions and objectives studied reflect the need to 
study outcomes based on careful observation and measurement of the 
objective reality. Depending on the nature of the specific research questions 
or objectives and methodology, the objective, measured, ‘real’ data may be 
used to determine prevalence, incidence, association or cause (taking into 
consideration issues of validity, reliability, bias, confounders etc.). Formal 
approaches to sample size calculation are employed, with researchers 






data, results and conclusions (see later). (Bowling 2009, Creswell 2013, 
Johnson and Onwuegbuzie 2004).  
Qualitative methodologies align with the interpretivism stance (although may 
also feature in realism and pragmatic approaches) and focus on the 
generation of rich data to allow in-depth description and understanding of 
phenomena, context, culture and the development of theory. While 
qualitative methodologies have traditionally been regarded as less scientific 
than quantitative approaches, their use and popularity in healthcare research 
has grown in more recent times. They are often used as part of mixed 
methods approaches (sequential, parallel, nested) to provide explanation of 
quantitative findings. While validity and reliability of quantitative research 
tools and data can be measured, tested and assured, quality assurance of 
qualitative research is much more challenging and cannot be measured or 
assured. Steps are taken to promote the trustworthiness of the data 
generation tools, methods and the data generated (see later). The main 
qualitative methodologies are narrative, phenomenology, grounded theory, 
ethnography and case studies. While quantitative research data are generally 
collected from larger sample sizes with the aspiration of internal and external 
validity, answering questions such as association, cause etc., this is not the 
case with qualitative research. Here, the approach generates detailed and 
rich description of the research topic from much smaller sample sizes. There 
is no intention of generalising the data, findings or conclusion beyond those 
studied. Approaches to data collection are varied, commonly involving 
interviews, focus groups, observation and documentary analysis. Data 
analysis approaches are markedly different compared to quantitative 
research, with no intention to test hypotheses. Indeed, qualitative research 
may results in the generation of theory which can then be used to develop 
hypotheses for future quantitative studies. The role of the researcher in 
quantitative research is one of data collector, with no influence on the data 
collected. In qualitative research, the research is a data generator hence the 
need for significant training, expertise and focus on research trustworthiness 
to reduce influence as much as possible (Bowling 2009, Creswell 2013, 






Key quantitative and qualitative research methodologies are described and 
compared in Table 2.3.  
Table 2.3. Description of commonly used quantitative and qualitative methodologies 







Quantitative methodologies Qualitative methodologies 
Randomised controlled trials (RCT) in 
which participants are randomised into 
different groups to received treatments 
of intervention, comparator or placebo. 
Sample sizes are generally large and 
determined based on the power of the 
study to identify a clinically important 
difference.  
Narrative relates to the spoken or written 
text describing a single event or a series 
of events from the perspectives of 
individuals, which are chronologically 
connected. Tends to include very small 
sample sizes.  
Cohort studies of individuals identified 
and followed up to identify how 
exposure affects defined outcomes. Data 
from exposed and non-exposed cohorts 
are compared, aligned to specific 
hypotheses. 
Phenomenology provides an 
understanding of the real-life 
experiences of the participants relating 
to a specific phenomenon or event. 
Often based on a specific theory or 
theoretical framework to capture and 
describe the essence of the experience.  
Case-control studies in which two groups 
differing in outcome are compared based 
on a supposed causal attribute. Cases 
and controls are selected from the same 
source population, with the distribution 
of exposure between cases and controls 
expressed as an odds ratio. 
 
Grounded theory aims to develop theory 
constructed from the data of individuals 
by making links between categories of 
data and postulating relationships. 
Involves analysing data through open 
coding, axial coding and selective 
coding.  
Surveys are an approach to describe 
phenomena in real-life situations to 
determine meanings and frequencies of 
the phenomenon under investigation. 
Data are collected through a specific 
data collection questionnaire. The 
specific nature could be cross-sectionals 
or longitudinal.  
Ethnography studies social interactions, 
behaviours and perceptions within 
groups, teams, organisations and 
communities. Aims to generate and an 
in-depth understanding of a particular 
culture.  
 
Case study explores a case (or multiple 
cases) through in-depth data generation 
involving multiple sources of information 







Following completion of the systematic review in phase 1, the next two 
phases were cross-sectional surveys to allow quantification of the views and 
experiences of prescribers of DOACs. A non-experimental, quantitative 
methodology was considered most appropriate to meet the specific aims and 
objectives, which were more objective in nature. While a qualitative or mixed 
methods approach would have generated in-depth data, the extent of free 
text comments received in response to the open questions were considered 
sufficient. These were analysed using a qualitative approach of summative 
content analysis. The next section describes cross-sectional studies in greater 
detail.  
 
2.4.2 CROSS-SECTIONAL SURVEYS  
A cross-sectional methodology is defined as a research design, which 
‘provides a quantitative or numeric description of trends, attitudes, or options 
of a population by studying a sample of that population’ (Creswell, 2014). 
Surveys can be used to describe a study population, to investigate any 
associations between variables, trends and determine if associations are 
statistically significant. As described earlier, these align with the positivist 
philosophical stance. The research aim, questions or objectives are framed in 
an objective manner, using terms such as ‘determine’, ‘quantify’, correlate’, 
‘associate’ etc. Sample sizes are much larger than for qualitative research 
and are calculated a priori., with the form of calculation depending on the 
specific research questions or objectives. The sample is usually drawn from a 
larger population (sampling frame) unless the population is relatively small. 
Defined inclusion and exclusion criteria are stated. The data collection tool is 
the questionnaire which may be self-administered by the research participant 
having been sent by mail or increasingly via email or other electronic modes 
(internet, social media etc). The questionnaire may be administered by a 
researcher, particularly if the questions are difficult to understand, the 
subject sensitive or the study population unable to complete. Table 2.4 







The questionnaire itself is developed according to the study research 
questions or objectives, reflecting the literature and grounded in any 
appropriate theory or theoretical framework (see later). The questionnaire is 
then pre-tested through a series of stages in terms of validity (e.g. face, 
content, construct, criterion) and reliability. This is then followed by piloting, 
which may be internal (i.e. using some of the future study participants) or 
external (i.e. using non-study participants but individuals similar to those 
described in the inclusion/ exclusion criteria).  
Given the specific study research questions, a cross-sectional survey was 
considered appropriate, with an electronic delivery mode selected for several 
reasons including convenience, an easily defined study population with email 
addresses available to the research team, and cost.  
 
Table 2.4. Advantages and disadvantages of electronic compared to paper based 
questionnaires (Bowling, 2014).  
Advantages  Disadvantages  
Greatly reduced costs in 
production and mailing  
  
Some evidence of lower response 
rate 
Less time taken in questionnaire 
administration 
 
Need access to participant emails 
Can have automatic data entry to 
analysis software 
  
Limited if internet connection 
problems  
 
Multiple approaches were used in an attempt to maximise the response rates 
(see Chapters 4 and 5). A systematic review by VanGeest et al. identified a 
number of evidence based approaches to maximizing questionnaire response 
rate. These included: design-based (e.g. personalized mails, design-friendly 
questionnaires); use of reminders; clear explanation of the potential benefits 
of the study; assurances of confidentiality and anonymity; and link to an 
academic institution (VanGeest et al., 2007). 
Sample size and sampling require specific consideration for surveys. 
Sampling is essentially the process of selecting of a particular group of 






studies, a number of probability approaches to sampling are available, as 
described in Table 2.5.  




For the cross-sectional surveys reported in Chapters 4 and 5, the number of 
participants with experience of prescribing DOACs was unknown and could 
not be determined prior to the study hence there was no sampling and the 
entire populations surveyed.  
The approach to data analysis in Chapters 4 and 5 was largely quantitative 
based on descriptive and inferential statistics. For the inferential statistics, 
several hypotheses were stated (null and alternative) and appropriate tests 
selected depending on the particular hypothesis, distribution of the data and 
number of dependent and independent variables. 
Given the number and extent of textual responses to the small number of 
open questions, a content analysis approach was considered the most 
appropriate. Content analysis essentially involves several steps of data 
coding, comparison, and the identification and description of categories or 
themes (Cavanagh, 1997; Bowling, 2009). Hsiech et al. (2005) describes 
three forms and approaches of content analysis, namely conventional, 
directed and summative.  
Types of sampling  Definition  
Random  Selected from the population based on 
chance. Each individual in the population 
has an equal opportunity of being 
selected 
 
Systematic Similar to simple random sampling, but 
participants are chosen at specific 
intervals, e.g. every 20th  
 
Stratified  Population is divided into homogenous 
subgroups, based on prior knowledge of 
the population (e.g. age, sex) before 
randomly sampling from each subgroup 
 
Cluster  Similar to stratified in that population 
exist in certain pre-defined groups (e.g. 






Conventional content analysis is generally considered to be observation 
driven, with codes identified during analysis and applied to the dataset. This 
is in contrast to conventional directed content analysis in which existing 
theory or prior research is used to develop the initial coding scheme prior to 
analysis. In summative content analysis, the approach is fundamentally 
different with the analysis focusing on single words (keywords) with analysis 
of the patterns leading to interpretation (Hsieh et al., 2005). This latter 
approach involves counting and classifying these keywords in analysis and for 
presentation of the findings. It should be noted that these keywords are 
‘counted’ rather than ‘quantified’ signaling that this is not a quantitative 
approach and that the counts are to allow interpretation rather than 
representing percentages of a specific population. Given that the textual data 
were generated in response to a small number of open ended statements in 
the questionnaire providing opportunity for further comment, a summative 
content analysis approach was considered most appropriate. There was no 
intention to either use theory or derive theory from the findings, more just to 
describe the responses hence a narrative synthesis was employed. As Heieh 
et al. state, summative content analysis approaches are ‘limited by their 
inattention to the broader meanings present in the data’ (Hsieh et al., 2005). 
 
 
2.5 Use of theory in research 
Theory is increasingly being used in quantitative, qualitative and mixed 
methods research. A theory is defined as ‘a set of interrelated constructs 
(variables), definitions and propositions that presents a systematic view of 
phenomena by specifying relations among variables, with the purpose of 
explaining natural phenomena’ (Kerlinger, 1979). Using theory in research 
increases the quality in several ways 
• Allows the researchers to justify the research rationale from a 
theoretical as well as pragmatic perspective 
• Encourages the researchers to state the research aim, questions, 






• Facilitates the development of research tools (questionnaires, interview 
schedules), which are comprehensive, considering a wide range of 
factors, issues etc.  
• Facilitates the development of comprehensive coding frameworks for 
qualitative research 
• Allows the researchers to consider data interpretation in a more 
theoretical and comprehensive manner 
• Allows the researchers to contribute to the development of the theory 
(Bradbury-Jones  et al., 2014) 
For the systematic review, theory was used in the quality assessment and 
data extraction stages and aided the identification of gaps in the literature. 
Theory was also used in the development of the cross-sectional survey 
questionnaires and in data analysis and interpretation.  
 
2.5.1 Theoretical Domains Framework 
Given that the focus of the research was the experiences resulting from 
prescribing DOACs (i.e. the practice or behaviour), behavioural theories were 
selected as being most relevant (Creswell, 2014). The Theoretical Domains 
Framework (TDF) is not a theory but rather a framework of theories of 
behaviour and behaviour change. TDF was developed by a group of 
psychological theorists, health service researchers and health psychologists 
(Michie et al. 2005). The aim of TDF is to ‘…simplify and integrate a plethora 
of behaviour change theories and make theory more accessible to, and 
usable by, other disciplines’. TDF was derived from 33 psychological theories 
and 128 theoretical constructs. These constructs are organised into 
overarching domains (groups of related theoretical constructs); initially there 
were 12 domains of TDF and this has now been extended to 14, as described 











Knowledge An awareness of the existence of something 
 




A coherent set of behaviours and displayed 
personal qualities of an individual in a social or 
work setting 
 
Beliefs about Capabilities Acceptance of the truth, reality, or validity about 
an ability, talent, or facility that a person can put 
to constructive use 
 
Optimism The confidence that things will happen for the 
best or that desired goals will be attained 
 
Beliefs about Consequences Acceptance of the truth, reality, or validity about 
outcomes of a behaviour in a given situation 
 
Reinforcement Increasing the probability of a response by 
arranging a dependent relationship, or 
contingency, between the response and a given 
stimulus 
 
Intentions A conscious decision to perform a behaviour or a 
resolve to act in a certain way 
 
Goals Mental representations of outcomes or end states 
that an individual wants to achieve 
 
Memory, Attention and 
Decision Processes 
The ability to retain information, focus selectively 
on aspects of the environment and choose 
between two or more alternatives 
 
 
Environmental Context and 
Resources 
Any circumstance of a person's situation or 
environment that discourages or encourages the 
development of skills and abilities, independence, 
social competence, and adaptive behaviour 
 
Social influences Those interpersonal processes that can cause 
individuals to change their thoughts, feelings, or 
behaviours 
 
Emotion A complex reaction pattern, involving 
experiential, behavioural, and physiological 
elements, by which the individual attempts to 
deal with a personally significant matter or event 
 
Behavioural Regulation Anything aimed at managing or changing 






TDF was used in the development of questionnaire items to allow 
comprehensive consideration of the positive and negative influences in 
prescribing, as described in Chapters 4 and 5.  
 
2.6 ROBUSTNESS AND RIGOUR IN RESEARCH  
2.6.1 ROBUSTNESS IN QUANTITATIVE RESEARCH  
Internal validity, external validity and reliability are the criteria to consider in 
achieving the goal of robustness in quantitative research. Essentially, validity 
is ‘the accuracy and truth of the data being produced in terms of the concepts 
being investigated’ (Heale  et al., 2015). Internal validity relates to the 
confidence placed in the research processes together with data collected 
while external validity (generalisability) is the extent to which the findings 
can be extrapolated to other populations, settings etc. (Hasson and Keeney, 
2011). While there are a number of different approaches to determining 
validity (e.g. face, content, construct, criterion, concurrent, predictive etc.) 
those employed in the cross-sectional surveys were largely face and content. 
Face validity is the extent to which a questionnaire covers the concepts it 
purports to measure in terms of transparency or relevance. Content validity 
considers the extent to which a questionnaire represents all facets of a given 
construct (Hasson F., Bolarinwa  2015, Holloway  2014).  
Reliability is the extent to which results are consistent over time. While there 
are several approaches to determining reliability of the tool (e.g. test-retest 
reliability) (Chahal et al., 2014), these could not be applied due to the online 
nature of the cross-sectional surveys. Internal consistency was determined 
(see later).  
2.6.2 Rigour in qualitative research 
In qualitative research, the concepts of validity and reliability are less 
relevant, with more attention given to the trustworthiness of the research 
processes, data, findings and conclusions. Trustworthiness is described as 







Table 2.7. Components of research trustworthiness applied to qualitative research 
(Tobin and Begly, 2004) 
 
Trustworthiness  Description 
Credibility  Credibility is similar to internal validity, asking whether 
the findings are a true reflection of reality. Promoted 
by: using well-established methodologies and 
methods; providing detailed description of the 
phenomenon studied; encouraging participant 
honesty; and meeting with team members frequently 
for debriefing sessions and peer review 
 
Dependability  Similar to reliability, described as the extent to which 
similar findings would be obtained if the study were 
repeated with the same methods etc.  
 
Transferability Similar to external validity. Achieved by providing 
detailed information to enable readers to consider the 
applicability of the study to their own setting  
 
Confirmability  Concerned with establishing that the data and 
interpretation of the findings are derived from the 




As a qualitative approach was only employed in the analysis of textual data, 
many of these concepts were not relevant, as described in later chapters.  
 
2.6.3 Bias as a threat to validity, reliability and trustworthiness 
Bias occurs when ‘systematic error is introduced into sampling or testing by 
selecting or encouraging one outcome or answer over others’ (Bowling, 
2014). The specific types of research bias and the approaches employed to 
minimise these when conducting and reporting the cross-sectional surveys 








Table 2.8 Research biases and approaches to minimize (Bowling, 2009)  
Bias Description Approach to minimise  
Selection (sampling) bias  Sample is not 
representative of the 
population interest 
All prescribers were 
invited to participate, with 
no selection (sampling) 
Acquiescence response 
bias  
Respondents more likely 
to respond positively  
 
Range of question styles 
used, including negatively 
worded items 
 
Response bias Respondents provides 
non-honest and inaccurate 
answers  
Clear statements of the 
purpose of the study, 
potential uses of the data 




Non-respondent bias Those responding have 
very different views and 
experiences to those not 
responding 
Various approaches to 
maximise the response 
rate 
Social Desirability bias The tendency to give a 
socially desirable answer 
even if it is not true  
Clear statements of the 
purpose of the study, 
potential uses of the data 




Missing data Incorrect interpretation as 
a result of excessive  
missing data  
  
Various approaches to 
encourage completion of 
all items 
Reporting, publication bias  Tendency to not report or 
publish negative findings 
 
Clear dissemination 






2.7 Ethical considerations in doctoral research  
2.7.1 Concepts of ethical research 
The four fundamental concepts in ethical research are autonomy, non-
maleficence, beneficence, and justice. 
Autonomy in research relates to respecting thought, intention, and action 






persuasion or coercion. Decisions to participate should be made of the basis 
of being fully informed. In the cross-sectional surveys in this doctoral 
research, all governance approvals were in place prior to any field work 
commencing, full study information was provided to potential participants 
who could elect whether or not to participate and could withdraw from the 
study at any time. While signed, informed consent was not collected, 
completion and submission of the questionnaire was taken as an indication of 
informed consent, as part of standard practice (Owonikoko, 2013)..  
Non-maleficence relates to the study causing no harm. While this cannot be 
guaranteed in all studies (e.g. RCTs of new or existing drug treatments), 
participation in a cross-sectional study is unlikely to cause harm, perhaps 
other than by breach of confidentiality.   
Beneficence relates to the study having the intention of doing ‘good’ thus 
promoting well-being. The governance reviews for this doctoral research 
involved assessment of risk and benefit. While there was unlikely benefit to 
the individual participant, the results had the potential to impact patient care 
and professional practice in the longer term.  
Justice in research relates to all participants being treated fairly. In these 
studies, all participants were subjected to exactly the same processes, 
namely completion of an electronic questionnaire.  
 
 
2.7.2 Research Governance 
Research governance describes the system of administration and supervision 
through which research is managed, subjects and staff are protected, and 
accountability is assured (Shaw et al., 2005). It relates to the regulations, 
principles and standards of good practice that ensure high quality research.  
All research conducted in Robert Gordon University must be conducted within 
the framework of the university research governance policy (Robert Gordon 
University, 2014). According to this policy, research governance ‘defines and 






approval, consent, data protection and consumer involvement); scientific 
quality; the performance of research; safety and finance’.   
This encompasses defining and communicating clear quality standards 
concerning  
• ethics (encompassing approval, consent, data protection and consumer 
involvement) 
• scientific quality 
• the performance of research 
• safety 
• finance. 
There are mechanisms to achieve these standards and associated monitoring 
of quality and assessing adherence to these standards. By adhering to this 
policy, researchers will improve research quality, protect research subjects 
and researchers and achieve public confidence in evidence. 
These standards were adhered to throughout this doctoral research by  
• ensuring that all governance approvals (ethics and research and 
development) were in place prior to any data collection 
• detailed research protocols were developed and approved for each 
phase 
• the doctoral student was trained in all processes and supervised by an 
experienced team 
• detailed, auditable records were maintained 
• participant consent was obtained (by virtue of completing 
questionnaires) 
• data were anonymised and protected throughout 
• participant and researcher safety were paramount 
• the research was costed prior to commencement and finance 
continuously monitored.  
 
. 
2.8 SUMMARY  
This chapter has presented many underlying methodological concepts which 
were applied in all phases of the research. The specific research methods are 






CHAPTER 3 - Clinicians’ views and experiences of direct-acting oral 
anticoagulants in the management of non-valvular atrial fibrillation: 
a systematic review 
3.1 INTRODUCTION 
This chapter provides the aim, method, results and discussion of a PROSPERO 
(International Prospective Register of Systematic Reviews) registered 
systematic review of clinicians’ views and experiences of the use of DOACs 
for the management of non-valvular AF. 
As highlighted in Chapter 1, while there are very many systematic reviews 
reporting efficacy, safety and cost effectiveness of DOACs in general and 
specifically relating to the management of non-valvular AF, none have 
focused on clinician’s perspectives. A preliminary search of the Joanna Briggs 
Institute Database of Systematic Reviews and Implementation Reports, the 
Cochrane Library the Centre for Reviews and Dissemination and PROSPERO  
revealed that there was no registered systematic review protocol in this area. 
Furthermore, a search of Medline indicated a number of published studies 
hence the potential for conducting a systematic review.  
3.2 AIM OF THE REVIEW  
The aim of the systematic review was to critically appraise, synthesise and 
present the available evidence of clinicians’ views and experiences of the use 
of DOACs for the management of non-valvular AF.  
3.2.1 Review questions 
In relation to DOACs for the management of non-valvular AF 
1. What are clinicians’ views of the use of DOACs? 
2. What are the influences on clinician’s use of DOACs? 







3.3 METHOD  
A systematic review protocol was created according to the standards of 
PRISMA-P (Preferred Reporting Items for Systematic review and Meta-
Analysis Protocols), a checklist of 17 numbered items (26 sub-items) that 
should be described, at minimum, in protocols of systematic reviews. 
PRISMA-P was developed and published in 2015 by an international 
collaboration with expertise in systematic review methodology, protocol 
registry development, and reporting guideline development (Moher et al., 
2015). PRIMSA-P items are categorised into three main sections:  
• administrative information (e.g. title, registration, authors) 
• introduction (e.g. rationale, aim), and  
• methods (e.g. eligibility criteria, information sources, search strategy) 
(Moher et al, 2015).  
The systematic review protocol was registered in PROSPERO in February 
2016 (Stewart et al., 2016). PROSPERO, which is based at the Centre for 
Reviews and Dissemination, University of York, UK, is an international 
database of registered systematic reviews in health and social care, welfare, 
public health, education, crime, justice, and international development, 
where there is a health related outcome ( Stewart et al., 2016).  For 
registration in PROSPERO, the protocol is submitted with key information 
about the design and conduct of the review, in line with the PRISMA-P 
statements. 
3.3.1 Inclusion criteria  
The inclusion criteria for the review were described in terms of the PICO 
acronym as follows. 
Population  
The review included clinicians, most likely doctors, nurses and pharmacists, 
as these were the key professions involved in prescribing, dispensing and 







Interventions/Phenomenon of interest    
The review focused on studies involving DOACs as a drug class or any of the 
individual DOACs (i.e. dabigatran, rivaroxaban, apixaban, edoxaban).  
Comparators 
There were no comparators for this review as there was no intention to 
compare the views and experiences across different groups of clinicians.  
Outcomes 
The review included studies which reported health professionals’ views, 
experiences and behaviours in relation to the prescribing and use of DOACs. 
Types of studies 
The review included primary research studies which employed qualitative, 
quantitative or mixed methodologies. Views and experiences may be 
researched using qualitative methodologies such as narrative, 
phenomenology, grounded theory, case studies and discourse analysis 
(Creswell 2014). In terms of quantitative methodologies, cross sectional 
sectional surveys may use closed questions, such as Likert type scales, to 
quantify views and experiences (Barua 2013).  
3.3.2 Search strategy  
A three-step search strategy was conducted as follows: 
1. An initial scoping search of Medline and the Cumulative Index of Nursing 
and Allied Health Literature (CINAHL) was undertaken, using search terms of 
[‘doctor*’ OR ‘nurse*’ OR ‘pharmacist*’] AND [‘novel oral anticoagulant*’ OR 
‘dabigatran’ OR ‘rivaroxaban’ OR ‘apixaban’ OR ‘edoxaban’] AND [‘view*’ OR 
‘experience*’]  
2. Using the keywords and main title and abstract words/phrases identified, 
searches of all databases were undertaken. The search string was applied 






3. The reference lists of all identified papers were reviewed to identify 
additional studies.  
The following bibliographic databases were used for this search: Medline, 
CINAHL, International pharmaceutical abstracts (IPA), Psycharticles, 
Cochrane Database of Systematic Reviews. Details of each database are 






  Table 3.1 Databases selected for the systematic review. 
Database Characteristic 
Medline Medical Literature Analysis and Retrieval System Online, or MEDLARS Online is a 
bibliographic database of life sciences and biomedical information. It includes bibliographic 
information for articles from academic journals covering medicine, nursing, pharmacy, 
dentistry, veterinary medicine, and health care. It contains over 14 million records (US 
National Library Of Medicine).  
CINAHL Cumulative Index to Nursing and Allied Health Literature (CINAHL) is a database of nursing, 
allied health articles, includes pharmacy, biomedicine and 17 allied health disciplines. Full 
articles and abstracts can be found. CINAHL also can provides books, conference abstracts, 
clinical trials results, nursing dissertations (EBSCO Health )  
IPA Database mostly includes articles in pharmacy (pharmacy practice) and other health related 
disciplines). Pharmacy and cosmetic journals are included. Masters and doctoral thesis of 
School of Pharmacy students can be searched. The American Society of Health-System 
Pharmacists (ASHP) developed the IPA, with the first abstract published in 1964 (Fishman et 
al., 1996).  
Embase A database for health care disciplines. It is possible to find rare case reports and find articles, 
which have not found by using Medline (Woods et al., 1998). 
Scopus A database of abstracts and citations of peer-reviewed documents: journals, books, 
conference abstracts in different disciplines, such as medicine, science, social sciences, etc.  
Psycarticles  Psycatricles is the American Psychological Association (APA) database which provides full text 
articles from 50 journals, some of which are official American Psychological Association, 
Canadian Psychological Association journals and APA specialty journals as well as book 
chapters (Piotrowski et al., 2003).  
Cochrane Database of Systematic 
Reviews  
Database of published systematic reviews in healthcare disciplines. Cochrane reviews are 
peer-reviewed, with each assessed by a Cochrane Review Group (Cochrane Library).  
 
Joanna Briggs Institute (JBI) 
Database of Systematic Reviews  
The online journal for published systematic reviews and systematic review protocols which 
have adhered to JBI requirements. Both qualitative and quantitative reviews can be published 
( Joanna Briggs Institute, 2011)   
Database of Abstracts of Reviews 
of Effectiveness (DARE) 
The DARE database of the Centre for Reviews and Dissemination, provides summaries of 






The final search terms (title, abstract, text, keyword) were: (clinician* OR 
doctor* OR surgeon* OR general practitioner* OR family doctor* OR 
physician* OR pharmacist* OR nurse* OR health professional* OR healthcare 
Professional* OR health carer* OR practitioner* OR prescriber* OR 
healthcare provider*) AND (new oral anticoagulant* OR novel oral 
anticoagulant* OR direct oral anticoagulant* OR non-vitamin K oral 
anticoagulant* OR dabigatran OR rivaroxaban* OR apixaban OR edoxaban) 
AND (experience* OR use* OR utility* OR evaluation* OR audit* OR behav* 
OR knowledge OR satisfaction OR skill* OR practice* OR practise* OR belief* 
OR attitude* OR view* OR opinion* OR perspective*). The reference lists of 
all identified papers were reviewed to identify additional studies. A random 
sample of 10% of titles, abstracts and full papers were screened by an 
independent researcher to confirm reliability of the screening process.  
The search comprised peer reviewed studies published in English from 
January 2006 (launch of DOACs) to the search date of July 2017, to include 
studies conducted post launch of DOACs. Abstracts, conference proceedings 
and letters etc. were excluded.  
3.3.3 Quality assessment  
All studies identified during database searching were assessed for relevance 
by two independent reviewers in terms of the review protocol (aim, 
questions, inclusion criteria) based on information contained within the study 
title, abstract and full paper. A third reviewer was consulted if consensus 
could not be reached.  
For quality assessment of the quantitative studies, the STROBE 
(Strengthening the Reporting of Observational Studies in Epidemiology) 
checklist for cross-sectional studies was applied (see Appendix 3.1). STROBE 
is an international, collaboration of epidemiologists, methodologists, 
statisticians, researchers and journal editors involved in the conduct and 
reporting of observational studies. The aim of STROBE is to improve the 
reporting of observational studies within the peer reviewed literature. 






on the study title, abstract, introduction, methods, results, and discussion 
sections of articles (von Elm et al., 2014).   
STROBE is a reporting checklist which is being used increasingly by journals 
as part of the peer review process. For quality assessment in this systematic 
review, the STROBE checklist was adapted to focus on those 15 items most 
relevant to potential study bias, as follows: 





6. Data sources/measurement 
7. Bias 
8. Study size 






15.Main results  
 
Each study was quality assessed independently by two reviewers, classifying 
each of the 13 items as ‘yes’ (present and satisfactory), ‘no’ (present but 
unsatisfactory) or ‘partly’, along with detailed justification. A third reviewer 
was used in instances of non-agreement.  
For quality assessment of any qualitative studies, the COREQ (Consolidated 
Criteria for Reporting Qualitative Research) checklist was applied (Appendix 
3.2). COREQ was developed and published in 2007, following a 
comprehensive search of many different databases (e.g. Medline, Cochrane, 
CINHAL) to identify reporting checklists for qualitative studies. Twenty-two 






items. The domains are: research team and reflexivity; study design; and 
data analysis and reporting. (Tong et al., 2007).  
As with STROBE, COREQ is a reporting checklist hence for the purposes of 
this review, an adapted 19-item checklist with focus on aspects of bias, was 
used as follows:  
1. Study aim/objectives 
2. Interviewer /facilitator 
3. Interviewer characteristics 
4. Methodological orientation and Theory 
5. Sampling 
6. Method of approach 
7. Sample size 
8. Non-participation 
9. Setting of data collection 





15.Number of data coders 
16.Description of the coding tree 
17.Deviation of themes 
18.Quotations presented 
19.Data and findings consistent 
 
Each study was quality assessed independently by two reviewers, classifying 
each of the 18 items as ‘yes’ (present and satisfactory), ‘no’ (present but 
unsatisfactory) or ‘partly’, along with detailed justification. A third reviewer 








3.3.4 Data extraction 
Quantitative and qualitative data were extracted independently by two 
reviewers from papers included in the review using a standardised data 
extraction tool (Appendix 3.3). The data extracted included specific details of 
significance to the objective and specific review questions. Data extracted 
were: 





• Theory applied 
• Number of participants (response rate) 
• Key findings 
 
3.3.5 Data synthesis  
The approach to data synthesis in a systematic review depends upon the 
nature of the data (quantitative of qualitative), the number of studies, the 
outcome measures and the quality of the data. 
In systematic review of quantitative studies and data, the ideal approach is a 
meta-analysis. This is a statistical technique with the results from each study 
pooled thereby increasing power compared to the single studies. For meta-
analysis to be valid, study populations and outcome measures need to be 
homogeneous. This is tested in two ways; the methodological information 
provided in the studies and specific computations during analysis. The results 
of meta-analysis are given graphically in a forest plot and by odds ratios 
(Akobeng, 2005). In this systematic review, quantitative studies were 
extremely heterogeneous in terms of study aims, populations, data collection 
approaches and outcome measures hence a meta-analysis approach was 






The most common approach to pooling of qualitative data and synthesis in 
conducting systematic reviews is meta-aggregative synthesis (Munn et al., 
2014). This involves aggregation of the findings (e.g. themes) provided by 
the authors of the specific studies into one overarching framework. It does 
not involve extracting and synthesising data from the individual study 
datasets (Hannes et al., 2012). While it had been intended that qualitative 
research would be pooled with aggregation or synthesis of findings to 
generate a set of statements that represented that aggregation, only one 
qualitative study was identified. 
3.4 RESULTS  
3.4.1 Searching 
The PRISMA flowchart is given in Figure 3.1 Removal of duplicates and 
screening of the titles reduced the number of papers from 979 to 394. 
Screening of the abstracts reduced this number to 195 and a further 186 
removed following screening of the full papers. Reasons for exclusion of full 
papers included: review articles (systematic and narrative, n=41); editorials 
and opinion papers (n=36); no data relating to DOACs (n=36); clinician 
reports of patient registries or databases (n=38); and primary research data 
on patients’ views and experiences only (n=35). Nine papers were retained 
for quality assessment plus one further paper identified from screening the 
reference lists of the nine papers. Of the ten papers, nine were quantitative 
(cross-sectional survey based methodology) and one qualitative (semi-








Figure 3.1. PRISMA Chart (Preferred Reporting Items of Systematic reviews and Meta-

































Full-text articles assessed 
for eligibility  
(n=196) 
Full-text articles excluded 
(n=186) 
Records identified through 
database searching 
(n=979) 
Records after duplicates removed (n=202) 
Titles screened (n=777) 
Abstracts screened  
(n=394) 
Studies included in 










3.4.2 Quality assessment  
The quality assessments are given in Tables 3.2 and 3.3 for the quantitative 
studies and the one qualitative study respectively. 
For the quantitative studies, key areas of strength were the clarity of 
statement of study aims and description of participants, settings and 
outcome measures. Fewer studies (Faraoni et al., 2013, Sauter et al., 2016)  
provided detailed information on sampling strategies, and justification of 
sample size was only provided in two studies (Huang et al., 2013, Faraoni et 
al., 2014). There was also a lack of detailed provided on the approaches to 
recruitment. Similarly, very few (Huang et al., 2013, Sauter et al., 2016, 
Faraoni et al., 2013) described any approach to questionnaire development, 
item selection and pre-testing. Notably theory was not used to support 
development of questionnaire domains and items in any of the studies 
reviewed.    
While the one qualitative study involved semi-structured interviews, the 
study methodology (e.g. phenomenology, grounded theory) was not stated. 
Key areas of strength were aspects of research trustworthiness (e.g. double 
coding of interview transcripts and representing the participants’ voices 
through illustrative quotes). Areas of weakness were: the lack of 
consideration of the researcher perspective, no theory to underpin the 
development of the interview schedule or coding framework, and the limited 
sample size of seven which reduced the potential of obtaining data 
saturation.  
All studies were, however, considered to be of sufficient quality to be included 







Table 3.2 Quality assessment of the nine cross-sectional studies using adapted STROBE criteria  
 
























Aim  State specific aim/ 
objectives 
Yes  Partly  Yes  Yes  Yes Yes Yes  Yes  Yes  
Methods 
Setting Describe the 
setting, locations, 
and relevant dates 
Yes 
 
 Partly  Yes   Yes  Partly   Partly  Partly  Partly Partly 
Participants  Give the eligibility 





Partly Partly  Partly  Partly  No  No  Partly  Partly Partly 
Variables Clearly define all 
outcomes 
Partly Partly  Partly  Partly Partly  Partly  Yes    Yes  Partly 
Data sources For each variable 
of interest, give 
sources of data 
and details of 
methods of 
assessment  
Yes  Partly  Partly Partly Partly  Partly  Partly   Yes   Partly  
Bias Describe any 
efforts to address 
potential sources 
of bias 
Partly No  No  No  No   No   Partly  Partly No 
Study size Explain how the 
study size was 
arrived at 







Yes  Partly  No   Yes 
 










(a) Describe all 
statistical methods 
Partly Partly  No  Yes 
 
Partly  Partly Partly  Partly No 
(b) Describe any 




Partly N/A No Yes  N/A N/A No  Partly N/A  
Participants (a) Report 
numbers of 
individuals at each 
stage of study 
 Yes  N/A Partly Yes  Yes Yes 
 
Partly  Partly  Yes 









study participants  
Yes 
 




missing data for 
each variable of 
interest 
 N/A No  No  Partly No  No  No  Yes  Yes  
Outcome 
data 
Report numbers of 
outcome events or 
summary 
measures 








Table 3.3 Quality assessment of the qualitative study using adapted COREQ criteria   
Criteria  Kirley et al., 2016 
Aim State specific aim/objectives Yes 
Personal Characteristics 
  
(a) Interviewer/facilitator. Which author/s conducted the interview or focus group? Yes    




orientation and Theory  
What methodological orientation was stated to underpin the study? No  
Sampling  How were participants selected?  Yes  
Method of approach  How were participants approached?  No  
Sample size  How many participants were in the study? Yes  
Non-participation  How many people refused to participate or dropped out? Reasons? No  
Setting of data collection Where were the data collected? No 
Description of sample  What are the important characteristics of the sample?  Partly 
Interview guide Were questions, prompts, guides provided by the authors? Was it pilot tested? Partial 
Audio/visual recording  Did the research use audio or visual recording to collect the data? Yes  
Field notes  Were field notes made during and/or after the interview or focus group? No 
Data saturation  Was data saturation discussed? Partly 
Number of data coders  How many data coders coded the data? Yes  
Description of the coding 
tree  
Did authors provide a description of the coding tree? No  
Derivation of themes Were themes identified in advance or derived from the data? Yes 
Quotations presented  Were participant quotations presented to illustrate the themes / findings? Was each 
quotation identified?  
Yes  
Data and findings 
consistent  







3.4.3 Data extraction 
Data extraction of these ten studies is given in Tables 3.4 and 3.5.  
All nine studies were of a cross-sectional survey methodology conducted largely 
in Europe (n=7) and North America (n=3), with one study reporting data from 
Europe and North America. DOACs as a group were the focus of eight studies 
with one specifically related to dabigatran. Populations studied were described 
as: GPs (n=4), centres of research networks (n=3), cardiologists (n=3), general 
internists (n=2), hospital doctors (n=1), members of associations (n=1) and 
non-medical prescribers (n=1), with many of the studies reporting data from 
more than one group. None of the studies referred to any theories (e.g. 
psychological, organisational) considered as part of data collection tool 
development. The number of respondents ranged from 38 to 450 with response 
rates of 9% to 35.9%. Only three studies quoted a response rate.  
The one qualitative study reported data from seven physicians in the USA. There 
was no description of any theory used in the stages of data generation, analysis 
























To identify factors 
that influence doctors’ 
decisions to prescribe 
dabigatran. To 



















(one not stated). 
 
In warfarin naive patients, the 
main influences were: affordability 
for patient; renal function; and 
CHADS2 score.  
 
For those prescribed warfarin, 
were: unstable INR; affordability 
for patient; missed appointments. 
 
Cardiologists preferred to 
prescribe dabigatran more often 
compared to general internists 
who were less comfortable 
prescribing cardiologists. 
 
Lip et al., 
2013 
To assess European 
clinical practice in 
relation to the use of 
oral anticoagulants for 
stroke prevention in 
AF with particular 
















No  No overall 
response rate 
given. Responses 







There were clear practice 
differences evident, and also the 
need for greater adherence to the 
guidelines, especially since 
guideline adherent management 
results in better outcomes. 
Reassuring information on current 
practice in Europe for the use of 
DOACs for stroke prevention in AF 
was evident, although VKA use 
remained dominant in some 










To assess: physicians’  
level of knowledge 
about perioperative 
management of 




to improve the 
management 



















No  450/5262 (9%) but 
only 117 completed 
all sections of the 
questionnaire. 
 
29% stated no guidelines on DOAC 
reversal used in their institution while 
28% used local 
guidelines, 35% national and 14% 
international 
guidelines.   
 
46% stated that no agreement had 
been reached in their institution on 
the use of guidelines and 18% 
believed that no guidelines had been 
established due to the lack evidence.  
97% thought guidelines were needed 
to improve management generally 
and particularly for monitoring (69%) 




To assess  the 
European practice of  
treatment of patients 
with non-valvular AF 
presenting with 















 No  No overall response 
rate given. 




surgery available in 
82.9%. 
 
Key findings were two important 
areas of uncertainty regarding: the 
optimal composition and duration of 
antithrombotic therapy with multiple 




et al.,  
2014 
To access physicians' 
acceptance and 
appreciation of the 









No  227 response from 
physicians.  
45.4% considered DOACs and VKAs 
to be equally safe and 82.8% to be 
equally effective. 
  
Bleeding complications following the 








Larsen et al., 
2015 
To assess the 
clinical practice in 
relation to the use 
of OAC therapy for 


































33.3% stated that DOACs were their 
preferred treatments. 
48.5% considered DOACs to be 
equally effective compared to VKAs.  
12% preferred using DOACs for dual 
antiplatelet therapy in AF patients 
undergoing percutaneous coronary 
intervention. 
Andrade et al., 
2016 






















Preferences regarding OAC therapy 
largely focused on characteristics 
related to safety and efficacy. 
Physicians stated preferred 
anticoagulant was apixaban (61%), 
however, 49% of physicians 
spontaneously stated rivaroxaban as 
their preferred agent (vs 25% 
apixaban). 
 





of awareness of 
the DOACs and to 
examine their 
understanding of 
the effects of 






















There were significant differences in 
awareness of DOACs. 88%, 80% and 
50%, respectively, recognised 
rivaroxaban, dabigatran, 
and apixaban to be DOACs.  
When provided with a routine clinical 
situation, 
only 13.5%, 17.5% and 16.8% 
respondents respectively recognised 
that the hypothetical patient was 
anticoagulated, and only 55–58% 
recognised that it was unsafe to 













and choice of 
DOACs, clinical 
follow up including 

















Participants treated 32.7% (±19) of 
their patients requiring oral 
anticoagulation with DOACs.  
New patients who had started oral 
anticoagulation received DOACs from 
92.5% but most would not switch 
patients from warfarin to DOACs.  
In the preceding 2 years, GPs had seen 
1.9 (±2.87) bleeding complications in 




Table 3.5 Data extraction of the one qualitative study 
 
Authors/years  Aim Country   Design  Participants  Theory 
applied  
Key findings  
Kirley et al. 
2016 




management in AF, with 
a specific focus on the 
















No Four themes emerged: the likelihood of 
prescribing DOACs depended upon their 
willingness to try new medications and 
experience; they typically balanced the benefits 
and risks of anticoagulation in AF patient; 
patient convenience and preferences, as well as 
physician convenience, were important; and 
concerns regarding out-of-pocket cost of DOACs 














3.4.4 Data synthesis  
The heterogeneity of the quantitative studies in terms of study aims and specific 
domains and items within the questionnaires limited the approach to data 
synthesis. Given that there was only one qualitative study, meta-synthesis of 
the qualitative findings was not possible. Table 3.6 gives the synthesis of the 
findings from the nine quantitative studies, highlighting the lack of homogeneity 
in the specific elements studied in each. While only one quantitative study 
reported factors influencing DOAC use (Huang et al., 2013), this was also the 
aim of the one qualitative study (Kirley at al., 2016). The quantitative study 
highlighted the top three factors determining eligibility for dabigatran in warfarin 
naïve patients as: cost to the patient (reported by 25% of respondents); non-
compromised renal function (21%); and CHADS2 score (18%). For patients on 
warfarin, these were: having an unstable INR (37%); patient affordability (9%); 
and missed appointments (17%) (Huang et al., 2013). Some of these also 
emerged in the qualitative study in terms of risks to the patient, patient 
convenience and cost, with additional themes of the clinician willingness to try 
new agents and their experience of these agents (Kirley et al., 2016).  
Six studies reported data on clinician preference for DOACs compared to 
warfarin (Huang et al., 2013, Lip et al., 2013, Wutzler et al., 2014, Larsen et al., 
2015, Andrade et al., 2016, Sauter et al., 2016).  In a study of 65 cardiologists 
and general internists, cardiologists were significantly more comfortable than 
general internists in prescribing DOACs over warfarin, as were those who had 
prescribed DOACs in more than ten patients (Wutzler et al., 2014). While DOACs 
were not the main focus of a study of 45 research network centres, there were 
differences across centres in the use of DOACs first line (Lip et al., 2013). Data 
from a further study of 38 of these centres identified that 33.3% of respondents 
preferred DOACs to warfarin, with 48.5% considering them to be equally safe 
(Larsen et al., 2015). Similar safety data were reported in a study of 227 
cardiologists and GPs, with over 80% considering DOACs as effective as warfarin 
(Wutzler et al., 2014). Rivaroxaban was selected as first line oral anticoagulant 






DOACs were also selected first line by 70% of 53 GPs attending a medical 
congress ( Sauter et al., 2016). Key reasons reported in these studies for DOAC 
preference were the perceptions of evidence of effectiveness equivalent or 
superior to warfarin and superior safety. While DOACs were largely considered 
more appropriate in warfarin naïve patients, there was less support for switching 
patients established on warfarin.  
DOAC associated bleeding was a key issue, being observed in patients of 40% 
(n=90) of cardiologists and GPs (Wutzler et al., 2014).  In the preceding two 
years, 53 GPs had seen 1.9 ± 2.87 (range 0–14) bleeding complications in 
patients prescribed DOACs, of which 0.5 ± 0.95 (range 0–5) were referred to 
hospital (Sauter et al., 2016).  Two studies reported the need for guidelines to 
support the use of DOACs in the management of AF, with respondents 
welcoming specific guidance on the management of DOAC induced bleeding (Lip 






Table 3.6 Synthesis of the key findings from the nine quantitative studies  
 Huang et al., 
2013 
 
Lip et al., 
2013 













Olaiya et al., 
2016 
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3.5 DISCUSSION  
3.5.1 Statement of key findings 
This systematic review has highlighted that relatively few studies have 
reported clinician perspectives; nine cross-sectional surveys and one 
qualitative study were included in the review, with marked heterogeneity in 
the specific outcomes reported. In those studies reporting preference, DOACs 
were first choice over warfarin in naïve patients based on perceptions of 
evidence of effectiveness equivalent or superior to warfarin and superior 
safety. Other advantageous factors were in those with an unstable INR and 
likely to miss appointments. There were, however, concerns relating to their 
experiences of observed bleeding rates.  
3.5.2 Strengths and weaknesses 
One key strength of this systematic review was conducted according to best 
practice and reported in accordance with the PRISMA (Preferred Reporting 
Items for Systematic Review and Meta-Analysis) standards (Moher et al., 
2009). However, the generalisability or transferability of review findings to 
other countries or cultures may be limited given that all were conducted in 
either Europe or the USA. None of the quantitative studies had response 
rates over 40%, increasing the likelihood of response bias thus threatening 
internal validity. Furthermore, to date, only one qualitative study and no 
mixed-methods studies have been reported. As noted earlier, the approach to 
synthesis was limited by the nature of the data.  
3.5.3 Interpretation 
This is the first systematic review which has focused on clinicians’ 
perspectives of DOACs which is rather surprising given the vast number of 
systematic reviews and meta-analyses of effectiveness and safety. While 
each of the studies was generally of good quality, reporting could be 
enhanced by referring to design specific checklists which are now hosted on 
the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) 
website. In particular, none of the studies reporting influences on prescribing 




Theoretical Domains Framework, which is derived from 33 psychological 
theories and 128 theoretical constructs, which are organised into 14 
overarching domains, would provide a more comprehensive approach thus 
facilitating development of behaviour change interventions if required (Michie 
et al., 2005).  
Despite the limited number of studies, review findings have highlighted a 
number of issues which merit further consideration given current prescribing 
levels and likely future increases (Loo et al., 2017). Positive factors 
influencing selection of a DOAC over warfarin, such as patient convenience, 
reduced risk and stability of INR reflect DOAC clinical pharmacological 
properties relating to mechanism of action eliminating the need for INR 
testing (Gomez-Outes et al., 2015). There appeared to be awareness of the 
evidence base of DOAC effectiveness and safety, although also a stated need 
for practice guidelines, particularly to support management of over-
anticoagulation and anticoagulant reversal. Given that idarucizumab is now 
licensed for use and is indicated to reverse dabigatran in patients with life 
threatening haemorrhage or need for urgent surgery (Pollack et al., 2015), it 
is likely that these issues will resolve in the near future.  
The findings of our systematic review provide some evidence of the need to 
support decision-making and management of those patients already 
established on warfarin and how to transfer safely to DOACs if appropriate. 
The recently updated 2018 European Heart Rhythm Association Practical 
Guide on the use of DOACs in non-valvular AF provides much needed 
protocols for tapering, stopping and switching from DOACs to warfarin and 
vice versa  (Steffel et al., 2018).   
Views of patients should also be central to decision-making around choice of 
oral anticoagulants. A systematic review of patients’ values and preferences 
for DOACs versus warfarin generated heterogeneous findings, highlighting 
the need for focusing on patients’ individual values and preferences (Loewen 
et al., 2017).  A further systematic review reported that stroke risk reduction 
and a moderate increase in the risk of bleeding were the most important 
attributes for patients when deciding between DOACs and warfarin (Wilke et 




highlighted within local, national and international guidelines (NICE 2014, 
Camm et al., 2010, January et al., 2014, Steffel et al., 2018).  
Forty percent of respondents in one study included in this systematic review 
reported observed bleeding complications in those prescribed DOACs (Wutzler 
et al., 2014). While the incidence and severity of bleeding were not reported, 
several systematic reviews have concluded that the risk of major bleeding is 
generally equivalent to or less than that with warfarin, there is a need for 
further high quality studies (Burr et al., 2017, Deitelzweig et al., 2017, Miller 
et al., 2017). There is therefore a need for intensive patient monitoring and 
reporting of events to national and international pharmacovigilance schemes. 
Given the limited evidence base, there is a need for more robust and rigorous 
research which systematically explores experiences, views and behaviours of 
clinicians, with the overall aim of optimising appropriate use of DOACs. Mixed 
quantitative-qualitative approaches are recommended to allow, specifically an 
explanatory, sequential mixed methods design characterised by the collection 
and analysis of quantitative data followed by generation and analysis of 
qualitative data. The qualitative findings will generate in-depth and rich data 
to assist in exploring, explaining and interpreting the statistically based 
results of the quantitative element. 
3.5.4 Conclusion 
This systematic review has identified a limited evidence base of clinicians’ 
views and experiences and a need for further research. While DOACs were 
first choice over warfarin in naïve patients based and perceptions being 
advantageous in those with an unstable INR and likely to miss appointments, 
there is a need to support prescribing and specifically the management of 
over-anticoagulation. 
3.5.5 Further research phases 
This systematic review has identified the lack of robust and rigorous research 
focusing on the perspectives of clinicians. Furthermore, there has been a 
notable absence of the use of theory in the development of data collection 










CHAPTER 4 A cross-sectional survey of prescribers in NHS Highland 
 
4.1 INTRODUCTION  
As noted in the previous chapter, there is a lack of high quality research on 
the views and experiences of clinicians prescribing DOACs in the 
management of non-valvular AF. The systematic review reported in Chapter 3 
provided a synthesis of the findings from only ten studies, nine cross-
sectional surveys and one qualitative study. This chapter presents the 
method, results and discussion of a cross-sectional survey of prescribers  
views, experiences and behaviours relating to prescribing DOACs for the 
management of non-valvular AF. 
4.2 RESEARCH AIM  
The aim of this phase of research was to determine prescribers’ behaviours, 
views and experiences and relating to prescribing DOACs for the 
management of non-valvular AF. 
4.2.1 Research questions 
In relation to prescribers and DOACs, the research questions were: 
1. how are DOACs initiated, prescribed and monitored? 
2. which behavioural determinants are potentially influential in  
prescribing DOACs?  
3. what are the perceived benefits and limitations of prescribing DOACs?  
4. what are the positive and negative experiences of prescribing DOACs? 
5. how could the appropriate use of DOACs in primary care be extended 
further? 
4.3 RESEARCH METHOD  
4.3.1 Research design 
A positivist, quantitative approach was employed with a cross-sectional 
survey methodology, as described in Chapter 2. 
4.3.2 Research Governance 




• the ethical review panel of the School of Pharmacy and Life Sciences, 
Robert Gordon University (Appendix 4.1) 
• NHS Highland Research & Development committee (Appendix 4.2) 
There was no requirement to obtain NHS ethics approval.  
4.3.3 Setting 
The research was conducted across primary and secondary care in NHS 
Highland, as described in Chapter 1. 
4.3.4 Inclusion and exclusion criteria 
All prescribers practising within NHS Highland were invited to participate. This 
included all medical prescribers of all grades and non-medical prescribers 
(nurse independent prescribers and pharmacist supplementary and 
independent prescribers). Full-time, part-time and sessional prescribers were 
included. There were no exclusion criteria. 
4.3.5 Sampling 
The entire population of prescribers practising within NHS Highland was 
included, without sampling. A sample size of 377 was required for a precision 
of 5% with 95% confidence intervals (Qualtrics, 2019). There were around 
270 general practitioners (GPs) registered within NHS Highland at the time of 
the study, with an estimated equivalent numbers of hospital based 
prescribers/non-medical prescribers. A response rate of around 50% would 
therefore generate sufficient data. 
4.3.6 Method of data collection 
Given that all prescribers within NHS Highland could be contacted via email, 
an online approach to data collection was adopted. Table 4.1 gives a 
comparison of the advantages and disadvantages of online versus postal 









Table 4.1. Comparison of online versus postal distribution of questionnaires 
(McKenzie-McHarg et al., 2005; Sahlvist et al., 2011) 
Mode of questionnaire 
distribution 
Advantages Disadvantages 
Online • lower cost 
• less time from 
creation to sending 
• may increase 
response rate 
• ease of sending 
reminders 
• no need for 
manual data entry  
• may be Internet 
connection issues 
• need access to 
email addresses 
• recruitment bias 
with those without 
email access 
• less of an evidence 
base to maximising 
response rates  
  
Postal • good evidence 
base around 
maximising 
response rates  
• easier to 
personalise  
• higher cost 
• time consuming 
process from 
creation to sending 
• requires manual 
data entry 
 
4.3.7 Questionnaire development 
A draft questionnaire were developed according to the specific research 
questions of views, experiences and behaviours. Notably, the systematic 
review presented in Chapter 3 identified very little literature on which the 
questionnaire could be based. As described in Chapter 2, TDF was selected as 
the most relevant theoretical framework on which to base questionnaire 
items relating to behavioural determinants. The questionnaire was presented 
in four distinct sections and comprised open, closed and Likert type items. 
 
The first section gathered data relating to respondents’ personal and practice 
demographics and characteristics. One question was included to characterise 
respondents using Rogers’ ‘Diffusion of Innovations’ typology of innovators, 
early adopters, early majority, late majority and laggards, based on 
receptivity to change (Rogers 2010). 
 
The second section attempted to gauge current practice in terms of initiating, 
continuing, altering and deprescribing of warfarin and DOACs. While the 
options of ‘weekly’, ‘monthly’, ‘annually’ and ‘never’ may have been difficult 




validity, it did allow identification of those who never prescribed (or would 
never prescribe) any oral anticoagulants. Items relating to specific knowledge 
of the NHS Highland guidelines (NHS Highland, 2017) were also included.  
 
The third section was the largest of the questionnaire and focused on 
behavioural determinants (i.e. influences) of prescribing. As described in 
Chapter 2, TDF was used as a basis for the development of these items. The 
Determinants of Implementation Behavior Questionnaire (Huijg et al., 2014) 
was used as a basis for the development of individual items, adapted as 
relevant to prescribing of DOACs. These items were presented as 5-point 
Likert scales (strongly agree to strongly disagree). 
 
The final section contained open questions on aspects of: benefits and 
limitations of DOACs; examples of positive and negative experiences of using 
DOACs; NHS guidelines; CPD undertaken or needed; and comments relating 
to extending the appropriate use of DOACs within NHS Highland.  
 
Following review by the research supervisory team, the draft questionnaires 
was tested for face and content validity (Humphrey, et al., 2013), as 
described in Chapter 2. Six leading researchers and practitioners were 
selected from the professional networks of the supervisors and invited by 
email to comment on the questionnaire in relation to the aims and objectives. 
The six comprised: a health psychologist; a general practitioner, a consultant 
medical physician; two senior pharmacist prescribers; and the lead for 
pharmacist prescribing at NHS Education for Scotland. Comments were 
emailed to the principal supervisor for review by the doctoral student and 
supervisory team. Comments were generally very supportive, with revisions 
suggested to the wording of specific questions. The main comment was to 
include additional questions on the initiation, continuation, monitoring, 
discontinuation of DOACs and warfarin, and switching between the two.  
 
Following modification of the questionnaire, the next stage was to undertaken 
‘think aloud testing’, which involves a small number of individuals voicing 
their interpretation of the items and their responses. This allows the 




planned (Smith et al, 2013). This was undertaken with one medical and one 
non-medical prescriber based outwith NHS Highland.  
 
The pilot version of the questionnaire was formatted in Snap 10 Professional® 
(software for web and email questionnaire design, publication, data entry and 
analysis) by an e-technologist at RGU. Piloting was undertaken for several 
reasons:  
i. to estimate likely survey the response rates 
ii. to test that questionnaire items are completed as intended (Bowden et 
al, 2002) 
iii. to determine the extent of completion of the open-ended questions 
(Simon et al, 2003; Bowden et al, 2002). 
The pilot was performed on a sample of 30 prescribers outwith NHS Highland, 
identified from the professional networks of the supervisors. Thirteen 
responses were received (response rate of 43.3%), review of which identified 
that no further changes to the questionnaire were required.  
4.3.8 Data collection 
The final questionnaire also included an information leaflet, which was 
prepared according to the standardised format required by NHS ethics 
committees in the UK (Appendix 4.3). The final questionnaire can be found in 
Appendix 4.4. Providing full information of the aims of the study, potential 
benefits and assuring anonymity and confidentiality has been shown to 
increase response rates. The following evidence based measures were also 
adopted to maximise the survey response rate: professional design; use of 
reminders; and incentives (invitation to be included in a draw for £50 of 
shopping vouchers) (Cottrell et al., 2015 ). 
 
The questionnaires were sent in January 2016 by a member of staff in NHS 
Highland with access to the database of prescribers’ emails. The email text 
was developed by the research team and contained the link to the 
information leaflet and questionnaire. Two reminder emails were sent at 




4.3.9 Quality in research: maximizing validity and reliability 
The following measures were adopted in an attempt to increase validity and 
reliability and hence the robustness of the study: 
i. questionnaire items were developed from the results of the 
systematic review in Chapter 3, the published literature around 
DOACs in general, TDF and the NHS guidelines, all of which 
enhanced criterion validity, as described in Chapter 2  
ii. the draft questionnaire was reviewed for face and content validity 
by key, targeted experts 
iii. a pilot study was performed to ensure the questionnaire quality  
iv. statistical testing was performed to established internal consistency 
(reliability) of any scales 
 
A number of approaches were taken in an attempt to reduce various forms of 
bias (Wyrick  et al.,2011), (Clifford et al., 2015), (Suárez-Alvarez et al., 
2018), (Whelan et al., 2008):  
i. the invitation email was sent to all prescribers within NHS Highland 
thus eliminating any recruitment bias 
ii. evidence based measures were adopted to increase response rate thus 
reducing any response bias 
iii. the questions were worded in such a way as to reduce social 
desirability and attention bias 
iv. questionnaire items were mainly Likert scales and close-ended 
questions to minimise acquiescence response set bias 
v. questionnaires responses were anonymous to minimise evaluation 
apprehension 
 
4.3.10 Data analysis 
The questionnaire generated anonymised emails of online submissions to the 
e-technologist at RGU. These were imported into Snap 10 Professional®  
before direct export to SPSS (SPSS Inc., Cary, NC version 21.0). As 
described earlier, the number of prescribers for whom prescribing of 




not be given. Respondent demographics were presented as descriptive 
statistics (e.g. frequencies, percentages, mean (standard deviation), median 
(interquartile range)).  
Results for the specific research questions were analysed as follows. 
RQ1. how are DOACs initiated, prescribed and monitored? 
 - descriptive statistics 
RQ2. which behavioural determinants are potentially influential in prescribing 
DOACs? 
 - descriptive statistics of responses to Likert scale items 
Relevant questionnaire items were subjected to exploratory factor analysis 
(principal component analysis (PCA) with varimax rotation), to identify a 
smaller number of components of interrelated variables. The Kaiser-Meyer-
Olkin (KMO) measure of sampling adequacy and the Bartlett’s Test of 
Sphericity were used to assess the suitability of the sample for PCA 
(Worthington and Whittaker 2006). 
The number of components to be retained was decided based on: 
• the Kaiser criterion (aiming for Eigenvalues ≥ than 1) 
• the scree plot, aiming for the point at which the ‘elbow’ flattended 
• meaningfulness of component items in relation to TDF (Costello and 
Osborne 2005, Hayton et al. 2004).  
 
Analysis included items that were not freestanding, cross-loading or 
decreasing the scale’s internal consistency, and that displayed acceptable 
communalities, with factor pattern/structure coefficients above 0.4 (Costello 
and Osborne, 2005, Fabrigar et al. 1999, Hogarty et al. 2005, Sharma 1996).  
Following PCA, internal consistency was determined by calculation of the  
Cronbach’s alpha for each component, with negatively worded items being 
reverse scored (DeVellis 2003). Cronbach’s alpha gives an indication of the 
average correlation among all of the items within the component scale. 




SPSS-survival- manual, version 12). Nunnally (1978) suggests a minimum 
level of 0.7 for the component scale to be considered reliable.  
If shown to be reliable, total component scores were obtained by assigning 
scores of 1 (strongly disagree) to 5 (strongly agree) to each of the Likert 
statement responses, with negatively worded items being reverse scored. 
The median and IQR scores of each reliable component were determined and 
compared to the mid-point of the component. 
Non-parametric statistics were used to determine any significant differences 
between the following and the scores for each component: 
• health profession 
• setting 
• years of experience as a health professional 
• years of experience as a prescriber 
• Rogers’ ‘Diffusion of Innovations’ typology 
 
Mann-Whitney U-test was used for two groups and Kruskall Wallis for more 
than two groups. p-values ≤0.05 were considered to be statistically 
significant. 
RQ3-5 
- what are the perceived benefits and limitations of prescribing DOACs?  
- what are the positive and negative experiences of prescribing DOACs? 
- how could the appropriate use of DOACs in primary care be extended further? 
Textual responses to the open questions were analysed using a summative 
content analysis approach involving the counting of keywords and content, 









4.4 RESULTS  
4.4.1 Demographics 
One hundred and fifty-four responses were received, 120 (77.9%) from 
doctors (76 general practitioners), 18 (11.7%) from nurse prescribers and 10 
(6.4%) from pharmacist prescribers, (6 did not state their profession). The 
mean age of the respondents was 43.3 years (standard deviation 11.9 
years). Respondents were experienced as health professionals, with just over 
half (n=84, 54.5%) having twenty of more years of experience as health 
professionals. Slightly less (n=61, 39.6%) had twenty of more years of 
experience as prescribers. Around one quarter (n=34, 22.1%) rated 
themselves as ‘innovators’ and 25 (16.2%) as ‘early adopters’. None of the 
respondents rated themselves as ‘laggards’. The demographic characteristics 
of the respondents are given in Table 4.2. Several prescribers within NHS 
Highland contacted members of the research team stating that the survey 
was not relevant to their fields of practice (e.g. psychiatry, dermatology etc.) 
hence a response rate could not be calculated. While the number of 
respondents was less than that planned (see section 4.3.5), it was still 





Table 4.2. Respondent demographics (N=154) 
Characteristic Percentage Frequency, n 
Profession 
Doctor 



















































































































Responses in relation to changing professional 
practice 
- I resist new ways of working 
- I am cautious in relation to new ways of 
working; I tend to change once most of my 
peers have done so 
- I think for some time before adopting new 
ways of working 
- I serve as a role model for others in relation 
to new ways of working 




























4.4.2 Current practice with warfarin and DOACs 
Current practice relating to the prescribing of warfarin and DOACs in given in 
Table 4.3. The most common behaviours were continuing prescribing warfarin 
if initiated by others (n=110, 71.4% weekly or monthly) and continuing 
DOACs if initiated by others (n=112, 72.8% weekly or monthly). Sixty-six 
respondents (42.9%) initiated DOACs either weekly or monthly.  
 
Table 4.3: Approximate frequency of anticoagulant prescribing behaviours (N=154) 




























































Switch individual patients 












Switch individual patients 
from DOACs to warfarin 








Continue DOACs if 

























Sixteen respondents (10.4%) never prescribed warfarin or DOACs under any 
circumstances and had no plans to prescribe in the future, hence were 
removed from any further analysis. These sixteen were seven nurses, five 





4.4.3 Responses to items based on NHS Highlands Guidelines 
Responses to items based on selected statements within the NHS Highlands 
Guidelines (NHS, 2018) are given in Table 4.4, with the correct response 
underlined.  
Table 4.4: Responses to questions within the NHS Highlands Guidelines (N=138) 









DOACs should be considered in patients 
whose INR is outside the INR window more 
than 60% of the time (as estimated by 
appropriate software which provides time in 










DOACs should be considered first line in 
































Rivaroxaban dose should be altered in the 










Patient must be able to swallow capsule 











Almost three quarters of respondents (n=99, 71.9%) were aware of initiation 
of dabigratran in relation to TTR and the INR window. However, around one 
fifth or greater answered ‘don’t know’ to each of the statements, with the 





4.4.4 Behavioral determinants 
The responses to items the TDF of behavioural determinants are given in 
Tables 4.5-4.16.  
 
Table 4.5. Response to items in the domain of knowledge (N=138) 


















I have sufficient knowledge of the 
guidelines to allow me to prescribe 














I have sufficient knowledge of the 
clinical pharmacology of DOACs to 
allow me to prescribe these safely 














I have sufficient knowledge of the 
evidence base of DOACs to allow me 















I have sufficient knowledge of how to 














I have sufficient knowledge of how to 















I have sufficient knowledge of when 
and how to switch patients from 














I have sufficient knowledge of when 
and how to switch patients from 














I have sufficient knowledge of how to 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
While responses to most statements were positive, those relating to 
monitoring DOACs for effectiveness and toxicity (n=76, 55.1% strongly 
agree/ agree), managing ADRs (n=64, 46.4% strongly agree/ agree) and 
switching patients from warfarin to DOACs (n=73, 52.9% strongly agree/ 




was that relating to switching patients from DOACs to warfarin (n=59, 42.7% 
strongly agree/ agree).  
 
Table 4.6 Response to items in the domain of professional role and identity (N=138) 


















It is part of my role to initiate the 














It is part of my role to initiate the 














I should only prescribe DOACs 















Only specialists should initiate the 














It is part of my role to switch 














It is part of my role to switch 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The majority of respondents were in agreement that the various prescribing 
actions relating to oral anticoagulants were part of their role and not 
restricted to specialists. For example, while almost three quarters of 
respondents (n=96, 69.6% agreed/ strongly agreed) that it was part of their 
role to initiate the prescribing of DOACs, over three quarters (n=110, 79.7%) 






Table 4.7. Response to items in the domain of belief of capabilities (N=138) 


















I am confident in my ability to initiate 














I am confident in my ability to initiate 














I am confident in switching patients 














I am confident in switching patients 














I am confident in my ability to 
prescribe DOACs when they have 














I am competent in initiating the 














I am competent in initiating the 














I am competent in continuing the 















I am competent in switching  patients 














I am competent in switching patients 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, 
missing) 
 
Respondents were in overwhelming agreement that they were both confident 
and competent in various prescribing activities relating to initiating oral 
anticoagulants. The lowest levels of agreement were in relation to switching 
from warfarin to DOACs (n=74, 53.6% agreed/ strongly agreed confident; 
n=83, 60.1% agreed/ strongly agreed competent) and lower for switching 
DOACs to warfarin (n=56, 40.6% agreed/ strongly agreed confident; n=67, 





Table 4.8. Response to items in the domain of optimism (N=138) 


















Implementing the guidelines on 













Implementing the guidelines on 















Implementing the guidelines on 
prescribing DOACs will be better for 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The majority of respondents were optimistic around the use of the NHS 
Highland guidelines on DOACs and benefits for patients (n=106, 76.8% 
agreed/ strongly agreed), themselves (n=107, 77.6% agreed/ strongly 





Table 4.9. Response to items in the domain of beliefs of consequences (N=138)  


















If I prescribe DOACs rather than 
warfarin, I believe that patients will 














If I prescribe DOACs rather than 
warfarin, I believe that patients will 














If I prescribe DOACs rather than 
warfarin, I believe that patients will 














If I do not prescribe DOACs according 















If I switch patients stabilized on 
warfarin to DOACs, I believe that 














If I prescribe DOACs rather than 
warfarin, I believe that my 
management of severe bleeding will 














I believe that If I prescribe DOACs 
rather than warfarin, over-













I believe that If I prescribe DOACs 
rather than warfarin, under-














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
Respondents, in general, were rather ambivalent about the consequences of 
prescribing DOACs in relation to outcomes of effectiveness (n=39, 28.2% 
agreed/ strongly agreed), safety (n=28, 20.3% agreed/ strongly agreed) and 
cost-effectiveness (n=23, 16.7%) in comparison to treatment with warfarin.  
There appeared to be some concern over switching patients stabilised on 
warfarin to DOACs, with 27 respondents (19.5%) agreeing/ strongly agreeing 
that patient care might be compromised. Almost two thirds of respondents 




bleeding would be more challenging in those prescribed DOACs. Just under 
half agreed/ strongly agreed that over-anticoagulation (n=59, 42.8%) and 
under-anticoagulation (n=60, 43.4%) would not be easily be detected.  
 
Table 4.10 Response to items in the domain of reinforcement (N=138) 

































The views of my colleagues are a 














Potentially increased scrutiny of my 
prescribing by the health board is a 














Potentially reduced workload in 
patient monitoring influences my 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
Just over half of respondents (n=77, 55.8%) disagreed/ strongly disagreed 
that cost was a deterrent to prescribing DOACs, with even more disagreeing/ 
strongly disagreeing in relation to colleague views (n=91, 65.9%) and health 
board scrutiny (n=89, 64.5%). However, 55 respondents (39.8%) agreed/ 
strongly agreed that reduced workload in monitoring of INR was a positive 





Table 4.11: Response to items in the domain of goals (N=138) 


















I have clear goals for prescribing 














I have clear goals relating to my 















Prescribing DOACs according to the 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
In relation to goals, more than half of respondents agreed/ strongly agreed 
that they had clear goals to prescribe DOACs according to the NHS guidelines 
(n=78, 56.5%) and that prescribing according to the guidelines was a high 
priority (n=82, 59.4%). However, as illustrated in Table 4.12, just under half 
(n=58, 42.1%) agreed/ strongly agreed that the guidelines the guidelines 
were easy to interpret and one quarter (n=36, 26.0%) that it was difficult to 
decide whether to prescribe DOACs or warfarin.  
 
Table 4.12. Response to items in the domain of memory, attention and decision 
processes (N=138) 

































I find it difficult to decide whether to 














Others have to remind me to 





















Table 4.13 Response items in the domain of environmental context and resources 
(N=138) 


















Prescribing DOACs is compatible with 





























My drug budget is sufficient to allow 



























I have sufficient support from 
specialists to enable me to prescribe 












The lack of need for monitoring 














The rurality of my practice influences 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
Of note, less than one third of respondents (n=37, 26.8%) agreed/ strongly 
agreed that their drug budget was sufficient for prescribing DOACs. The 
absence of need for INR monitoring when prescribing DOACs was an 
influence of prescribing for just over half (n=72, 52.2%), with rurality being 








Table 4.14. Response to items in the domain of social influences (N=138) 


















Professionals who are important to 












Members of the multidisciplinary 














My prescribing of DOAC is 














My prescribing of DOAC is 















My prescribing of DOAC is 














My prescribing of DOAC is 

























Patients put me under pressure to 
prescribe DOACs in situations where 












Family members and carers of 
patients put me under pressure to 
prescribe DOACs in situations where 











(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
Notably, very few respondents agreed that patients, family members or 
carers exerted any pressure for prescribing DOACs (n=10, 7.2%; n=7, 5.1%; 
n=4, 2.9% respectively) and no respondents strongly agreed with these 
statements. There were, however, influences from key professionals (n=95, 
68.8%) and the multidisciplinary team (n=61, 44.2%). The vast majority 
disagreed/ strongly disagreed that prescribing was discouraged by their peers 






Table 4.15. Response to items in the domain of emotions (N=138) 


















I feel comfortable when initiating the 














I feel comfortable when switching 













I feel comfortable when prescribing 















I get professional satisfaction when 














I get professional satisfaction when 















I get professional satisfaction when 













I get professional satisfaction when 
prescribing DOACs which have been 














I feel anxious when initiating the 














I feel anxious when switching patients 














I feel anxious when switching patients 














I feel anxious when prescribing 













(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
In terms of emotions, there appeared to be very little issues around comfort 
when prescribing DOACs, either when initiating (n=74, 65.5% agreeing/ 
strongly agreeing) or continuing prescribing initiated by others (n=115, 
83.3% agreeing/ strongly agreeing). Slightly fewer were comfortable when 
switching from warfarin to DOACs (n=67, 55.8% agreeing/ strongly 




continuing or changing were much less with the highest being when switching 
from DOACs to warfarin (n=26, 18.8%).   
Table 4.16. Response to items in the domain of behavioural regulation (N=138) 


















I have ways of monitoring the quality 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
Less than one quarter or respondents (n=33, 23.9%) agreed/ strongly agreed 
that they had ways of monitoring the quality of DOAC prescribing.  
4.4.5 Principal component analysis 
As described earlier, PCA is a statistical approach to identify a smaller 
number of components of interrelated variables which can then be used as 
outcome measures for further statistical analysis. Given the number of 
questionnaire responses, it was necessary to reduce the number of items to 
include in PCA. Those items which referred to ‘prescribing’ of DOACs in 
general were retained and those which referred to sub-actions of prescribing 
(e.g. initiating, switching, discontinuing) were excluded. While this may have 
some limitations (see discussion), it was considered that the more general 
‘prescribing’ would also encompass the sub-actions. Table 4.17 lists the 33 





Table 4.17. Questionnaire items retained for PCA 
Questionnaire items 
I have sufficient knowledge of the guidelines to allow me to prescribe DOACs 
appropriately 
I have sufficient knowledge of the clinical pharmacology of DOACs to allow me to 
prescribe these safely and effectively 
I have sufficient knowledge of the evidence base of DOACs to allow me to prescribe 
these safely and effectively 
I have sufficient knowledge of how to initiate the prescribing of DOACs 
I have sufficient knowledge of how to monitor the effectiveness and toxicity of 
DOACs 
I have sufficient knowledge of how to manage adverse reactions of DOACs 
It is part of my role to initiate the prescribing of DOACs 
I should only prescribe DOACs when they have been initiated by others 
Only specialists should initiate the prescribing of DOACs 
I am confident in my ability to initiate the prescribing of DOACs 
I am competent in initiating the prescribing of DOACs 
Implementing the guidelines on prescribing DOACs will be better for patients 
Implementing the guidelines on prescribing DOACs will be better for my NHS 
organisation 
If I prescribe DOACs rather than warfarin, I believe that patients will be treated 
more effectively 
If I prescribe DOACs rather than warfarin, I believe that patients will have less 
adverse effect 
If I prescribe DOACs rather than warfarin, I believe that patients will be treated 
more cost effectively 
If I prescribe DOACs rather than warfarin, I believe that my management of severe 
bleeding will be more challenging 
I believe that If I prescribe DOACs rather than warfarin, over-anticoagulation will 
not be easily detected 
I believe that If I prescribe DOACs rather than warfarin, under-anticoagulation will 
not be easily detected 
Cost is a deterrent to my prescribing of DOACs 
Potentially increased scrutiny of my prescribing by the health board is a deterrent 
to my prescribing of DOACs 
Potentially reduced workload in patient monitoring influences my prescribing of 
DOACs rather than warfarin 
I find the guidelines on DOACs easy to interpret 
I find it difficult to decide whether to prescribe DOACs or warfarin 
Others have to remind me to prescribe DOACs according to the guidelines 
I have sufficient support from specialists to enable me to prescribe DOACs safely 
and effectively 
The lack of need for monitoring influences my prescribing of DOACs 
The rurality of my practice influences my prescribing of DOACs 
My prescribing of NOAC is discouraged by my peers 
My prescribing of DOAC is discouraged by my organisation 
My prescribing of DOAC is discouraged by specialists 
Patients put me under pressure to prescribe DOACs 







When all 33 items were subjected to PCA, the Kaiser–Meyer–Olkin measure 
of sampling adequacy (0.721) and Bartlett’s test of sphericity (significance 
<0.001) confirmed the factorability of the items. Many of the the correlation 
matrix scores were greater than 0.3. 
The number of components to be retained was determined by observation of 
the scree plot, the Eigenvalues and cumulative percentage variance. The 
Scree plot is given in Figure 4.1. Ideally, the number of components is 
identified at the ‘elbow’ point where the curve starts to flatten. In Figure 4.1, 











Table 4.18 gives those components with Eigenvalues greater than 1 and their 
associated number of items per component. 
 




Number of items  Eigenvalues 
1 16 7.644 
2 10                 3.322 
3 11 2.829 
4 4 2.339 
5 6                 1.692 
6 8 1.593 
7 4 1.405 
8 2 1.334 
9 4                 1.214 
10 3 1.007 
 
While those components with Eigenvalues over 1 could be retained, six of 
these had low numbers of items loading (≤6). The remaining four 
components had a cumulate percentage variance of 48.9% which was 
adequate hence a four component solution was retained. Table 4.19 gives the 





Table 4.19. Loading of questionnaire items onto each of the four components 
Questionnaire items 1 2 3 4 
I have sufficient knowledge of the guidelines to allow me to 
prescribe DOACs appropriately 
0.698    
I have sufficient knowledge of the clinical pharmacology of 
DOACs to allow me to prescribe these safely and effectively 
0.823    
I have sufficient knowledge of the evidence base of DOACs to 
allow me to prescribe these safely and effectively 
0.840    
I have sufficient knowledge of how to initiate the prescribing 
of DOACs 
0.877    
I have sufficient knowledge of how to monitor the 
effectiveness and toxicity of DOACs 
0.787    
I have sufficient knowledge of how to manage adverse 
reactions of DOACs 
0.715    
It is part of my role to initiate the prescribing of DOACs 0.718    
I should only prescribe DOACs when they have been initiated 
by others 
-0.616    
Only specialists should initiate the prescribing of DOACs -0.429    
I am confident in my ability to initiate the prescribing of 
DOACs 
0.869    
I am competent in initiating the prescribing of DOACs 0.772    
Implementing the guidelines on prescribing DOACs will be 
better for patients 
  0.601  
Implementing the guidelines on prescribing DOACs will be 
better for my NHS organisation 
  0.449 -
0.37
8 
If I prescribe DOACs rather than warfarin, I believe that 
patients will be treated more effectively 
  0.694  
If I prescribe DOACs rather than warfarin, I believe that 
patients will have less adverse effect 
  0.645  
If I prescribe DOACs rather than warfarin, I believe that 
patients will be treated more cost effectively 
  0.685  
If I prescribe DOACs rather than warfarin, I believe that my 
management of severe bleeding will be more challenging 
   0.54
9 
I believe that If I prescribe DOACs rather than warfarin, 
over-anticoagulation will not be easily detected 
   0.72
9 
I believe that If I prescribe DOACs rather than warfarin, 
under-anticoagulation will not be easily detected 
   0.68
3 
Cost is a deterrent to my prescribing of DOACs  0.451   
Potentially increased scrutiny of my prescribing by the health 
board is a deterrent to my prescribing of DOACs 
 0.689   
Potentially reduced workload in patient monitoring influences 
my prescribing of DOACs rather than warfarin 
  0.604 0.33
4 
I find the guidelines on DOACs easy to interpret 0.306    
I find it difficult to decide whether to prescribe DOACs or 
warfarin 
-0.460    
Others have to remind me to prescribe DOACs according to 
the guidelines 
-0.449    
I have sufficient support from specialists to enable me to 
prescribe DOACs safely and effectively 
0.316    
The lack of need for monitoring influences my prescribing of 
DOACs 
  0.362 0.56
3 
The rurality of my practice influences my prescribing of 
DOACs 
   0.37
7 
My prescribing of NOAC is discouraged by my peers  0.851   
My prescribing of DOAC is discouraged by my organisation  0.781   
My prescribing of DOAC is discouraged by specialists  0.818   
Patients put me under pressure to prescribe DOACs*     
I feel anxious when initiating the prescribing of DOACs -0.573    




Tables 4.20-4.23 list the items within each component and the TDF domain 
as per the original questionnaire. 
Table 4.20. Component 1, items related to ‘the role of professionals and their 




I have sufficient knowledge of the guidelines to allow me to 
prescribe DOACs appropriately 
 
Knowledge 
I have sufficient knowledge of the clinical pharmacology of 
DOACs to allow me to prescribe these safely and effectively 
 
Knowledge 
I have sufficient knowledge of the evidence base of DOACs to 
allow me to prescribe these safely and effectively 
 
Knowledge  




I have sufficient knowledge of how to monitor the 
effectiveness and toxicity of DOACs 
 
Knowledge  
I have sufficient knowledge of how to manage adverse 
reactions of DOACs 
 
Knowledge  
It is part of my role to initiate the prescribing of DOACs Professional role and 
identity  
I should only prescribe DOACs when they have been initiated 
by others 
 
Professional role and 
identity 
Only specialists should initiate the prescribing of DOACs Professional role and 
identity  
I am confident in my ability to initiate the prescribing of 
DOACs 
Beliefs of capabilities  
I am competent in initiating the prescribing of DOACs Beliefs of capabilities  
I find the guidelines on DOACs easy to interpret Memory, attention 
and decision process  
I find it difficult to decide whether to prescribe DOACs or 
warfarin 
Memory, attention 
and decision process 
Others have to remind me to prescribe DOACs according to 
the guidelines 
Memory, attention 
and decision process 
I have sufficient support from specialists to enable me to 








Sixteen items loaded onto component 1 and these originated largely from 
TDF domains of knowledge, professional role, beliefs of capabilities and 
decision process. This component was therefore labelled ‘the role of 





Table 4.21. Component 2, items related to ‘influences on prescribing’ (n=5) 
Statement TDF domain 
 
Cost is a deterrent to my prescribing of DOACs 
 
Reinforcement  
Potentially increased scrutiny of my prescribing by the health 
board is a deterrent to my prescribing of DOACs 
 
Reinforcement  
My prescribing of DOACs is discouraged by my peers 
 
Social influences  
My prescribing of DOACs is discouraged by my organisation 
 
Social influences 
My prescribing of DOACs is discouraged by specialists Social influences 
 
Five items loaded onto component 2 and these all originated from the TDF 
domain of social influences and reinforcement. This component was therefore 
labelled ‘influences on prescribing’. 
 
 
Table 4.22. Component 3, items related to ‘consequences of prescribing’ (n=6) 
Statement Original TDF 
 




Implementing the guidelines on prescribing DOACs will be better 
for my NHS organisation 
 
Optimism  
If I prescribe DOACs rather than warfarin, I believe that patients 




If I prescribe DOACs rather than warfarin, I believe that patients 




If I prescribe DOACs rather than warfarin, I believe that patients 




Potentially reduced workload in patient monitoring influences my 




Six items loaded onto component 3 and these all originated from the TDF 
domains of beliefs of consequences and optimism. This component was 








Table 4.23. Component 4, items related to ‘monitoring for safety and effectiveness’  
(n=5) 
Statement TDF domain 
 
If I prescribe DOACs rather than warfarin, I believe that 
my management of severe bleeding will be more 
challenging 
 
Beliefs of consequences  
I believe that If I prescribe DOACs rather than warfarin, 
over-anticoagulation will not be easily detected 
 
Beliefs of consequences 
I believe that If I prescribe DOACs rather than warfarin, 
under-anticoagulation will not be easily detected 
 
Beliefs of consequences 




and resources  





Five items loaded onto component 4 and these all originated from the TDF 
domains of beliefs of consequences and environmental context and 




Internal consistency values (Cronbach's alpha) were calculated for each of 
the four components, aiming for values over 0.7, with all negatively worded 
items reversed.  
Tables 4.24-4.27 give the item responses and Cronbach's alpha values for 






Table 4.24. Component 1, responses to items related to ‘the role of professionals and 




















I have sufficient knowledge of the guidelines 














I have sufficient knowledge of the clinical 
pharmacology of DOACs to allow me to 













I have sufficient knowledge of the evidence 
base of DOACs to allow me to prescribe 













I have sufficient knowledge of how to initiate 














I have sufficient knowledge of how to 














I have sufficient knowledge of how to 





























*I should only prescribe DOACs when they 














*Only specialists should initiate the 














I am confident in my ability to initiate the 












































*I find it difficult to decide whether to 














*Others have to remind me to prescribe 














I have sufficient support from specialists to 












*I feel anxious when initiating the 



















The Cronbach’s alpha value at 0.904 is in excess of 0.7 therefore the scale is 
considered to be reliable. Scoring 1 for strongly disagree to 5 for strongly 
agree (negatively worded items reverse scored) gives the minimum possible 
value for the scale of 16 (representing most negative responses) and the 
maximum possible value for the scale of 80 (representing most positive 
responses) and a midscale point of 48.  
With a median value of 61 and IQR of 54-64 (minimum 36, maximum 79), 










































*Potentially increased scrutiny of my 
prescribing by the health board is a 
















*My prescribing of DOAC is discouraged 
















*My prescribing of DOAC is discouraged 




























(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing; * reverse 
scored) 
 
The Cronbach’s alpha value at 0.802 is in excess of 0.7 hence the scale is 
considered to be reliable. Scoring 1 for strongly disagree to 5 for strongly 
agree (negatively worded items reverse scored) gives the minimum possible 
value for the scale of 5 (representing most negative responses) and the 
maximum possible value for the scale of 25 (representing most positive 
responses) and a midscale point of 15. 
With a median value of 19 and IQR of 17-20 (minimum 8, maximum 25), 



























Implementing the guidelines on 













Implementing the guidelines on 
prescribing DOACs will be better for 
















If I prescribe DOACs rather than 
warfarin, I believe that patients will 

















If I prescribe DOACs rather than 
warfarin, I believe that patients will 














If I prescribe DOACs rather than 
warfarin, I believe that patients will 














Potentially reduced workload in 
patient monitoring influences my 















(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The Cronbach’s alpha value at 0.714 is in excess of 0.7 hence the scale is 
considered to be reliable. Scoring 1 for strongly disagree to 5 for strongly 
agree gives the minimum possible value for the scale of 6 (representing most 
negative responses) and the maximum possible value for the scale of 30 
(representing most positive responses) and a midscale point of 18.  
With a median value of 19 and IQR of 17-21.25 (minimum 12, maximum 30) 
respondents generally gave more neutral responses. Fifty-three respondents 


























If I prescribe DOACs rather than 
warfarin, I believe that my 
management of severe bleeding will 














I believe that If I prescribe DOACs 
rather than warfarin, over-















I believe that If I prescribe DOACs 
rather than warfarin, under-


















The lack of need for monitoring 














The rurality of my practice influences 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The Cronbach’s alpha value at 0.612 is lower than 0.7 hence the scale may 
lack reliability. Scoring 1 for strongly disagree to 5 for strongly agree gives 
the minimum possible value for the scale of 5 (representing most negative 
responses) and the maximum possible value for the scale of 25 (representing 
most positive responses) and a midscale point of 15.  
With a median value of 17 and IQR of 14-19 (minimum 9, maximum 25), 
respondents gave more neutral responses. Thirty-eight respondents (27.5%) 








4.4.6 Exploring relationships between demographic variables and 
component scores 
Independent Samples Mann-Whitney U tests (two variables) Kruska Wallis 
tests (more than two variables) were used to compare the component scores 
across key demographic variables: 
• the null hypotheses were that there were no differences in scores 
• the alternative hypotheses were that there were differences in scores 
 
Note that the study may not have been sufficiently powered to detect 
important differences hence the findings should be interpreted with caution. 
 
Health professions 
Comparison of scores for each component and the different health 
professions is given in Table 4.28. Given the number of pharmacist and nurse 
prescribers, these were combined as non-medical prescribers. 
 
Table 4.28. Comparison of component scores for doctors and non-medical prescribers 
(nurses and pharmacists) (N=138) 
 
Component Profession  Median  IQR P-value Decision  




and skills’  
Doctor 
 
61 54-64 0.496 Retain the 
null 
hypothesis; 









19.5 17.5-20 0.306 Retain the 
null 
hypothesis; 









19 17-21.5 0.601 Retain the 
null 
hypothesis; 










17 15-19 0.254 Retain the 
null 
hypothesis; 













Comparison of scores for each component and the different settings of 
primary and secondary care is given in Table 4.29.  
 
Table 4.29. Comparison of component scores across primary and secondary care 
setting (N=138) 
 
Component Setting Median  IQR P-value Decision  




and skills’  
Primary care 
 
62 56-64 0.033 Reject the 
null 
hypothesis; 









19 16-20 0.033 Reject the 
null 
hypothesis; 









19 17-21 0.078 Retain the 
null 
hypothesis; 
there is no 
difference  
Secondary care 20 18-23 
‘monitoring 




17 15-19 0.732 Retain the 
null 
hypothesis; 
there is no 
difference  
Secondary care 16 14-20 
 
While statistically significant differences were found in terms of ‘the role of 
professionals and their knowledge and skills’ and ‘influences on prescribing’, 
all scores were generally high and above the midpoint of 48 (‘the role of 
professionals and their knowledge and skills’) and 15 (‘influences on 
prescribing’). Those in primary care were more positive around items on their 
professional role and knowledge and skills while those in secondary care were 







Years registered as a health professional 
Comparison of scores for each component and the number of years each 
respondent had been registered as a health professional is given in Table 
4.30. 
 





Median  IQR P-value Decision  




and skills’  
≤5 52 51-54 0.011 Reject the 
null 
hypothesis; 




6-10 63 53.5-64 
11-15 56 51-59 
16-20 62 55-63 
21-25 60 56-64 
26-30 64 58-69 
≥30 62 58-71 
‘influences on 
prescribing’ 
≤5 20 20-21 0.537 Retain the 
null 
hypothesis; 
there is no 
difference  
6-10 20 17-20 
11-15 18.5 17.5-20 
16-20 19 17.5-20 
21-25 19 18-20 
26-30 20 16-20 
≥30 18 16-21 
‘consequences 
of prescribing’ 
≤5 21 18-24 0.243 Retain the 
null 
hypothesis; 
there is no 
difference 
6-10 21 19-24 
11-15 19 17-20 
16-20 19 18-20 
21-25 18 17-21 
26-30 18 16-22 
≥30 19 18-21 
‘monitoring 
for safety and 
effectiveness’ 
≤5 15 14-17 0.264 Retain the 
null 
hypothesis; 
there is no 
difference 
6-10 18.5 14-20 
11-15 16 14-16 
16-20 17 16-19 
21-25 16 14-19 




While a statistically significant difference was found in terms of ‘the role of 
professionals and their knowledge and skills’, all scores were generally high 
and above the midpoint of 48. Those with the least experience scored 






Years registered as a as prescriber 
Comparison of scores for each component and the number of years each 
respondent had been registered as a prescriber is given in Table 4.31. 
 





Median  IQR P-value Decision  




and skills’  
≤5 52 49-58 <0.001 Reject the 
null 
hypothesis; 




6-10 63 55-64 
11-15 52 51-56 
16-20 63 60-64 
21-25 59.5 54-63 
26-30 64 63-65 
≥30 61 57-72 
‘influences on 
prescribing’ 
≤5 20 18-20 0.823 Retain the 
null 
hypothesis; 
there is no 
difference 
6-10 20 17-20 
11-15 18 17-20 
16-20 19 17-20 
21-25 19 18-20 
26-30 20 16-20 
≥30 18 16-21 
‘consequences 
of prescribing’ 
≤5 21 18-23 0.017 Reject the 
null 
hypothesis; 




6-10 21 19-24 
11-15 19 17.5-
21.5 
16-20 19 16-20 
21-25 18 17-20 
26-30 18 16-20 
≥30 19 16-20 
‘monitoring 
for safety and 
effectiveness’ 
≤5 15 14-18 0.041 Reject the 
null 
hypothesis; 




6-10 19 14-20 
11-15 15 13-16 
16-20 16.5 16-19 
21-25 16 14-18 
26-30 18 16-19.5 
≥30 18.5 16-20 
 
While a statistically significant difference was found in terms of ‘the role of 
professionals and their knowledge and skills’, all scores were generally high 
and above the midpoint of 48. Those with the least experience as prescribers 
scored significantly lower than those with most experience. Overall, the 
scores for ‘consequences of prescribing’ and ‘monitoring for safety and 




scored more positively in around the ‘consequences of prescribing’ but less 
positively for ‘monitoring effectiveness and safety’.  
 
4.4.7 Analysis of textual responses to open questions 
This section provides findings generated from the content analysis of the 
responses to the open questions of: perceived benefits and limitations of 
prescribing DOACs; positive and negative experiences of prescribing DOACs; 
and how the appropriate use of DOACs in primary care be further extended. 
These are presented using a narrative synthesis approach with brief labelling 
of respondents to protect anonymity. 
Perceived benefits and limitations 
Ninety-nine respondents (71.7%) provided responses. The overwhelming 
benefit, cited by 47 respondents was the absence of need for INR monitoring, 
 “we have been overwhelmed with the need to do regular blood 
monitoring of patients in recent years. This includes warfarin and 
DMARDS. No additional resources have been made available in spite of 
a 300% increase in blood tests we are doing for all types of 
monitoring. Therefore anything which reduces this, such as the use of 
DOACs instead of warfarin helps us to survive” 
[general practitioner, 26-30yrs prescriber] 
The absence of need for monitoring was often mentioned in the context of 
other benefits such as particular patient groups, 
 “no need for monitoring, especially practical in elderly/housebound” 
                                   [general practitioner, years not stated] 
 “good for rural practice and younger patients who can reliably take 
tablets every day” 
                                  [general practitioner, years not started] 




 “no need to monitor therefore cost effective”. 
                                             [general practitioner, 21-25 yrs prescriber] 
Thirteen respondents commented on the likelihood of better adherence, 
”patients understand why they take these drugs and often state how it 
is much easier to take than warfarin especially with the interactions of 
diet and alcohol”. 
                                  [nurse, <5 yrs prescriber]  
Eleven respondents noted benefits in terms of the evidence base, 
 “overall the evidence is that DOACs are at least as good as warfarin 
for preventing stoke and have a lower incidence of fatal bleeding”. 
                               [cardiologist, years not started] 
Ten respondents commented on the more favourable dosing regimens 
compared to warfarin, 
 “…and a single daily dose, not changing like warfarin”. 
                                      [general practitioner, >5 yrs. prescriber] 
A similar number remarked on the benefits in those with labile INRs, 
“less likely to get out of therapeutic range…suitable for patients with 
fluctuating INR”.           [anaesthetist, >30 yrs. prescriber] 
 
Less commonly cited benefits were: better use of GP time, especially in 





The key limitation, cited by 31 respondents, was the lack of a suitable 
reversal agent, 
 “significant concerns regarding how to reverse anticoagulation in 
patient who then sustain injury/ head trauma” 
                                    [secondary care doctor, years not started] 
 “anxious about the lack of an easily available reversal agent” 
                                          [general practitioner, years not started] 
 “no antidote yet for rivaroxaban or apixaban” 
                                           [consultant, >30 yrs prescriber] 
The high cost of DOACs compared to warfarin was considered a limitation by 
17 respondents, 
 “I'd prescribe it more for patients with AF if health board not breathing 
down my neck about cost” 
                                      [general practitioner, 16-20 yrs prescriber] 
One respondent commented that whilst the drug costs were higher, there 
were savings when considering other associated costs,  
 “costly but saves on nurse/lab/doctor time to dose warfarin”  
                                                [general practitioner, 16-20 yrs prescriber] 
Ten respondents were concerned by the lack of ability to monitor 
anticoagulation status,  
 “the main negative is the lack of longer term follow up to ensure 
patients CONTINUE to take the drug as prescribed regularly and on 
time”.     [consultant, 21-25 yrs prescriber] 





“When injecting a joint I prefer to know a patient is on Warfarin as I 
can just check their INR. If they are on DOAC they have to stop their 
medication the previous day, I then have to book them in early in the 
morning and then they take their next dose mid-day. This reduces 
patient choice as to when I can see them”. 
                                                [physiotherapist, <5 yrs prescriber] 
Eight respondents noted their concerns over the lack of long term evidence of 
benefit, 
 “concerned that long term benefits may not be as great as expected, 
i.e.  problems of this group of drugs will show after they have been 
used for more years especially in elderly patients” 
                           [general practitioner, >30 yrs prescriber] 
“I have concerns about the widespread adoption of these drugs and suspect 
the risks of warfarin are over estimated from old studies not based on 
efficient, well run, safe monitor in primary care” 
and adverse effects,  
“I think we do need robust evidence of the risks across the population 
over the next few years”. 
Less commonly cited limitations were around perceptions of increased 
prevalence of adverse effects and dose adjustment in renal impairment.  
Positive experiences 
Seventy-two respondents (52.2%) provided descriptions of their positive 
experiences of DOACs. As with the benefits of DOACs, the main positive 
experiences surrounded the absence of need to monitor INR, cited by 38 
respondents, 
“90 year old on warfarin for AF for 20 years. Became unable to drive 
and a lot of strain on family for weekly INR with no capacity in single 




                            [general practitioner, years not started] 
“a gentleman who had stopped his warfarin due to the difficulties of 
coming in to get his INR checked as he was away a lot. Changed to 
DOAC”.                   [general practitioner, 21-25 yrs prescriber] 
“patient working abroad was able to continue work because INR 
monitoring was no longer required” 
                                  [general practitioner, 21-25 yrs, prescriber] 
Several respondents described similar experiences which were considered 
particularly relevant to those living in remote areas, 
“Initiating anti-coagulation in patient who lives miles away, avoiding 
blood tests, living over 30 miles from GP surgery”. 
                                 [general practitioner, 26-30 yrs prescriber] 
Nineteen respondents gave descriptions of positive feedback from patients, 
 “Feedback from patients has been positive - they no longer have to 
frequently attend the surgery, they can go on holiday more easily, they 
can be more relaxed with the choice of diet” 
                              [general practitioner, 26-30 yrs prescriber] 
“Quality of life improved by not having to come to the practice for his 
INR bloods and not having to alter dosage” 
                                   [general practitioner, years not started] 
In some situations, patients had declined warfarin but were willing to 
commence DOACs, 
 “another patient would not accept warfarin but did DOAC”. 
                                       [general practitioner, years not started] 
Seven respondents commented on enhanced management of those with 




“a patient whose INR was impossible to keep in therapeutic range was 
able to get proper treatment”. 
                                      [general practitioner, 16-20 yrs prescriber] 
Less commonly cited experiences were around better patient management 
and more rapid, effective anticoagulation. 
Negative patient experiences 
Descriptions of negative patient experiences were provided by 64 
respondents (46.4%), with an additional 19 (13.8%) stating that they had no 
negative experiences to report. 
The key negative experience was around adverse events of bleeding, 
described by 24 respondents, 
“patient admitted with severe upper GI bleed while on prophylactic 
dose after hip replacement”, 
                                   [consultant, 21-25 yrs prescriber] 
“brisk bleed requiring admission (epistaxis) on switching from warfarin.  
Specialist initiated and within guideline”, 
                         [general practitioner, 26-30 yrs prescriber] 
“a patient developed a large knee effusion (no trauma) which was 
heavily bloodstained. I stopped his DOAC”. 
                                [general practitioner, >30 yrs prescriber] 
Two of these respondents reported that bleeding had led to death of the 
patient, 
“death of a patient from an intracranial bleed on rivaroxaban”. 
                                            [general practitioner, years not started] 
An additional five respondents commented on issues related to bleeds, 
“emergency admission for surgery - prolonged operation due to 
increased (but not unmanageable) bleeding”. 




Thirteen respondents commented on their experiences of non-bleeding 
adverse events of varying severity and with diverse consequences, 
“patient developed side effect from DOACs (severe nausea) and 
returned to warfarin”.        [general practitioner, years not started] 
“terrible oesophagitis with dabigatran” 
                          [general practitioner, >30 yrs prescriber] 
Three respondents described issues relating to the consequences of rapid 
anticoagulation on discontinuing DOACs, 
“we have had 3 patients who have had strokes shortly after 
discontinuing DOACS”.  [general practitioner, >30 yrs prescriber] 
Less commonly cited negative experiences included issues relating to 
inadequate monitoring of patients prior to commencing DOACs, 
“colleagues not monitoring renal function and LFTs so overdosed DOAC 
and patient admitted”.     [general practitioner, >30 yrs prescriber] 
Several described issues related to clinician lack of recognition of the names 
of DOACs as anticoagulants, 
“DOAC not stopped despite bleeding as not noted as a blood thinner in 
same way as warfarin”.    [consultant, 21-25 yrs prescriber] 
“Prescription of dabigatran when enoxaparin hadn't been stopped” 
                                                [consultant, years not stated] 
and patient anxiety, 
“patients are often wary to start treatment with a DOAC as they are 
aware of the lack of antidote”. 
                                             [pharmacist, < 5yrs prescriber] 
Comments on NHS Highland guidelines 
Seventy-four respondents (53.6%) provided comments in relation to the NHS 
Highland guidelines. Forty respondents considered these to be accessible, 




 “easily accessible in NHS Highland formulary”, 
                                       [general practitioner, years not started] 
“guidelines in formulary good. Cardiologists always happy to help if 
patients not quite fitting n guidelines but I felt merited it”, 
                                    [general practitioner, years not started] 
“NHS highland guidance is excellent and clear for this”. 
                             [general practitioner, years not started] 
Thirteen respondents commented that they were not aware of the guidelines 
or had not read them, 
 “unfamiliarity with them - both for myself and colleagues. People more 
familiar with warfarin therefore more comfortable”, 
                                [general practitioner, years not started] 
“…but I will look them up now”.    [nurse, years not started] 
Seven respondents raised concerns over significant differences between 
guidelines from different sources and also product marketing authorisations, 
“don't know that apixaban should be third line, Greater Glasgow and 
Clyde now has it first line. The guidelines specify renal function as 
eGFR but the license for all these drugs is CrCl. This can be 
substantially different. Have had to insert a calculator on Vision to 
work this out and have had to make sure nurses are updating height 
and weight etc”.       [pharmacist, years not started]  
Similarly, five respondents commented that the guidelines were out of date,  
“Highland guidance appears to be out of date although it could be 
formulary is too old”    [general practitioner, years not started] 
Continuing professional development (CPD) 
Thirty-seven respondents (26.8%) described a range of CPD activities 





“attended anticoagulation symposium this year in Stirling on the 
subject”.                                     [nurse, years not started]  
 “cardiology Heart of the Matter events very useful refresher and 
update”.                    [general practitioner, > 30 yrs. prescriber] 
 “I read several journal articles on DOACs in AF when they were first 
coming into use which I found useful”. 
                                     [general practitioner, years not started] 
 
Forty respondents (29.0%) remarked on CPD they were planning or would 
like to see provided. Eleven commented on their own needs to read the NHS 
guidelines,  
 “I need to look at the guidelines and the suggested learning module”. 
                                        [general practitioner, years not started] 
Nine respondents suggested further face-to-face events, 
“face-to-face to allow questions and answers would be immensely 
valuable”.              [nurse, years not started] 
with some suggesting specific topics, 
“I think a simple update from a pharmacist on interactions, prescribing 
considerations e.g. dose alterations in renal function, taking with meals 
etc. would be useful. I am also unfamiliar with if and when monitoring 
is indicated”.                          [cardiologist, years not started] 
One described the need for development of the entire multidisciplinary team, 
even those not prescribing DOACs, 
“I also feel monitoring INRs and dosing widely done by HCAs 
[healthcare assistants] and nurses with no understanding of warfarin 




everyone involved in INR testing/warfarin monitoring should have to 
undertake at least once”. 
 
Extending the appropriate use of DOACs 
Forty-eight respondents (34.8%) provided comments on extending the 
appropriate use of DOACs. CPD related activities were described by 11 
respondents,  
“further training of safety aspect - a lot of misinformation still being 
given to patients”.          [general practitioner, years not started] 
Several of these respondents commented more appropriate use would be 
derived through increased experience, 
“need more confidence in using which comes with experience and 
training. More training will likely lead to more use and eventually more 
confidence’.       [general practitioner, years not started]  
Seven respondents suggested reviewing all patients prescribed 
anticoagulants for consideration of DOACs, 
“consideration of switching to DOAC when attending anticoagulation 
clinic - patients tend to stay on meds long term not always with good 
reason or proper review”.  
[general practitioner, 16-20 yrs prescriber] 
Seven respondents remarked on the need to review the NHS Highland 
guidelines. One of these respondents considered the guideline to be 
restrictive, 
“prescribing freedom for prescribers i.e. no restrictive guideline or fear 
of budgets etc. if they were able to just consider what would be best 




Four respondents, however, commented on the need to be cautious in 
extending the use of DOACs, particularly the need for longer term evidence of 
safety, 
“I'd need to hear convincing arguments about why we should - I'm 
concerned that the potential harms of widespread use are not yet 
apparent”.                  [general practitioner, >30 yrs prescriber] 
“We generally avoid, where possible, starting our patients on any new 
drugs in our practice until ten years post licensing, although there are 
situations when we might start new drugs. This is because often 
problems are not immediately apparent at the time of licensing or in 
the first few years afterwards, or worse, withheld by drug companies”. 
    [general practitioner, >30 yrs prescriber] 
  
4.5 DISCUSSION  
4.5.1 Main findings 
This survey captured data from mostly experienced medical and nonmedical 
prescribers across different settings. PCA of the TDF determinants gave 4 
components: the role of professionals, their knowledge and skills; influences 
on prescribing; consequences of prescribing; and monitoring for safety and 
effectiveness. While component scores for the role of professionals, their 
knowledge and skills, and influences on prescribing were positive, those for 
the other 2 components were more neutral. There were low levels of 
agreement for statements relating to more effective, safer and cost‐effective 
treatment when prescribing DOACs rather than warfarin. There were similar 
responses around the complexity of bleeding management and detection of 
over and under‐anticoagulation. The lack of need for INR monitoring was, 
however, identified as a positive aspect of DOAC use. 
4.5.2 Strength and weaknesses 
This study adds to the limited evidence base on prescribers' perspectives of 




review (Generalova et al, 2018). Furthermore, this is the first study which 
based questionnaire items on a theoretical framework thus increasing the 
likely construct and criterion validity. There are, however, several limitations 
to the study hence the findings should be interpreted with caution. Although 
a response rate could not be determined, the number of responses, 
particularly from secondary care, appears low. As a self‐reported study, it 
may be subject to biases such as social desirability and acquiescence biases. 
Furthermore, the study was conducted in 1 remote and rural geographical 
area of Scotland thus the results and conclusions may lack external validity. 
While the analysis of the open comments add some explanation, this was not 
a mixed-methods study and hence the summative content analysis does not 
represent qualitative methodology. Furthermore, the summative content 
analysis was descriptive and not intended to generate any theory during 
synthesis.  
 
4.5.3 Interpretation of findings 
This study is both relevant and timely given the increase in DOAC prescribing 
(Loo et al, 2017), and being the first‐line recommendation for non‐AF 
management in national and international guidelines (NICE, 2014, January et 
al, 2014, Kirchhof et al, 2016, Steffel et al 2018). The consequences of 
prescribing and monitoring for safety and effectiveness had neutral scores. 
While there was general agreement that implementing DOAC guidelines 
would be good for patients and organisations, there was markedly less 
agreement that patients prescribed DOACs in preference to warfarin would be 
treated more effectively, safely and cost‐effectively. At first glance, these 
findings appear contradictory but it may be that prescribers consider 
guidelines beneficial to patient care but are less aware of the specific 
evidence from which the guidelines are derived. Notably, less experienced 
prescribers were statistically significantly more positive in their responses, 
which could be as a result of more recent university and practice‐based 
education and training on DOACs or having less real world experience to 
question the results of even large randomised controlled trials. The majority 
of respondents in a survey of German physicians considered DOACs equally 





In terms of monitoring for safety and effectiveness, few respondents 
disagreed that DOAC related bleeding would be more challenging to manage 
than warfarin. These concerns were also identified in previous surveys of 
European research network centres and German physicians (Lip et al., 2013, 
Wutzler et al., 2014). Given that idarucizumab is now licensed for use and is 
indicated to reverse dabigatran in patients with life threatening haemorrhage 
or need for urgent surgery (Pollack et al., 2015 ) and that reversal agents for 
other DOACs are being developed (Arbit et al., 2016) , it is likely that these 
concerns will be abated. Many respondents believed that DOAC‐related over 
and under‐anticoagulation could not easily be detected. Again, less 
experienced prescribers were statistically significantly more positive in their 
responses. Analysis of the open comments also identified this as a potential 
issue in relation to non adherence. The specific site of action of DOACs on the 
coagulation cascade, together with the predictable pharmacokinetic and 
pharmacodynamic properties and fixed drug dosages (other than renal 
impairment) eliminate the need and usefulness of INR monitoring (Gómez‐
Outes et al., 2015). The scores for the role of professionals, their knowledge 
and skills, and influences on prescribing were much more positive. Responses 
indicated self‐reported knowledge of aspects of DOAC guidelines, evidence 
base and clinical pharmacology. They were aware of how to initiate and 
monitor DOACs, responding that this was part of their role, and that they 
were generally competent and confident. While there were mixed responses 
on deciding between DOACs and warfarin, local and national guidelines have 
since been updated with DOACs as first line. For influences on prescribing, 
the most negative responses were in relation to cost and scrutiny by the 
health board. Systematic reviews of the cost‐effectiveness of DOACs 
compared to warfarin have recommended that, while further real‐world data 
are required 
DOACs are more cost‐effective than warfarin despite the higher acquisition 
costs (Jegathisawaran et al., 2017, Pinyol et al., 2016).  The specific findings 
of the more neutral components and statements with negative responses 
should be considered to optimise DOAC prescribing for nonvalvular AF. In 
2017, Healthcare Improvement Scotland updated their guidance on the use 




effectiveness (HIS, 2017). The lack of direct comparisons between DOACs 
was noted hence the recommendations were based entirely on indirect 
evidence from published network meta‐analyses. Edoxaban is now 
recommended as first‐line treatment for nonvalvular AF with the other 3 
DOACs being second line. The local guidelines in NHS Highland, along with 
other health boards in Scotland, have been adapted accordingly. 
As well as raising awareness of the updated guidance, attention should 
be paid to specific aspects including the evidence base of effectiveness, 
safety and cost effectiveness, management of bleeding, issues of over‐ and 
under‐anticoagulation. 
Content analysis of the textual comments captured in this survey 
complement the quantitative data. Not having to monitor INR was the most 
cited benefit, particularly for prescribers and patients in remote and rural 
settings, followed by potentially improved patient adherence. These benefits 
were reflected in descriptions of positive experiences and patient feedback. 
The main limitations were the lack of reversal agents, cost and inability to 
monitor anticoagulation status. Many described experiences of adverse 
effects including fatal and non-fatal bleeding, and upper GI disturbances.   
This study adds to the limited evidence base of prescribers’ experiences of 
DOACs, and is timely given that DOACs are now recommended first line for 
those with non-valvular AF (NICE, 2014, January et al., 2014, Kirchhof et al., 
2016, Steffel et al., 2018, Loo et al., 2017). However, given that data were 
collected in one remote and rural area of Scotland, the results may lack 
generalisability and transferability to other settings. Furthermore, the data 
were collected using a crosssectional survey methodology rather than 
through a qualitative approach (e.g. interviews and focus groups) which 
limited the depth of enquiry. As the findings represent perceptions of benefits 
and limitations, the analysis was not informed by any theoretical framework.   
Studies of healthcare provision in remote and rural areas have identified 
access as an issue, particularly in older populations and those with higher 
healthcare utility (Prior et al., 2010, Haggerty et al., 2014, Wong at el., 2009, 
Manthorpe J et al., 2008, King et al., 2009, Rushworth et al., 2018). While 
many positive perceptions of DOACs identified in this study may be generic to 




action of DOACs on the coagulation cascade, predictable pharmacokinetic and 
pharmacodynamic properties and fixed dosages eliminate the need and 
usefulness of INR monitoring (Gomez-Outes et al., 2015). Not having to 
monitor was perceived as a major benefit, and was highlighted in descriptions 
of patient positive experiences. However, lack of monitoring was also 
perceived a limitation, specifically the lack of ability to closely monitor 
coagulation status. These are original findings, not having been reported in 
the systematic review of clinicians’ experiences, nor any systematic reviews 
of patients’ experiences (Generalova et al., 2018, Loewen  et al., 2017, Wilke 
et al., 2017).  
Adverse reactions, most notably bleeding related, were described by many 
respondents. It is, however, worth noting that evidence so far indicates that 
DOACs are associated with clinically important reductions in the frequency of 
major bleeding, including life-threatening bleeding events and, especially, 
intracranial bleeding, when compared with patients receiving warfarin( 
January et al., 2014, Kirchhof at al., 2016, Steffel et al., 2018). In the UK, 
DOACs are labelled ‘black triangle drugs’ meriting reporting of all adverse 
reactions (irrespective of severity) to the Medicines and Healthcare products 
Regulatory Agency (MHRA). Given that under-reporting is a major limitation 
of pharmacovigilance processes, further research on DOAC reporting is 
warranted. There were also descriptions of adverse events attributed to rapid 
reversal of anticoagulation following DOAC discontinuation prior to surgical 
intervention, as noted by others (Gonzalez-Gonzalez et al., 2013, Levy et al., 
2016). Guidelines on the management of patients prescribed DOACs requiring 
elective and emergency procedures are emerging (Gomez-Outes et al., 
2015).  Concerns of managing DOAC related bleeding may also diminish with 
the licensing of idarucizumab to reverse dabigatran in patients with life 
threatening haemorrhage or need for urgent surgery (Pollack et al., 2017).    
Andexanet alfa, a class-specific antidote for the factor Xa inhibitors, is now 
available and other DOAC reversal agents are in development (Arbit et al., 
2016).   
Different views were given in relation to DOAC cost, with some describing 
cost as a limitation while others believed costs reduced given the additional 




analyses of the cost-effectiveness of DOACs versus warfarin have 
recommended that, while further real world data are required, DOACs are 
more cost-effective despite higher prescribing costs ( Jegathisawaran et al., 
2017, Pinyol et al., 2016).   
There was a range of views around the widespread adoption of DOACs with 
some supporting the evidence base of effectiveness, cost-effectiveness and 
safety while others were more cautious due to the lack of real-life, longterm 
evidence. This finding has been identified for many newly launched agents; in 
a recent study of the adoption of cardiovascular drugs in the United States, 
physicians were found to be generally conservative, with a minority adopting 
dabigatran, aliskiren or pitavastatin in the first 15 months of market launch 
market (Anderson  et al., 2018).  
4.5.4 Conclusion 
This study has demonstrated that prescriber respondents in NHS Highland 
perceive themselves to be knowledgeable, confident and competent in the 
use of DOACs for nonvalvular AF. There was, however, markedly less 
awareness of the evidence base of the effectiveness, safety and cost‐
effectiveness of DOACs. There were issues around the management of DOAC 
related bleeding and the identification of over‐ and under‐anticoagulation. 
Further emphasis of these aspects is required during continuing professional 
development, and implementation and evaluation of guidelines. 
4.6 Reflections and future directions 
Given that the guidance issued nationally in Scotland recommends edoxaban 
first line (HIS, 2017 ), and that this recommendation has been adopted in 
NHS Highland (NHS Highland, 2018) there is merit in conducting research 
relating to edoxaban prescribing in the management of non-valvular AF and 








CHAPTER 5 A cross-sectional survey of prescribers in NHS Highland: 
determining views and experiences relating to prescribing edoxaban 
for the management of non-valvular AF 
 
5.1 INTRODUCTION  
As noted in Chapter 4, there is a need to focus on edoxaban given its primary 
role in national and local guidelines. This chapter presents the method, 
results and discussion of a cross-sectional survey of prescribers’ behaviours, 
views and experiences relating to prescribing edoxaban for the management 
of non-valvular AF. 
 
5.2 RESEARCH AIM  
The aim of this phase of research was to determine prescribers’ behaviours, 
views and experiences relating to prescribing edoxaban for the management 
of non-valvular AF. 
 
5.2.1 Research questions  
In relation to prescribers and edoxaban, the research questions were: 
1. how is edoxaban initiated, prescribed and monitored? 
2. which behavioural determinants potentially impact behaviours around 
prescribing edoxaban?  
3. what are the perceived benefits and limitations of prescribing DOACs?  
4. what are the positive and negative experiences of prescribing DOACs? 
 
5.3 RESEARCH METHOD   
The research methodology and method was replicated as described in 
Chapter 4 with the following exceptions.  
i. Questionnaire items focused on edoxaban, rather than DOACs as a 
group 
ii. Increased emphasis was placed on aspects of pharmacovigilance given 
the issues highlighted in the previous chapter 




iv. Given that the behavioural determinant items were very similar, the 
PCA components identified from the previous survey were used in 
analysis. Also note that the number of respondents was insufficient to 
undertake PCA  
v. The number of responses precluded any inferential analysis  
The final questionnaire can be found in Appendix 5.1 
5.4 RESULTS  
5.4.1 Demographics 
One hundred and three responses were received, 96 (93.2%) from doctors 
(67 general practitioners), six (5.8%) from pharmacist prescribers and one 
(1.6%) from a nurse prescriber. As explained in Chapter 4, a response rate 
could not be calculated. The mean age of the respondents was 45.3 years 
(standard deviation 11.9 years). Respondents were experienced as health 
professionals, with just under half (n=48, 46.6%) having twenty of more 
years of experience as health professionals. Slightly less (n=46, 44.7%) had 
twenty or more years of experience as prescribers. The demographic 





Table 5.1. Respondent demographics (N=103) 





























































































































5.4.2 Current practice with edoxaban  
Current practice relating to the prescribing of edoxaban, and in relation to 
other DOACs in given in Table 5.2 
 
Table 5.2. Approximate frequency of edoxaban prescribing behaviours (N=103) 
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Switch patients from 











Twenty-nine respondents never prescribed edoxaban and were not likely to 
do so in the near future hence were excluded from further analysis. These 29 
respondents were psychiatrists, anaesthetists, anaesthetic specialists, renal 
specialists, orthopaedic/trauma/emergency medicine specialists and GPs.   
 
Of the 74 respondents prescribing edoxaban, the majority (n=64, 86.5%) 
reported being aware that edoxaban was the first line recommendation within 
the NHS guidelines. Almost all respondents (n=61, 88.9%) had been 
encouraged to implement this recommendation. Only around one third 
(n=26, 35.1%) had switched all appropriate patients from warfarin to 
edoxaban, with slightly more (n=30, 40.5%) having switched all appropriate 
patients from other DOACs to edoxaban.  
 
Seven respondents (9.5%) reported that patients had experienced adverse 
drug reactions to edoxaban. Of these, two respondents (28.6%) had 
submitted a Yellow Card report to the Medicines and Healthcare products 
Regulatory Agency (MHRA). Twenty-seven respondents (36.5%) reported 
that patients had experienced adverse drug reactions to other DOACs, five 





5.4.3 Behavioral determinants 
The responses to items the TDF of behavioural determinants are given in 
Tables 5.3-5.10. 
 
Table 5.3. Response to items in the domain of knowledge (N=74) 


















I have sufficient knowledge of the 
guidelines to allow me to prescribe 













I have sufficient knowledge of the 
clinical pharmacology of edoxaban to 














I have sufficient knowledge of the 
evidence base of edoxaban to allow 


























I have sufficient knowledge of how to 













I have sufficient knowledge of when 
and how to switch patients from 














I have sufficient knowledge of when 
and how to switch patients from other 














I have sufficient knowledge of how to 











0 0  
 
(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
While responses to most statements were positive, there was less agreement 
relating to knowledge around switching patients from warfarin to edoxaban 
(n=48, 64.9% strongly agree/ agree), switching patients from other DOACs 
to edoxaban (n=36, 48.7% strongly agree/ agree) and monitoring adverse 






Table 5.4 Response to items in the domain of professional role and identity (N=74) 

































I should only prescribe edoxaban 



























It is part of my role to switch patients 











0 1.4  
(1) 
(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The majority of respondents were in agreement that the various prescribing 
actions relating to edoxaban were part of their role and not restricted to 
specialists. Three quarters of respondents (n=56, 75.7% agreed/ strongly 
agreed) that it was part of their role to initiate edoxaban, with slightly less (n 
= 49, 66.2% agreed/strongly agreed) that it was their role to switch patients 






Table 5.5. Response to items in the domain of belief of capabilities (N=74) 






























I am confident in switching patients 










0  0 
I am confident in switching patients 









 0 1.4  
(1) 
 










 0 2.7 
(2) 
I am competent in switching  patients 










0  1.4 
(1) 
I am competent in switching patients 











(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
Respondents were in agreement that they were both confident and 
competent in various prescribing activities relating to initiating edoxaban, 
switching patients from warfarin to edoxaban and switching patients from 
other DOACs to edoxaban. The lowest levels of agreement were in relation to 
being confident in switching from other DOACs to edoxaban (n=46, 62.2% 
agreed/ strongly agreed) and for being confident in switching from warfarin 
to edoxaban (n=49, 66.3% agreed/ strongly agreed).  
 
Table 5.6. Response to items in the domain of optimism (N=74) 


















Implementing the guidelines on 
prescribing edoxaban will be better 










 0  4.1 
(3) 
Implementing the guidelines on 
prescribing edoxaban will be better 


















The majority of respondents were optimistic around the use of the NHS 
Highland guidelines on edoxaban and benefits for patients (n=38, 51.4% 
agreed/ strongly agreed), and the organisation (n=51, 68.9%).  
 
Table 5.7. Response to items in the domain of beliefs of consequences (N=74)  


















If I prescribe edoxaban rather than 
warfarin, I believe that patients will 












If I prescribe edoxaban  rather than 
warfarin, I believe that patients will 









0  2.7 
(2) 
If I prescribe edoxaban rather than 
warfarin, I believe that patients will 














If I prescribe edoxaban rather than 
other DOACs, I believe that patients 
will be treated more effectively  
 










If I prescribe edoxaban  rather than 
other DOACs, I believe that patients 












If I prescribe edoxaban rather than 
other DOACs , I believe that patients 














If I switch patients  on other DOACs 
to edoxaban, I believe that patient 














If I prescribe edoxaban rather than 
other DOACs, I believe that my 
management of severe bleeding will 












(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
  
Respondents, in general, were rather ambivalent about the consequences of 
prescribing edoxaban in relation to outcomes of effectiveness (n=41, 55.4% 
agreed/ strongly agreed), safety (n= 31, 41.9% agreed/ strongly agreed) 




warfarin. There was much less agreement around the consequences of 
prescribing edoxaban rather than other DOACs in terms of effectiveness 
(n=15, 20.3% agreed) and safety (n=10, 13.5% agreed). However, there 
was more agreement relating to cost-effectiveness (n=43, 57.1% agreed/ 
strongly agreed). There was uncertainty around compromising patient care 
by switching patients on other DOACs to edoxaban (n=31, 41.9% unsure/ 
agreed/ strongly agreed), and that management of severe bleeding will be 
more challenging when prescribing edoxaban rather than other DOACs (n = 
38, 51.4% unsure/ agreed).  
Table 5.8. Response to items in the domain of memory, attention and decision 
processes (N=74) 


















I find the guidelines on edoxaban 












I find it difficult to decide whether to 
prescribe edoxaban, rivaroxaban, 














Others have to remind me to 













Unless contra-indicated, I intend to 
prescribe edoxaban for all new 










 0 2.7  
(2) 
I have sufficient support from 
specialists to enable me to prescribe 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The responses from more than one third of respondents indicated difficulty in 
selecting a DOAC (n=29, 39.2% unsure/ agree/ strongly agree). Two thirds 
of respondents agreed/ strongly agreed that they had sufficient support from 






Table 5.9. Response to items in the domain of social influences (N=74) 


















My prescribing of edoxaban is 












My prescribing of edoxaban is 
discouraged by my organisation 
 
0 0 10.8 
(8) 






My prescribing of edoxaban is 
discouraged by specialists 
 








(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
Responses within this domain were positive with few agreeing that 
prescribing of edoxaban was discouraged by their peers, specialists or their 
organisation).  
 
Table 5.10. Response to items in the domain of emotions (N=74) 


















I feel anxious when initiating 
edoxaban 
 










I feel anxious when switching patients 












I feel anxious when switching patients 












(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
In terms of emotions, there appeared to be few issues around prescriber 
anxiety when either initiative edoxaban or switching patients from either 






5.4.4 Principal component analysis 
As described earlier, PCA is a statistical approach to identify a smaller 
number of components of interrelated variables which can then be used as 
outcome measures for further statistical analysis. Given the number of 
responses to the edoxaban questionnaire, it was not possible to undertake 
PCA. With 33 questionnaire TDF items, this would have required a minimum 
of 33 x 5 = 165 response. However, as the TDF items were largely the same 
as those used in the survey reported in Chapter 4, the edoxaban TDF items 






Table 5.11. Component 1, items related to ‘the role of professionals and their 




I have sufficient knowledge of the guidelines to allow me to 
prescribe edoxaban safely and effectively  
 
Knowledge 
I have sufficient knowledge of the clinical pharmacology of 
edoxaban to allow me to prescribe safely and effectively 
 
Knowledge 
I  have sufficient knowledge of the evidence base of edoxaban 
to allow me to prescribe safely and effectively 
 
Knowledge  
I have sufficient knowledge of how to initiate edoxaban 
 
Knowledge  
I have sufficient knowledge of how to monitor the 
effectiveness and toxicity of edoxaban 
 
Knowledge  
I have sufficient knowledge of how to manage adverse 
reactions of edoxaban 
 
Knowledge  
It is part of my role to initiate edoxaban 
 
Professional role and 
identity  
I should only prescribe edoxaban when initiated by others Professional role and 
identity 
Only specialists should initiate edoxaban Professional role and 
identity  
I am confident in my ability to initiate edoxaban 
 
Beliefs of capabilities  
I am competent in initiating edoxaban Beliefs of capabilities  
I find the guidelines on edoxaban easy to interpret 
 
Memory, attention 
and decision process  
I find it difficult to decide whether to prescribe edoxaban, 
rivaroxaban, dabigatran and apixaban 
 
Memory, attention 
and decision process 




and decision process 
I have sufficient support from specialists to enable me to 











Table 5.12. Component 2, items related to ‘influences on prescribing’ (n=3) 
Statement TDF domain 
 
 Social influences  
My prescribing of edoxaban is discouraged by my organisation  
 
Social influences 





Table 5.13. Component 3, items related to ‘consequences of prescribing’ (n=5) 
Statement Original TDF 
 
Implementing the guidelines on prescribing edoxaban will be 
better for patients 
 
Optimism  
Implementing the guidelines on prescribing edoxaban will be 
better for my NHS organization 
 
Optimism  
If I prescribe edoxaban rather than warfarin, I believe that 




If I prescribe edoxaban  rather than warfarin, I believe that 




If I prescribe edoxaban rather than warfarin, I believe that 





Table 5.14. Component 4, items related to ‘monitoring for safety and effectiveness’  
(n=1) 
Statement TDF domain 
 
If I prescribe edoxaban rather than other DOACs, I 
believe that my management of severe bleeding will be 
more challenging 
 
Beliefs of consequences  
 
Given that there is only one item within this component, this will not feature 
in any further analysis. 
Internal consistency values (Cronbach's alpha) were calculated for the three 
remaining components, aiming for values greater than 0.7, with all negatively 
worded items reversed.  
Tables 5.15-5.17 give the item responses and Cronbach's alpha values for 





Table 5.15. Component 1, responses to items related to ‘the role of professionals and 




















I have sufficient knowledge of the guidelines 














I have sufficient knowledge of the clinical 
pharmacology of edoxaban to allow me to 













I  have sufficient knowledge of the evidence 
base of edoxaban to allow me to prescribe 
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*I find it difficult to decide whether to 















*Others have to remind me to prescribe 












I have sufficient support from specialists to 






























(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing; * reverse 
scored) 
The Cronbach’s alpha value at 0.874 is greater than 0.7 therefore the scale is 
considered to be reliable. Scoring 1 for strongly disagree to 5 for strongly 
agree (negatively worded items reverse scored) gives the minimum possible 
value for the scale of 16 (representing most negative responses) and the 
maximum possible value for the scale of 80 (representing most positive 
responses) and a midscale point of 48.  
With a median value of 61 and IQR of 58-64 (minimum 38, maximum 76), 
respondents generally gave positive responses.  





















*My prescribing of edoxaban is 












*My prescribing of edoxaban is 












*My prescribing of edoxaban is 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing; * reverse 
scored) 
The Cronbach’s alpha value at 0.852 is greater than 0.7 therefore the scale is 
considered to be reliable. Scoring 1 for strongly disagree to 5 for strongly 
agree (negatively worded items reverse scored) gives the minimum possible 
value for the scale of 3 (representing most negative responses) and the 
maximum possible value for the scale of 15 (representing most positive 
responses) and a midscale point of 9.  
With a median value of 12 and IQR of 12-12 (minimum 9, maximum 15), 


























Implementing the guidelines on 













Implementing the guidelines on 
prescribing edoxaban will be better for 
















If I prescribe edoxaban rather than 
warfarin, I believe that patients will 















If I prescribe edoxaban  rather than 
warfarin, I believe that patients will 












If I prescribe edoxaban rather than 
warfarin, I believe that patients will 














(SA, strongly agree; A, agree; U, unsure; D, disagree; SD, strongly disagree; M, missing) 
 
The Cronbach’s alpha value at 0.733 is greater than 0.7 therefore the scale is 
considered to be reliable. Scoring 1 for strongly disagree to 5 for strongly 
agree (negatively worded items reverse scored) gives the minimum possible 
value for the scale of 5 (representing most negative responses) and the 
maximum possible value for the scale of 25 (representing most positive 
responses) and a midscale point of 15.  
With a median value of 17 and IQR of 16-19.75 (minimum 9, maximum 24), 
respondents generally gave neutral responses.  
Given the number of responses, sub-analysis to rest for differences in scores 




5.4.5 Analysis of textual responses to open questions 
As in Chapter 4, this section provides findings generated from the content 
analysis of the responses to the open questions of:  oral anticoagulant of 
choice for new patients with non-valvular AF; perceived benefits and 
limitations of implementing of guidelines on edoxaban; and patient adverse 
reactions to either edoxaban or other DOACs. 
  
Oral anticoagulant of choice for new patients with non-valvular AF  
All respondents provided comments, with three quarters (n=56, 75.7%) 
opting for the guideline recommendation of edoxaban, and a minority for 
rivaroxaban (n=9, 12.2%), apixaban (n=4, 5.4%), warfarin (n=4, 5.4%), 
and one respondent stating ‘NOAC’.   
Justification was largely in the form of edoxaban being recommended within 
the guidelines (n=36),  
 “Because it is the current formulary choice”. 
                                   [general practitioner, 26-30 yrs prescriber] 
 
The selection of five respondents was based on familiarity,  
 “Familiar with this”.  [general practitioner, 26-30 yrs. prescriber] 
“I can remember the dosing and interactions”.   
                                             [general practitioner, 26-30 yrs. prescriber] 
Four respondents based choice on adverse event profile, 
 “Less bleeds for same stroke prevention as rivaroxaban”. 
                                           [general prescriber, 16-20 yrs prescriber] 
Several noted issues relating to edoxaban in those with compromised renal 




“We have had several incidences of patients being discharged from 
Raigmore on the wrong dose of edoxaban for renal function or weight”. 
                                     [general practitioner, 5-10 yrs prescriber] 
Other less commonly cited justification included advice from specialists, cost, 
adherence and drug-drug interactions.  
 
Benefits relating to implementing of guidelines on edoxaban  
Thirty-one respondents (41.9%) provided comments in relation to benefits.  
The main benefit, cited by nine respondents, was the lack of INR monitoring,  
 
 “Patients do not require monitoring of INR and this has meant 
increased availability of nurse appointments”. 
                                 [general practitioner, 21-25 yrs prescriber] 
Eight respondents cited cost implications,  
“... cost benefit mainly”. 
                                     [general practitioner, 16-20 yrs prescriber] 
 
Less commonly cited benefits were related to immediate anticoagulation, 
easier dosing, being ‘better’ for patients and health professionals, and safety.  
 
Limitations relating to implementing of guidelines on edoxaban 
Twenty-four responses (32.4%) were provided, describing a range of aspects 
of edoxaban prescribing. 
Four respondents described issues relating to patients’ concerns, particularly 
around switching from one anticoagulant to another,  
 “Hassle for doctors and patients switching medicines that are long-
standing and patients happy with the old way”,  





“Patients anxious about switching to new medicine as many have been 
on warfarin for long time”. 
                                   [general practitioner, 21-25 yrs prescriber]  
Four respondents remarked on issues around dosing in patients with renal 
insufficiency, 
 “…dosage reductions required in renal impairment”. 
                                                        [pharmacist, 5-10 yrs prescribers] 
Three respondents noted issues relating to easy access of information on the 
NHS guidelines,  
 “Difficult to access any NHS Highland guidelines when working as a 
locum as requires access to NHS intranet. GPs cannot access this from 
outwith a practice (unless they purchase an IT key system)”. 
                                               [general practitioner, >30 yrs prescriber] 
Three cited concerns around the evidence base to support the use of 
edoxaban compared to other DOACs, 
 “Less good outcomes compared to other DOACS and higher risk of 
bleeding”.   [general practitioner, 26-30 yrs prescriber] 
Less comply cited limitations were the time and hassle of switching and not 
being able to monitor coagulation status.  
Patient adverse events on receiving edoxaban or other DOACs 
Twenty-four respondents (32.4%) provided descriptions of adverse events, 
most commonly bleeding which was cited by 22 respondents. Three of these 
respondents described cases of cerebral haemorrhage and intracranial 
haemorrhage and two others stated “major” bleeds. Several noted that while 
patients had experienced bleeding, they believed that this would have 
happened irrespective of the anticoagulant,  
 “Occasional bleeding as they would have had were they on warfarin”, 




“Nose bleeds but would have happened whichever type of 
anticoagulant”.  [general practitioner, 16-20 yrs prescriber] 
Less commonly cited adverse events were rash, arthralgia and 
gastrointestinal problems 
Other comments on prescribing edoxaban and other DOACs. 
Eight respondents (10.8%) provided responses in relation to “any other 
comments”. These included DOACs being easier for patients, and being 
resistant to change to edoxaban as familiar with other DOACs.  
One respondent commented on the need to ensure consistent information in 
all sources,  
 “Update NHS highland shared clinical guidelines to reflect formulary”. 
                                        [general practitioner, 16-20 yrs prescriber] 
Others noted specific issues in relation to providing guidance in specific 
situations,  
“Formulary guidelines need to take account of adults potentially being 
on DOAC and give a guide on what to do (e.g. contraindications) 
especially with guidelines that initiate heparin/ Fondaparinux. Better 
guidance needed on what to do if adults present needing emergency 
surgery e.g. appendicitis or hip fracture. In my view access to Factor 
Xa test is an essential going forward to help deal with these situations 
and others, e.g. adults with CVA where unclear if has taken the DOAC 
or not can have a big impact on emergency treatment decisions, e.g. 
around lysis”.   [consultant, 21-25 yrs prescriber] 
 
 “Perhaps a risk-based approach could be used by some specialists. 
Apixaban for patients with high risk of events (bleeding or stroke). 
Apixaban has the lowest HR for major bleeding, except unlicensed 
edoxaban half-dose which has questionable efficacy”, 





5.5 DISCUSSION  
5.5.1 Main findings 
This survey captured data from mostly experienced medical and nonmedical 
prescribers across different settings. While almost all respondents had been 
encouraged to implement this recommendation of prescribing edoxaban, less 
than one third had either switched patients from warfarin or other DOACs to 
edoxaban. The following three PCA components identified in the previous 
survey were applied to the TDF determinants 4: the role of professionals, 
their knowledge and skills; influences on prescribing; and consequences of 
prescribing. While component scores for the first two components were 
positive, the scores for consequences of prescribing were more neutral. 
Although a number of respondents described edoxaban (and other DOAC) 
related ADRs, very few had submitted a Yellow Card report to the MHRA.  
 
5.5.2 Strength and weaknesses 
 
Many of the study strengths and weaknesses are as described for the survey 
reported in Chapter 4 hence these are not repeated here. One further 
strength is the focus on edoxaban which is therefore highly relevant given the 
policy and practice direction in Scotland and NHS Highland. The main 
additional weakness surrounds the number or response. As explained in 
Chapter 4, a response rate cannot be determined but the number of 
responses for the edoxaban survey is markedly lower across all professional 
groups than that for the DOACs survey. While a number of factors may have 
influenced this reduced uptake, there may be questionnaire fatigue. 
Furthermore, while the theoretical base of the questionnaire items may 
enhance content and construct validity, this resulted in a rather long 
questionnaire. One consequence of the relatively low number of responses 
was that it was not statistically valid to conduct PCA which requires a 
minimum number of responses for five times (or even time times) the 
number of questionnaire items. The decision was taken to use the PCA 
components generated from Chapter 4. While this may be reasonable given 




validity of the findings, interpretation and conclusions. The low number of 
responses, both generally and across specific sub-populations, precluded any 
inferential analysis.  
 
5.5.3 Interpretation of findings 
This study is both relevant and timely. As noted earlier, DOAC prescribing in 
the UK has significantly increased in recent years (Loo et al, 2017). In a more 
recent publication, Sheth et al. (2019) studied the association of stroke and 
bleed events in nonvalvular AF patients with DOACs in NHS England between 
2013 and 2016. The results on DOAC prescribing demonstrated an increase 
in the number of anticoagulation prescriptions, with the mean proportion of 
DOAC prescriptions increasing from 4.4% to 21.4% from 2013 to 2016, 
giving an average increase in the proportion of DOAC prescriptions by 122% 
per annum. The focus on edoxaban is particularly important given its first line 
recommendation for non-valvular AF nationally and locally. Guidance for 
Scotland produced by HIS in 2017 and updated in 2018 based on a rapid 
review of the literature identified little differences in clinical efficacy between 
the different DOACs. Given the significant differences in cost, edoxaban was 
recommended as the first line DOAC (NICE, 2015). This recommendation was 
adopted in NHS Highland in the regional drug formulary (NHS, Highland 
2018). In the study reported in this chapter, the majority of respondents 
(86.5%) were aware that edoxaban was the first line recommendation. 
Similarly, the majority (75.5%) stated that edoxaban was their first choice 
DOAC, largely for reasons of this being the formulary recommendation and 
familiarity in prescribing.  
While the majority of respondents (88.9%) had been encouraged to 
implement the national and local recommendation of edoxaban being first 
line recommendation, fewer (35.1%) had switched all appropriate patients 
from warfarin to edoxaban, with slightly more (n=30, 40.5%) having 
switched all appropriate patients from other DOACs to edoxaban. There could 
be several explanations for these data on switching. Caution in prescribing 
new agents due to the lack of real-life, long-term evidence has been 




adoption of cardiovascular drugs by a cohort of primary care physicians and 
cardiologists in the United States. Those sampled regularly prescribed 
anticoagulants, antihypertensives and statins. The physicians were found to 
be generally conservative, with a minority adopting dabigatran, aliskiren or 
pitavastatin in the first 15 months of market launch market (Anderson et al., 
2018).  
There may also be issues of lack of knowledge, confidence and competence in 
relation to switching. While responses to most knowledge statements were 
positive, there was less agreement relating to knowledge around switching 
patients from warfarin to edoxaban (64.9% strongly agree/ agree) and 
switching patients from other DOACs to edoxaban (48.7% strongly agree/ 
agree). Similarly, for statements relating to belief of capabilities, the lowest 
levels of agreement were in relation to being confident in switching from 
other DOACs to edoxaban (62.2% agreed/ strongly agreed), and for being 
confident in switching from warfarin to edoxaban (66.3% agreed/ strongly 
agreed) confident. Furthermore, respondents were rather ambivalent about 
the consequences of prescribing edoxaban in relation to outcomes of 
effectiveness (55.4% agreed/ strongly agreed), safety (41.9% agreed/ 
strongly agreed) and cost-effectiveness (45.9%) in comparison to treatment 
with warfarin. There was much less agreement around the consequences of 
prescribing edoxaban rather than other DOACs in terms of effectiveness 
(20.3% agreed) and safety (n=10, 13.5% agreed). There was uncertainty 
around compromising patient care by switching patients on other DOACs to 
edoxaban (41.9% unsure/ agreed/ strongly agreed). These findings are 
similar to those presented in Chapter 4 in terms of responses to items on 
DOACs in general.  
There is also a notable lack of guidance on several of the key international 
guidelines described in Chapter 1.  
The 2014 American College of Cardiology/ American Heart Association Task 
Force on Practice Guidelines and the Heart Rhythm Society provide no 
guidance on switching from warfarin to DOACs of switching DOACs. The 2016 
European Society of Cardiology provide little specific guidance on switching 




that should a patient suffer a stroke or TIA whilst taking an anticoagulant, 
switching to another anticoagulant should be considered. In addition, there is 
the recommendation of switching from warfarin to a DOAC when a high time 
in therapeutic range cannot be sustained (Kirchhof et al., 2016). However, 
the 2018 European Heart Rhythm Association guidance provides detailed 
information on switching from warfarin to DOAC, and vice versa, and how to 
switch from one DOAC to another. In switching from warfarin, it is 
recommended that the DOAC can immediately be initiated once the INR is 
<2.0, delaying immediately or delaying till the next day if between 2.0 and 
2.5, and rechecking in one to three days if greater than 2.5. In switching 
between DOACs, an alternative can be initiated when the next dose of the 
DOAC is due, except in situations where higher than therapeutic plasma 
concentrations are expected (e.g. in a patient with impaired renal function). 
In such situations, a longer interval in between DOACs is recommended 
(Barrett et al., 2017). 
In Scotland, neither the national guidance on DOACs published in 2018 nor 
the local guidelines provide any detail on how to switch patients for either 
warfarin or other DOACs to edoxaban (NHS Highland, 2018). It is clear from 
the results of this study that such guidance is warranted, and the European 
Heart Rhythm Association guidance could form the basis of such 
recommendations. 
A small number of studies have also reported data relating to switching from 
warfarin to DOACs or from one DOAC to another. Of the studies in the 
systematic review in Chapter 3, Andrade et al. reported some data on 
switching. In a study of 175 physicians in Canada, prior use of warfarin was 
reported in 55% of apixaban, 83% of dabigatran, and 48% of rivaroxaban 
patients respectively.  The main reason to switch the anticoagulation therapy 
was the physician’s recommendation in just over half of the respondents 
(Andrade et al., 2016). No data were reported on physicians views and 
experiences of switching.  
 
Hale et al (2016) aimed to test the hypothesis that warfarin-treated patients 




comorbidities as compared to those patients who chose to remain on warfarin 
(Hale et al., 2016). Data of demographics and comorbid conditions, stroke 
and bleeding risk scores, and reasons for switching were abstracted for 3873 
patients. Patients who switched from warfarin to a DOAC had similar baseline 
characteristics, risk scores, and insurance status but differed in baseline 
creatinine clearance. The most common reasons for switching were patient 
related ease of use concerns as opposed to clinical reasons. A minority of 
patients that switched to a DOAC switched back to warfarin by the end of the 
study period (Hale et al., 2016). 
Baker et al. (2019) examined switching and discontinuation rates for the 
three most frequently initiated DOACs in non-valvular AF patients in the US. 
Data of over forty thousand patients were extracted from a prescription 
claims database. During the follow-up period, the drug switching rates of 
patients treated with apixaban, rivaroxaban, and dabigatran were 3.6%, 
6.3%, and 11.1%, respectively. After controlling for differences in patient 
characteristics, patients treated with rivaroxaban and dabigatran  had a 
significantly greater likelihood for drug switching than patients treated with 
apixaban. No data were provided on the reasons for switching or the 
experiences of prescribers and patients.  
A small study in Ireland aimed to identify the reasons for patients switching 
from a DOAC to (or back to) warfarin. Data were prospectively collected from 
a four year period in a warfarin dose adjustment clinic. Of the 40 patients 
identified as having switched from a DOAC to warfarin, the most common 
reasons for switching were bleeding, re thrombosis and renal deterioration. 
Other reasons included medication interactions and adverse events. The 
authors concluded that switching from a DOAC to warfarin was seldom 
deemed necessary by clinicians.  
In those situations where a switch in treatment is planned, patients must be 
part of the decision-making process. The need for this is outlined in many 
evidence-based guidelines and statements and is central to the guidance 
issued by NICE in 2009 entitled, ‘Medicines adherence: involving patients in 
decisions about prescribed medicines and supporting adherence’. Patient 




valvular AF management is also highlighted in the local, national and 
international documents previously described (NICE, 2009, ).  
As described earlier, the PCA components identified from the analysis of the 
data in Chapter 4 were adopted in Chapter 5, namely ‘the role of 
professionals and their knowledge and skills’, ‘influences on prescribing’ and 
‘consequences of prescribing’. While this may have introduced limitations, it 
permit easy comparison of results. In general, the results of the two chapters 
are similar, with positive response for the first two components and more 
neutral responses for the third component. Notably, there was less 
agreement for edoxaban being more effective, safer and cost-effective 
compared to other DOACs (levels of agreement 20.3%, 13.5%, 57.1%) than 
compared to warfarin (levels of agreement 55.2%, 41.9%, 45.9%). The 
findings in relation to other DOACs in terms of effectiveness and safety are 
not too surprising given that the guidance from HIS states that results for 
efficacy and safety were generally similar, with some differences between 
particular DOACs and doses. For example, ‘the effects of apixaban 5mg, 
edoxaban 60mg and dabigatran 150mg on stroke and systemic embolism 
prevention were similar’ (HIS, 2017). The higher percentage of respondents 
in agreement around cost-effectiveness also reflects the national selection of 
edoxaban largely based on cost. The results of agreement in relation to 
effectiveness, safety and cost-effectiveness in relation to warfarin were 
largely the same as for Chapter 4 and perhaps for the same reasons. 
Notably, the benefits and limitations in the open comments were also similar 
to those described by the respondents in Chapter 4.  
The questionnaire in Chapter 5 had greater focus on issues of ADRs and 
reporting of ADRs compared to the questionnaire in Chapter 4. In the UK, 
DOACs are labelled ‘black triangle drugs’ meriting reporting of all adverse 
reactions (irrespective of severity) to the Medicines and Healthcare products 
Regulatory Agency [30] via the ‘Yellow Card Scheme’. Many respondents in 
Chapters 4 and 5 described DOAC related ADRs, and ADRs to edoxaban 
specifically were captured in Chapter 5. Despite these being black triangle 
drugs, few prescribers had submitted Yellow Card reports. Notably, there are 
no published papers describing analysis of DOAC ADR reports submitted to 




Under-reporting of ADRs is a significant limitation to the Yellow Card Scheme 
and all other spontaneous reporting schemes. Hazell et al. (2006) reported a 
systematic review to estimate the extent of under-reporting of ADRs to 
spontaneous reporting systems and to investigate whether there were 
differences between different types of ADRs. The 37 studies identified from 
12 countries used a wide variety of surveillance methods, generating 43 
numerical estimates of under-reporting. The median under-reporting rate 
across the 37 studies was 94% (interquartile range 82–98%). Five of the ten 
primary care based provided evidence of a higher median under-reporting 
rate for all ADRs compared with more serious or severe ADRs (95% and 
80%, respectively). It is therefore evident that black triangle status made no 
difference to ADR reporting. While it should be borne in mind that this 
systematic review was published in 2006, other more recent studies have 
demonstrated that under-reporting remains a significant issue. A later 
systematic review by Lopez-Gonzalez et al. (2009) reported the reasons for 
under-reporting, synthesised from 45 studies. Key reasons were: lack of 
confidence in identifying ADRs; not being confident that the drug was the 
cause of the ADR; ignorance that only severe ADRs should be reported; belief 
that the ADR was already well known; lack of knowledge of the reporting 
system; difficulty of reporting; and lack of time. A further systematic review 
by Varallo et al. (2014) also reported reasons for under-reporting pooled 
from 29 studies. The main reasons were ignorance, insecurity and 
indifference (lack of time, lack of interest to register ADRs).  
 
5.5.4 Conclusion 
This study has demonstrated that prescribers in NHS Highland have 
knowledge, confidence and competence how to prescribe edoxaban for 
management of nonvalvular AF. There was lack of knowledge, confidence and 
competence in relation to switching edoxaban and other DOACs.  There was 
less agreement for edoxaban being more effective, safer and cost-effective 
compared to other DOACs. There were less agreement about the 
consequences of prescribing edoxaban in relation to outcomes of 




prescribers have registered ADRs of edoxaban and other DOACs and very few 





CHAPTER 6: DISCUSSION 
6.1 AIMS AND KEY FINDINGS 
The overall aim of this research was to determine clinicians’ views and 
experiences of the use of DOACs for the management of non-valvular AF. The 
doctoral research was conducted in three phases, the key findings of which 
are briefly revisited for completion. Prior to conducting the primary research, 
a systematic review of published literature on clinicians’ views and 
experiences of the use of DOACs for the management of non-valvular AF was 
undertaken. From the very limited number of relevant papers, there were 
limited findings of perceptions of evidence of effectiveness equivalent or 
superior to warfarin and superior safety, the lack of need for INR testing. The 
systematic review highlighted the lack of theory informed research which 
reinforced the initial ideas for the primary research. This was based on a 
positivist approach comprising two consecutive cross-sectional surveys, both 
of which were grounded in behavioural theories and conducted in NHS 
Highlands. The first focused on DOACs in general with key findings that 
responses to items on consequences of prescribing and monitoring for safety 
and effectiveness were rather neutral. Summative content analysis of free 
text responses identified key themes of benefit of not having to monitor INR, 
potentially improved patient adherence and the evidence base. Limitations 
were around the lack of a reversal agent, higher medication costs, not being 
able to monitor coagulation status and adverse effects. Given the policy 
recommendation in Scotland to use edoxaban first line, this was the focus of 
the second cross-sectional survey. Again, the main finding was that 
responses for consequences of prescribing were more neutral. One additional 
aspect not explored in detail in the first survey related to ADRs. Although a 
number of respondents described edoxaban (and other DOACs) related ADRs, 
very few had submitted a Yellow Card report to the MHRA.  
 
6.2 CRITICAL COMMENTARY ON THE DOCTORAL RESEARCH 
This section provides critical commentary on the research design, synthesis 
of findings from the three research phases and contextualization of the 





6.2.1. Research design justification 
The doctoral research was designed using a multiple methods approach of 
systematic review followed by primary research. As with many research 
studies, a number of methodological approaches could be employed mapped 
to the specific aims and research questions/ objectives. While all literature 
reviews should be undertaken systematically, the first phase was a 
systematic review of the peer reviewed, published literature to answer 
specific review questions following a protocol led approach (Stewart et al., 
2016, Moher et al., 2015), and conducted and reported according to specific, 
accepted criteria (Liberati et al., 2009). A scoping systematic review could 
have been conducted as an alternative to a systematic review. This would 
have captured a broader range of studies with greater variation in study 
designs, and is more appropriate to summarise and describe literature in a 
specific field. Given the vast number of available systematic reviews on 
aspects of DOACs (as highlighted in Chapter 1), it was considered that a 
systematic review with specific questions was more appropriate. In addition 
to answering the specific review questions, the systematic review also 
highlighted gaps in the current literature and the limitations of the current 
literature which reinforced the planned primary study research design.  
 
6.2.2 Research philosophy, methodology and methods justification 
and reflection 
As noted in Chapters 2, the research onion highlights the interplay between 
philosophy, approaches and methodologies. Systematic reviews follow 
defined methodological pathways, with the philosophical stance being 
dictated by the specific review questions and the nature of studies, designs 
and outcomes captured. In this systematic review, all but one of the studies 
was cross-sectional, with quantitative outcome measures hence were 
positivist in nature. The diverse range of specific outcomes, and lack of 
application of any consistent outcome measures between studies, greatly 
limited the synthesis which was restricted to being narrative. As more studies 
are published with greater homogeneity, then a more meta-analysis type 




captured only one qualitative study. Again, as more studies are published 
with an interpretivism based philosophical stance, then a meta-synthesis 
approach can be taken.  
Given the lack of theory driven cross-sectional surveys, this methodological 
approach was selected for phases 2 and 3, aligned to the more quantitative 
research aims and objectives hence a positivist philosophical approach. TDF 
was selected as a theoretical framework capturing 33 behaviour change 
theories and their associated constructs. The questionnaire provided 
opportunity for free text comment and extensive comments were provided by 
the respondents. While a mixed methods, explanatory sequential approach of 
cross-sectional survey followed by qualitative research could have been 
undertaken, it was considered by the research team that this would have 
added little to the analysis of summative content analysis. On reflection, a 
truly qualitative phase would have allowed greater exploration of the survey 
findings than was afforded through the open comments. This would have 
provided opportunity to probe findings and allow more extensive synthesis 
linking the context and mechanism to the analysis.  
Despite this limitation, there are key strengths to this doctoral research. As 
noted earlier, the systematic review allowed clear identification of the gap in 
the literature and was itself conducted according to best practice. This robust 
approach provides assurance of the validity and reliability of the findings. The 
questionnaire were grounded in TDF which is being extensively used in 
healthcare research to allow identification of potential behavioural 
determinants acting as facilitators (positive effects) or barriers (negative 
effects). The findings can then for the targets for any behaviour change 
interventions. While there was no specific measure of prescribing behaviour 
in this doctoral research, the findings allow reflection on particular potentially 
positive and negative influences on DOAC prescribing. Given the established 
nature of TDF and that it is derived from established theories, this added 
elements of content, construct and criterion validity to the studies. There 
were also measures to attempt to confirm the face and content validity of the 
questionnaires themselves. In terms of validity, the key limitation of the 
cross-sectional surveys relates to external validity (generalisability). The 




the findings may not be representative of the larger population of prescribing 
in Scotland and beyond. While this is accepted as a limitation, the atypical 
remote and rural nature of NHS Highland in itself is worthy of investigation. 
The results of the surveys have to be interpreted cautiously given the many 
potential biases which are inherent in this research methodology which may 
affect the validity of any findings. Key biases are response (provide non-
honest, inaccurate answers), non-respondent (respondents have different 
views to non-respondents), social desirability (tendency to give socially 
desirable responses) and acquiescence response (more likely to respond 
positively). While a number of measures described in Chapter 2 were taken 
to minimize these, they can never be completely eliminated.  
In addition to issues of validity, reliability should be considered. As noted 
earlier, the online delivery of the questionnaire precluded any test-retest 
reliability hence only internal reliability calculations were undertaken.  
Further strengths of the cross-sectional surveys lie in the analytical approach 
of the quantitative data. PCA is an established statistical approach which was 
undertaken according to best practice. The limitations of the inferential 
analysis in terms of potential issues with sample size and power are 
highlighted in earlier chapters.  
While a content analysis approach of open comments does not satisfy the 
definition and description of qualitative research, attempts were made to 
enhance trustworthiness in analysis and data interpretation. These included 
considerations of credibility (well established methods, frequent research 
team meetings and discussion of data), dependability (attention to 
processes), transferability (description of setting and participants) and 
confirmability (reflecting the participants’ voices). 
Reflecting on the philosophical and methodological approaches of the doctoral 
research, the systematic review was entirely appropriate and would be 
repeated if starting the research at this point in time. In terms of the survey 
approach, on reflection and if starting at this point in time, a mixed-methods 
methodology (sequential explanatory) would be selected encompassing 
positivist and interpretivism based philosophical stances. The cross-sectional 




allow comparisons (e.g. for different geographical regions). The 
questionnaires would still be grounded in TDF with an attempt to link 
behavioural determinants to DOAC prescribing behaviours. These changes 
have impacts in terms of feasibility and resources hence these issues would 
have required in-depth review prior to commencing the research.  
 
6.3 SYNTHESIS OF THE FINDINGS OF ALL RESEARCH PHASES  
This section provides synthesis of the findings of all three research phases 
while avoiding repetition of the discussions in Chapters 3-5. As noted, the 
systematic review highlighted a paucity of relevant research studies with 
generally poor methodologies and methods and limited collection of specific 
data related to clinicians’ views and experiences of research. It is therefore 
difficult to synthesise these results in terms of the survey results; rather they 
simply highlight the need for the robust, theory informed cross-sectional 
surveys. In addition, the aims of the two surveys were very similar with the 
first focusing on DOACs in general and the second specifically on edoxaban. 
This similarity was also reflected in the two questionnaires which were also 
very similar hence the synthesis is limited to being more comparison of the 
differences observed in the findings. Furthermore, the lower number of 
responses for the edoxaban precluded PCA being undertaken and the four 
PCA components for the first survey used in the second. Interestingly, and 
perhaps not unsurprising, the PCA findings for both survey were similar with 
the scores for the components of (i) role of professionals, their knowledge 
and skills and (ii) influences on prescribing being positive. Those for (iii) 
consequences of prescribing and (iv) monitoring for safety and effectiveness 
were more neutral, with statistically significantly more positive scores of 
health lower scores for consequences of prescribing from less experienced 
prescribers. In both surveys there were generally low levels of agreement for 
statements relating to DOACs and edoxaban being more effective, safer and 
cost‐effective than warfarin. There were similar responses around the 
complexity of bleeding management and detection of over and under‐
anticoagulation. The lack of need for INR monitoring was, however, identified 
as a positive aspect of DOAC and edoxaban use. The themes identified in the 




themes of not having to monitor INR, potentially improved patient adherence 
and the evidence base. Limitation were in themes of the lack of a reversal 
agent, higher medication costs, not being able to monitor coagulation status 
and adverse effects. These findings and their implications are discussed at 
length in Chapters 4 and 5. It is also worth noting that since completing this 
doctoral research, no additional studies on clinicians’ or prescribers’ views 
and experiences of DOACs (as a group or individual agents) have been 
published.  
The remainder of this section focuses on interpretation of the findings. Note 
that no new findings of the doctoral research are presented; the studies and 
any supporting data are derived from the peer reviewed literature and 
publicly available sources. 
TDF provided a theoretical framework for the development of the 
questionnaire items. The rationale for applying TDF to this study was to 
provide comprehensive coverage of the potential factors (including positive 
and negative views) which may have influenced DOAC prescribing. Given that 
TDF is an integrative framework of behaviour change theories, it could be 
used to inform the development of interventions to improve DOAC 
prescribing. However, in this doctoral research, no data were collected to 
indicate that prescribing was suboptimal and outwith national and local 
guidance.  
While respondents reported being knowledgeable, confident and competent in 
initiating and monitoring DOACs, responses were less positive in relation to 
switching. This included switching from warfarin to DOACs (including 
edoxaban) and also switching between DOACs. This is relevant given the 
national and local policy statements. There were also less positive responses 
in relation to aspects of the evidence of DOACs in terms of their 
effectiveness, safety and cost-effectiveness, and also monitoring and 
management of over and under anticoagulation. There is therefore a need to 
focus on these aspects in future prescribing guidelines, as described in 
previous chapters. Specific attention should also be placed on the 





A literature search was conducted to identify evidence to support guideline 
implementation. The search was conducted in Medline, CINAHL and 
International pharmaceutical abstracts (IPA) databases to identify systematic 
reviews published in English from 2000 to April 2020. Search terms were 
guideline* (title) AND systematic review* (title) AND implement* (abstract). 
While many of the systematic reviews identified were for specific drug groups 
(e.g. antidepressants, heart failure treatments etc.), Table 6.1 gives those 
which were more general in nature and scope. It is clear from the findings of 
these reviews that there is no robust evidence on effective guideline 
implementation strategies. In the seminal review in this field, Grimshaw et al. 
(2004) reviewed the evidence from 235 studies concluding that studies were 
of varied and generally poor quality and that a number of different 
approaches should be undertaken simultaneously to optimise effectiveness. 
In a further piece of work published in 2010, the same group (Davies et al., 
2010) reviewed these 235 studies in terms of the application of theory (e.g. 
behaviour change theory, implementation theory) as part of guideline 
intervention. They noted that a minority of studies used theory and often 
with little or no justification for the choice of theory. It is worth noting that 
the studies included in this review preceded the development of TDF as a 
framework of behaviour change theories. It should also be borne in mind that 
TDF was included in this doctoral research to provide comprehensive 
coverage of potential influences on prescribing behaviours and not 
behaviours around guideline implementation. The results relating to TDF 
cannot therefore be used as part of intervention development to enhance 
guideline implementation.  
Translating these findings to NHS Highland and Scotland in terms of the 
implementation of DOAC guidelines, a number of multifaceted 
implementation strategies should be employed including: interactive 
education and training activities; high quality printed materials; user friendly 
checklists and tools; clinical reminder systems; use of reminders; audit and 
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69  The following aspects were central 
elements of successful strategies for 
guideline implementation: 
dissemination, education and training, 
social interaction, decision support 
systems and standing orders 
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32  Education for professionals or patients 
and print material were the most 
commonly employed strategies for 
translating guidelines to practice. 
Mapping of strategies onto the 
published taxonomy identified gaps in 
guideline implementation that 
represented opportunities for future 
research and expanded the taxonomy 












88  Multiple approaches using teams of 
healthcare providers were reported to 





















knowledge, practice and or outcomes.  
Team-based healthcare helps to endure 
that patients receive optimum 
assistance to manage complex health 
problems. Authors described complex 
healthcare requiring increasingly 
complex approaches to ensure 
evidence-based guidelines were utilised 
into practice, including using multiple 
dissemination and implementation 
strategies.  
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235 Fifty-three were judged to have 
employed theories, 42 of which used 
only one theory. Twenty-five different 
theories were used. There was poor 
justification of use of theory in 
implementation research. Greater use 
of explicit theory to understand 
barriers, design interventions, and 
explore mediating pathways and 
moderators is needed to advance the 
science of implementation research. 











































Implementation strategies were varied, 
rarely comparable, with variable 
outcomes. Effective implementation 
strategies included multifaceted 
interventions, interactive education and 
clinical reminder systems. Didactic 
education and passive dissemination 
strategies were ineffective. Cost-
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235 There is an imperfect evidence base to 
support decisions about which guideline 
dissemination and implementation 
strategies are likely to be efficient 
under different circumstances. Decision 
makers need to use considerable 
judgement about how. This should 
include consideration of the lmited 
resources they have to 







While many of the survey respondents in Chapters 4 and 5 described negative 
patient experiences with DOACs, it appears that very few Yellow Card reports 
had been submitted to the MHRA.  
The MHRA website provides freely available information on ADR reports 
submitted via the Yellow Card Scheme. Interactive Drug Analysis Profiles 
(iDAPs) are provided for all licensed drugs for reports of suspected ADRs have 
been received ( iDAPs, MHRA). Each iDAP contains data for all spontaneous 
suspected ADR reports submitted by healthcare professionals and patients. At 
April 2020, key data for each of the four DOACs were as follows: 
 
• Dabigatran, first report submitted in 2008; total number of reports = 
1977; total number of ADRs = 4253 (many reports described more than 
one ADR); total number of serious ADRs = 1523; total number of fatal 
ADRs = 165.  
• Rivaroxaban, first report submitted in 2009; the total number of reports = 
6594; total number of ADRs = 13570; total number of serious ADRs = 
4930; total number of fatal ADRs = 420.  
• Apixaban, first report submitted in 2009; the total number of reports = 
4084; total number of ADRs = 8231; total number of serious ADRs = 
3041; total number of fatal ADRs = 282.  
• Edoxaban, first report submitted in 2016; the total number of reports = 
648; total number of ADRs = 1158; total number of serious ADRs = 429; 
total number of fatal ADRs = 29.  
 












Table 6.2 Number of ADRs (non-serious, serious, fatal) submitted to the MHRA 
Year Dabigatran  Rivaroxaban Apixaban Edoxaban 
2008 2    
2009 101 117 1  
2010 115 168 0  
2011 133 147 1  
2012 315 192 14  
2013 406 510 53  
2014 252 766 213  
2015 200 1165 507  
2016 151 1195 665 18 
2017 142 957 831 74 
2018 77 735 840 169 
2019 68 537 792 287 
2020 15 105 167 100 
 
Table 6.3 provides the number of fatal ADRs for each of the four DOACs.  
 
Table 6.3 Number of fatal ADRs (non-serious, serious, fatal) submitted to the MHRA 
Reaction Dabigatran  Rivaroxaban Apixaban Edoxaban 
Cardiac disorders 17 23 16 0 
Gastrointestinal disorders 38 57 42 5 
General disorders and 
administration site 
conditions 
25 30 24 3 
Nervous system disorders 39 216 144 13 
Respiratory, thoracic and 
mediastinal disorders 
10 18 5 2 
Vascular disorders 8 23 19 1 
Other 28 53 34 5 
 
As discussed in Chapters 4 and 5, DOACs are black triangle hence all ADRs, 
irrespective of severity, should be reported to the MHRA. The number of reports 
described for edoxaban in Chapter 5 and the data in Table 6.2 indicate likely 
under-reporting. Indeed, data for DOAC prescribing in NHS Highland in Chapter 
1 (Figure 1.6) indicates in excess of ten thousand dispensing episodes in quarter 
3 of 2018/ 2019. Further work is therefore required to increase ADR reporting 





A very recent systematic review by Li et al. (2020) aimed to assess the impact 
of various strategies to improve ADR reporting published in the last decade and 
compare this with the strategies identified in a previous systematic review. 
Papers published between 2010 and 2019 were identified from a search of 
Medline and Embase databases. Study designs included were: quasi‐
experimental and time series studies; randomised/non‐randomised controlled 
studies; and cluster‐randomised controlled studies. A total of 13 publications 
were included in the review, the majority of which were conducted in Europe. 
Most studies examined the effectiveness of a single form of intervention to 
improve ADR reporting, the most common of which was educational 
(presentations, lectures etc.). Of note, single interventions studies produced a 
seven-fold increase in reporting rate compared to nine-fold for multifaceted 
strategies. The most effective intervention centred on the use of electronic 
reporting tools to improve ADR reporting, with an increase in reporting rate of 
thirteen-fold. The authors of the review highlighted the general poor quality of 
the studies included in the review which was implications for the interpretation 
of the findings. Further limitations included the absence of behavioural theory 
and behaviour change theory in intervention development and the absence of 
studies investigating the sustainability of interventions.  
It appears that further research is required to develop, implement and sustain 
approaches to optimise ADR reporting in general and specifically for DOACs.  
While this doctoral research focused on the perspectives of prescribers, the 
perspectives of patients are clearly highly important. As with the perspectives of 
prescribers, there have been relatively few studies on patients compared to the 
vast number of studies of effectiveness, safety and cost-effectiveness. In 2019, 
Afzal et al. published a systematic review which aimed to analyse the impact of 
patient-reported outcomes in patients on direct oral anticoagulant treatment, 
prescribed for any indication (for example, venous thromboembolism treatment 
or atrial fibrillation) using controlled trials and real‐world observational studies. 
Outcomes of interest were those related to health‐related quality of life (HRQoL), 
satisfaction, adherence and compliance. Included studies were published in 




PubMed, CINAHL, Medline and Embase. Twenty-one articles were retrieved, six 
controlled trials and 15 observational studies, the majority of which were 
conducted in Europe and the US. In those studies researching HRQoL, scores 
were similar in those patients prescribed DOACs or warfarin. The majority of 
those studies measuring patient satisfaction (using self-reported scales) 
described enhanced satisfaction in those prescribed DOACs compared to those 
prescribed warfarin with significantly lower burden and increased perceived 
benefit scores. Studies of patient‐reported adherence (largely using the 8‐point 
Morisky Medication Adherence Scale tool) gave similar results for those 
prescribed DOACs or warfarin.   
 
6.4 ORIGINALITY OF THE RESEARCH 
These three phases of research have generated original findings which extend eth 
knowledge of the views of prescribers in relation to the use of DOACs for non-
valvular AF. As noted throughout, while there is an extensive evidence based of 
the efficacy, effectiveness, safety and cost-effectiveness of DOACs in non-valvular 
AF, little attention has been placed on the perspectives of those prescribing DOACs 
and managing patients.  
The phase one systematic review protocol was registered with PROSPERO and 
the systematic review itself published in the British Journal of Clinical 
Pharmacology. This is the first published systematic review focusing on the 
perspectives of clinicians.  
The systematic review identified the gap in the literature given that only ten 
primary studies on the views and experiences of clinicians had been published. 
All studies had limitations, particularly the lack of any theoretical framework. 
The studies in the following two phases aimed to add to the evidence and were 
theoretically informed surveys conducted in the remote and rural setting of NHS 
Highland. The questionnaires were based upon the TDF to provide 
comprehensive coverage of potential determinants of DOAC prescribing. The 
findings of the first survey on DOACs formed the basis of a publication in the 




doctoral thesis, a paper describing the second survey focusing on edoxaban was 
under review. Taken together, the systematic review and the two surveys 
provide a comprehensive and linked study of prescribers’ views and experiences 
of DOACs in the management of non-valvular AF. 
Study strengths and weaknesses are described in each chapter. One further 
strength is that the studies are linked, with each being based on the findings of 
the previous study. In addition, the surveys reflect changing practice in Scotland 
from the initial HIS recommendations on the use of DOACs to the later 
recommendation on the use of edoxaban.   
 
6.5 FURTHER RESEARCH 
In addition to a focus on guideline implementation, as discussed earlier, to key 
areas for further research surround switching patients from warfarin to DOACs 
or from one DOAC to another, and issues of ADR reporting.  
6.5.1 Study 1 
The aim of the first study is to explore the views and experiences of prescribers 
and patients on switching from warfarin to DOACs or from one DOAC to another. 
This is important given the specific results on switching (i.e. knowledge, 
confidence and competence) highlighted in the surveys reported in Chapters 5 
and 6. A qualitative, constructivist approach is more appropriate than a 
quantitative positivist approach to provide rich data and in depth understanding. 
Semi-structured interviews would be conducted with samples of prescribers with 
experience of switching and their patients, with sampling and recruitment 
continued to the point of saturation in both groups. Sampling would be 
purposive to include a range of prescribers (medical and non-medical, remote 
and rural, experienced and less experienced) and patients (different age ranges, 
remote and rural). Analysis would be thematic using a framework approach. The 
findings would provide in depth understanding of how switching was planned, 
effected, the positive and negative aspects and would inform further DOAC 





6.5.2 Study 2 
Given the prevalence of DOAC prescribing, and the likely future increases, 
further work is required to promote submission of ADR reports to the MHRA. The 
second study aims to determine the impact of interventions on ADR reports 
relating to DOACs. There are two approaches to developing the intervention. The 
first would be based on the findings of the recent systematic review by Li et al. 
(2020). As described earlier in this chapter, multifaceted strategies were more 
effective than single strategies, with the use of electronic reporting tools 
appearing particularly effective. The second approach would be to conduct 
primary research on the determinants of the behaviour of not reporting ADRs. 
TDF could be used in a mixed methods study to determine and explore these 
determinants and then interventions developed based on these specific findings. 
The limitation of this approach is that it would take much longer to develop and 
implement the intervention.  
Baseline data would be collected on the number and types of ADRs reported 
over a defined period of time. After implementing the intervention, targeting 
health professionals and patients, a post-intervention period of data collection 
would be conducted and the results pre and post-intervention compared.  
 
6.6 IMPACT OF RESEARCH 
 
Research impact is defined as being a situation in which, “…the knowledge 
generated by our research contributes to, benefits and influences society, 
culture, our environment and the economy” (What is research impact, University 
of York). This research has potential to impact at several different levels, as 
described below. It should, however, be noted that the research described in 





6.6.1 Academic impact 
Conducting this research has impacted the doctoral student, the members of the 
supervisory and advisory teams and the university. Presentation of the findings 
at international conferences (European Society of Clinical Pharmacy) and 
publication in peer-reviewed journals (British Journal of Clinical Pharmacology) 
has added to the knowledge and evidence base around the use of DOACs in 
clinical practice. Throughout the doctoral research attempts have been made to 
highlight gaps in the evidence base and potential for further research.  
 
6.6.2 The healthcare organisation 
The findings have potential to impact healthcare organisations within Scotland 
and beyond. Reflection on the results of the systematic review allows greater 
consideration of the findings of influences on DOAC prescribing. Similarly, 
reflection on the findings of the two surveys will allow health organisations to 
consider specific aspects of how to support those prescribing DOACs, specifically 
in relation to switching. There is need to consider issues of switching in further 
versions of any local, national or international guidelines. Furthermore, there is 
a need for organisations to highlight the specific evidence base for the 
effectiveness, cost-effectiveness and safety of DOACs. Healthcare organisations 
need to support ADR reporting by health professionals and patients.  
 
6.6.3 Health professionals 
Many of the impacts relating to health organisations also apply at the level of 
health professionals. In addition, reflection on the findings of the systematic 
review and the two surveys will allow further consideration of the facilitators and 
barriers relating to DOAC prescribing in comparison to their peers. They will also 
be able to review the positive and negative patient experiences.  
 
6.6.4 Patients 
While noting that patients were not included as participants in the doctoral 
research, they could be impacted as described for healthcare organisations and 





This doctoral research has generated original findings in relation to prescribers’   
views and experiences of DOACs in the management of patients with non-
valvular AF.  The specific conclusions are as follows 
• The systematic review identified a limited evidence base of prescribers’ 
views and experiences and a need for further research.  
• Findings of the systematic review identified that DOACs were first choice 
over warfarin in naïve patients based and perceptions being 
advantageous in those with an unstable INR and likely to miss 
appointments.  
• The two surveys identified positive and negative views and experiences 
of prescribing DOACs.  
• Prescriber respondents in NHS Highland perceived themselves to be 
knowledgeable, confident and competent in the use of DOACs for 
nonvalvular AF.  
• There was, however, markedly less awareness of the evidence base of 
the effectiveness, safety and cost‐effectiveness of DOACs. There were 
issues around the management of DOAC related bleeding and the 
identification of over‐ and under‐anticoagulation.  
• In relation to edoxaban, a minority of respondents had either switched 
patients from warfarin or other DOACs to edoxaban.  
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Appendix 3.1 Critical appraisal tool  
 







Comment  Yes  No  
Objectives 1 State specific objectives, 
including any pre specified 
hypotheses 
    
Methods    
Setting 2 Describe the setting, 
locations, and relevant 
dates, including periods of 
recruitment, exposure, 
follow-up, and data 
collection 
   
  3 Cross-sectional study—Give 
the eligibility criteria, and 
the sources and methods of 
selection of participants 
    
 
Variables 
4 Clearly define all outcomes, 
exposures, predictors, 
potential confounders, and 
effect modifiers. Give 
diagnostic criteria, if 
applicable 




5*  For each variable of 
interest, give sources of data 
and details of methods of 
assessment (measurement). 
Describe comparability of 
assessment methods if there 
is more than one group 
    
Bias 6 Describe any efforts to 
address potential sources of 
bias 
   
Study size 7 Explain how the study size 
was arrived at 






8 Explain how quantitative 
variables were handled in 
the analyses. If applicable, 
describe which groupings 
were chosen and why 
   
Statistical 
methods 
9 (a) Describe all statistical 
methods, including those 
used to control for 
confounding 
   
(b) Describe any methods 
used to examine subgroups 
and interactions 
    
    
(c) Explain how missing data 
were addressed 
   
Cross-sectional study—If 
applicable, describe 
analytical methods taking 
account of sampling strategy 
   
 
Results 
Participants 10* (a) Report numbers of individuals 
at each stage of study—eg 
numbers potentially eligible, 
examined for eligibility, confirmed 
eligible, included in the study, 
completing follow-up, and analysed 
    
(b) Give reasons for non-
participation at each stage 
   
(c) Consider use of a flow diagram     
Descriptive 
data 
11* (a) Give characteristics of study 
participants (eg demographic, 
clinical, social) and information on 
exposures and potential 
confounders 
   
(b) Indicate number of participants 
with missing data for each variable 
of interest 






12* Cross-sectional study—Report 
numbers of outcome events or 
summary measures 
     
Main 
results 
13 (a) Give unadjusted estimates and, 
if applicable, confounder-adjusted 
estimates and their precision (eg, 
95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 
included 
   
 
*Give information separately for cases and controls in case-control studies and, if 
applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives 
methodological background and published examples of transparent reporting. The 
STROBE checklist is best used in conjunction with this article (freely available on the 
Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal 
Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). 





Appendix 3.2 Clinical appraisal tool  








Comment  Yes  No  
Domain 1: Research team and reflexivity 
Personal 
Characteristics 
1 Interviewer/facilitator Which 
author/s conducted the 
interview or focus group? 
   
 2 Interviewer characteristics 
What characteristics were 
reported about the 
interviewer/facilitator? e.g. 
Bias, assumptions, reasons 
and interests in the research 
topic 
   





3 What methodological 
orientation was stated to 
underpin the study? e.g. 




     
Participant selection 
 Sampling  4 How were participants 
selected? e.g. purposive, 
convenience, consecutive, 
snowball 
   
Method of 
approach 
5 How were participants 
approached? e.g. face-to-
face, telephone, mail, email 
    
Sample size 6 How many participants were 
in the study? 
   
Non-
participation 
7 How many people refused to 
participate or dropped out? 
Reasons? 





Setting of data 
collection 
8 Where was the data 
collected? e.g. home, clinic, 
workplace 
    
Description of 
sample 
9  What are the important 
characteristics of the sample? 
e.g. demographic data, date 




10 Were questions, prompts, 
guides provided by the 
authors? Was it pilot tested? 
   
Audio/visual 
recording 
11 Did the research use audio or 
visual recording to collect the 
data? 
   
Field notes 12 Were field notes made during 
and/or after the interview or 
focus group? 
 
   
Data 
saturation 
13 Was data saturation 
discussed? 
   
 
Domain 3: analysis and findings 




14 How many data coders coded the 
data? 




15 Did authors provide a description of 
the coding tree? 




Were themes identified in advance 
or derived from the data? 




17 Were participant quotations 
presented to illustrate the themes / 
findings? Was eachquotation 
identified? e.g. participant number 







18 Was there consistency between the 
data presented and the findings? 
 
















Design   Participants  Theory applied Number of 
participants 
(response rate)  
Key findings  
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Dear Prof Leslie, 
 
Management Approval for Non Commercial Research 
 
I am pleased to tell you that you now have Management Approval for the research 
project entitled: 'A cross-sectional survey of prescribers in NHS Highland: 
determining views, experiences and behaviours relating to prescribing novel oral 
anticoagulants (NOACs) for the management of non- valvular atrial fibrillation'. 
[Protocol V1 16/11/15]. I acknowledge that: 
 
• The project is sponsored by Robert Gordon  University. 
• The project does not require external  funding. 







• The project is Site-Specific  Assessment exempt. 
 
 
The following conditions apply: 
 
• The responsibility for monitoring and auditing this project lies with the 
Robert Gordon University. 
• This study will be subject to ongoing monitoring for Research Governance 
purposes and may be audited to ensure compliance with the Research  
Governance  Framework   for   Health   and  Community   Care  in  Scotland   (2006,   
2nd Edition), 







NHS Highland, Assynt House, Beechwood Park, 







Highland  NHS Board is the common name of Highland  






















PhD student, Daria Generalova  Professor Stephen Leslie  Mrs 
Laura McIver 
Professor Derek Stewart   Mr Gordon Rushworth 
Dr Scott Cunningham 
 
PARTICIPANT INFORMATION LEAFLET 
 
A cross-sectional survey of prescribers in NHS Highland: determining views 
and experiences relating to prescribing edoxaban for the management of non-
valvular atrial fibrillation 
 
Dear prescriber 
You are being invited to take part in a research study about your views and experiences 
relating to  
prescribing edoxaban for the management of non-valvular atrial fibrillation (AF). Thank you 
for taking  
the time to read the following information carefully. It is important that you understand why 
the research  
is being done and what it will involve. Please ask if there is anything that is not clear or if you 
would like  
more information. Take your time to decide whether or not you wish to take part.  
 
What is the purpose of the study? 
A recent review published by Healthcare Improvement Scotland (HIS) of clinical 
effectiveness of Direct Acting Oral Anticoagulants (DOACs) for the prevention of stroke 
and pulmonary embolism in adult patients with non-valvular AF recommends edoxaban 




are interested in your views and experiences with edoxaban and implementing this 
recommendation in practice.  
 
Why have I been chosen? 
This invitation has been sent to all prescribers (doctors, nurse independent prescribers and 
pharmacist independent/supplementary prescribers) within NHS Highland.  
 
Do I have to take part? 
No. Participation in this study is voluntary so you may withdraw at any time. 
What will happen to me if I take part? 
If you decide to take part, you should complete and submit the following questionnaire. This 
should  
take no more than 30 minutes to complete the questionnaire. At the end of the questionnaire, 
you  
will be given the option of entering a prize draw for £50 of shopping vouchers.  
 
What are the possible benefits of taking part? 
While the research will be of no direct benefit to you, the findings will help us to 
understand better the prescribers’ views and experiences and hence, as such, may 
inform further developments.  
 
Will my contribution to this study be kept confidential?  
Yes. The questionnaire is completely anonymous and we cannot link the details you give for 
the entering  
the prize draw with your questionnaire responses.  
 
What will happen to the results of the research study? 
We can send you a short report of the findings on request. The full findings of the study will 
be  





reviewed journal.  
 
Who is organising and funding the research? 
This project is being conducted as part of the PhD programme of Daria Generalova, a student 
at Robert  
Gordon University, in collaboration with NHS Highland and Healthcare Improvement Scotland.  
There is no external funding for this work.  
 
 
Who has reviewed the study? 
The aims and intentions of the study have been reviewed by academic experts and approved 
by the  
ethical review panel of the School of Pharmacy and Life Sciences at Robert Gordon University. 
The study  
is exempt from NHS ethical review but has been approved by the Research, Development and  







If you decide to take part in the research, please complete and submit the questionnaire.  
 
On behalf of the research team, thank you for your time and consideration in reading this 
information sheet.  
If you have further questions about this study please contact the PhD principal supervisor, or 
one of the individuals named above. Best wishes 
 
 
Professor Derek Stewart  
 



















Appendix 4.4 A cross-sectional survey of prescribers in NHS Highland: 
Determining views, experiences and behaviours relating to prescribing 
novel oral anticoagulants for the management of non-valvular atrial 
fibrillation. 
 
Section A - some questions about you and your practice 
 
What is your profession?: 
�Doctor 
  Nurse 
  Pharmacist 
 
What is your job title? 
 
What is your specialty, if any? 
 
Which of the following academic qualifications do you have? 
  PhD 
  MSc 
  Postgraduate Diploma 
  Postgraduate Certificate 
�MBChB 
  BSc 
  MPharm 
 
What is your main practice setting? 
  primary care 
  secondary care 
  community pharmacy 
  care home 






What is the postcode or address of your main practice setting? 
 
How many years have you worked as a health professional? 
  ≤5 �5-10   11-15 �16-20   21-25 �26-30   ≥30 
 
How many years have you worked as a prescriber? 
  ≤5 �5-10 �11-15 �16-20 �21-25   26-30   ≥30 
 
What is your age? 
 
What is your gender? 
  Male 




In relation to changes to your professional practice, choose one phrase which best 
describes your approach 




I am cautious in relation to new ways of working; I tend to change once most of my peers have done 
so 
I think for some time before adopting new ways of working 








I am innovative with new ways of working 
 
Section B - some questions about your current practice with 
warfarin and NOACs 
 
 
Approximately how frequently do you initiate warfarin? 
 
 
Approximately how frequently do you continue prescribing warfarin if initiated by another? 
 
 
Approximately how frequently do you discontinue warfarin? 
 
 
Approximately how frequently do you initiate NOACs? 
 
 
























































Approximately how frequently do you switch individual patients from NOACs to warfarin? 
 
 



















Approximately how frequently do you continue NOACs if initiated by another? 
 
 










Approximately how frequently do you discontinue NOACs? 
 
 



























Section C - some attitudinal questions about NOACs 
 




I have sufficient knowledge of the guidelines to allow me to prescribe NOACs appropriately 
 
 
I have sufficient knowledge of the clinical pharmacology of NOACs to allow me to prescribe 
these safely and effectively 
 
 
I have sufficient knowledge of the evidence base of NOACs to allow me to prescribe 
these safely and effectively 
 
 
I have sufficient knowledge of how to initiate the prescribing of NOACs 
 
 








































































































I have sufficient knowledge of how to manage adverse reactions of NOACs 
 






It is part of my role to initiate the prescribing of warfarin 
 
 
I should only prescribe NOACs when they have been initiated by others 
 
 

































































































It is part of my role to switch patients from warfarin to NOACs where indicated 
 
 
It is part of my role to switch patients from NOACs to warfarin where indicated 
 























































I am confident in my ability to initiate the prescribing of warfarin 
 
 
I am confident in switching patients from warfarin to NOACs 
 
 
I am confident in switching patients from NOACs to warfarin 
 
 
I am confident in my ability to prescribe NOACs when they have been initiated by others 
 
 
I am competent in initiating the prescribing of NOACs 
 
 









































































































































I am competent in switching patients from NOACs to warfarin 
 








































Implementing the guidelines on prescribing NOACs will be better for patients 
 
 
Implementing the guidelines on prescribing NOACs will be better for me 
 
 
Implementing the guidelines on prescribing NOACs will be better for my NHS organisation 
 





































































If I prescribe NOACs rather than warfarin, I believe that my management of severe bleeding will 

































































































If I prescribe NOACs rather than warfarin, I believe that my management of severe bleeding will 




















not be easily detected 
 
 
I believe that If I prescribe NOACs rather than warfarin, under-anticoagulation will not be easily 
detected 
 























































The views of my colleagues are a deterrent to my prescribing of NOACs 
 
 
Potentially increased scrutiny of my prescribing by the healthboard is a deterrent to my 
prescribing of NOACs 
 
 
Potentially reduced workload in patient monitoring influences my prescribing of NOACs rather 
than warfarin 
 






































































I have clear goals relating to my continuing professional development around NOACs 
 
 
Prescribing NOACs according to the guidelines is high priority for me 
 























































I find it difficult to decide whether to prescribe NOACs or warfarin 
 
 
Others have to remind me to prescribe NOACs according to the guidelines 
 























































I have sufficient time to prescribe NOACs 
 
 
My drug budget is sufficient to allow me to prescribe NOACs 
 
 
My prescribing systems enable me to prescribe NOACs 
 
 
I have sufficient support from specialists to enable me to prescribe NOACs safely and effectively 
 
 
The lack of need for monitoring influences my prescribing of NOACs 
 
 
































































































Please add any comments you wish to make 
























Members of the multidisciplinary team prescribe NOACs 
 
 
My prescribing of NOAC is discouraged by my peers 
 
 
My prescribing of NOAC is discouraged by my multidisciplinary team 
 
 
My prescribing of NOAC is discouraged by my organisation 
 
 
My prescribing of NOAC is discouraged by specialists 
 
 





















































































































NOACs in situations where they are not indicated 
 








































I feel comfortable when switching patients from warfarin to NOACs 
 
 
I feel comfortable when prescribing NOACs which have been initiated by others 
 
 
I get professional satisfaction when initiating the prescribing of NOACs 
 
 
I get professional satisfaction when switching patients from warfarin to NOACs 
 
 
I get professional satisfaction when switching patients from NOACs to warfarin 
 
 









































































































































I feel anxious when switching patients from NOACs to warfarin 
 
 
I feel anxious when prescribing NOACs which have been initiated by others 
 



























































Please answer the following in relation to the NHS guidelines on the use of NOACs in non-valvular 
AF. For each question, answer as TRUE, FALSE, DON’T KNOW 
 
 
NOACs should be considered in patients whose INR is outside the INR window more than 60% 




NOACs should be considered first line in patients likely or known to be non- adherent 
 
 
Dabigatran is the first choice NOAC 
 
 
Apixaban is the second choice NOAC 
 
 
Rivaroxaban dose should be altered in the elderly, irrespective of renal function 
 
 
















































Section D: some other questions 
 
Please give your views on benefits and limitations of prescribing NOACs. 
 
Please describe ONE positive patient experience you have encountered in prescribing 
NOACs. 
 
Please describe ONE negative patient experience you have encountered in prescribing 
NOACs. 
 
Please give any views you have on the guidelines (e.g. accessibility, ease of use etc) 
 
If you have undertaken any training or other form of continuing professional development 
relating to NOACS please describe briefly the format, content and usefulness 
 
Please describe any additional training or other form of continuing professional 
development relating to NOACS you feel you need 
 




Please add any other comments you think are relevant. 
  
Thank you for your time 
 
If you would like to be entered into the prize draw for £50 of shopping vouchers, please give your 










Professor Derek Stewart 
 





Appendix 5.1 A cross-sectional survey of prescribers in NHS Highland: 
determining views and experiences relating to prescribing edoxaban for the 
management on non- valvular  atrial fibrillation 
1. What is your profession?�
  Doctor 
  Nurse 
  Pharmacist 
2. What is your job title? 
 
3. What is your specialty, if any? 
 
4. Which of the following academic qualifications do you have? 
  PhD 
  MSc 
  Postgraduate Diploma 
  Postgraduate Certificate 
MBChB 
If you selected Other, please specify: 
5. What is your main practice setting? 
  primary care 
  secondary care 
  community pharmacy 
  care home 
  other (please state) 









<5 5-10 11-15 16-20 21-25 26-30 >30 





8. What is your age? 
9.What is your gender? 
Male 
Female 
Rather not indicate  
10. Approximately how frequently do you initiate edoxaban? 
 
 
10a. If "never" do you plan to do this in the future? 
 
 
11. Approximately how frequently do you switch individual patients from warfarin to edoxaban? 
 
 











12a. If “never" do you plan to do this in the future? 
Yes No Not sure 
 
13. Which is your oral anticoagulant of choice for new patients with non-valvular AF? 
 
 
13a. What are the reasons for this choice? 
Yes No 
Yes  No  




















14. Are you aware of the NHS Highland guidelines which recommend edoxaban as first line 
treatment in non-valvular AF? 
Yes No 
 
14a. If "yes" do you support this recommendation? 
14b. Please give any comments on the NHS Highland guidelines. 
 




15a. If "yes" please give us some details of who and  how. 
 
16. Have you switched, where relevant, all patients from warfarin to edoxaban? 
Yes  No  
 
16a. If not, please give any comments about future plans and intentions. 
17 .Have you switched, where relevant, all patients from other DOACs to edoxaban? 
 
Yes  No  
 
17a. If not, please give any comments about future plans and intentions. 
 




19.I have sufficient knowledge of the clinical pharmacology of edoxaban to allow me to 
prescribe safely and effectively. 
 
 
















































21.I have sufficient knowledge of how to initiate edoxaban 
 
 
22. I have sufficient knowledge of how to monitor the effectiveness and toxicity of edoxaban. 
 
 
23. I have sufficient knowledge of when and how to switch patients from warfarin to edoxaban. 
 
 
24. I  have  sufficient knowledge  of  when and how  to  switch patients  from  other DOACs  to edoxaban. 
 
 




26. It is part of my role to initiate edoxaban 
 















































































































28. Only specialists should initiate edoxaban. 
 
 
29. It is part of my role to switch patients from other DOACs to edoxaban where indicated. 
 
 
30. I am confident in my  ability to initiate edoxaban. 
 
31. I am confident in switching patients from warfarin to edoxaban. 
 
 




33. I am competent in initiating edoxaban. 
 
 
















































































































35. I am competent in switching patients from other DOACs to edoxaban. 
 
 
36. Please add any comments you wish to make. 
37. Implementing the guidelines on prescribing edoxaban will be better for patients. 
 
 
38. Implementing the guidelines on prescribing edoxaban will be better for my NHS organisation. 
 
 
















































































  40. If I prescribe edoxaban rather than warfarin, I believe that patients will have less  adverse effects. 
 
 
41. If I prescribe edoxaban rather than warfarin, I believe that patients will be treated more cost effectively. 
 
 



























































45. If I switch patients on other DOACs to edoxaban, I believe that patient care may be compromised. 
 
 
46. If I prescribe edoxaban rather than other DOACs, I believe that my management of severe 

































































47. I find the  guidelines  on edoxaban easy  to interpret. 
 
 
48.  I find it difficult to decide whether to prescribe edoxaban, rivaroxaban, dabigatran and apixaban. 
 
 49. Others have to remind me to prescribe edoxaban according to the guidelines. 
 
 




















































50. Unless contraindicated, I intend to prescribe edoxaban for all new patients with non-valvular AF 
 
 




52. My prescribing of edoxaban is discouraged by my peers. 
 
 

































































 54. My prescribing of edoxaban is discouraged by specialists. 
 
 
55. I feel anxious when initiating edoxaban. 
 
 



















































57. I feel anxious when switching patients  from edoxaban to other DOACs. 
 
 
58. Please add any comments you wish to make. 
 
59 Please describe any benefits you consider relating to the 
implementation of the guidelines on edoxaban. 
 
60.Please describe any limitations you consider relating to the 
implementation of the guidelines on edoxaban. 
 
61 Have any of your patients experienced adverse reactions with edoxaban? 
 
 
61a If "yes", please describe the most impactful. 
 
61 b Was a yellow card completed? 
No  Yes  
 




62a. If "yes" please describe the most impactful. 
 




No  Yes  
No  Yes  


















63. Please add any other comments on prescribing edoxaban or other 
DOACs for the management of non-valvular AF. 
